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Gold compounds have been used in medicine dating back as early as 2500 BC. Over the 
years gold(I) and gold(III) compounds have been used and designed to target rheumatoid 
arthritis, cancer, and viral diseases. New drug targets have been found for gold compounds that 
give insight into their mechanisms of action. Here we focus on the synthesis of Au(III) 
compounds designed to selectively target zinc finger (ZF) proteins. 
ZF proteins exhibit a variety of functions, including transcription, DNA repair, and 
apoptosis. Displacement of the central zinc ion, along with mutation of coordinated amino acids 
can result in a loss of biological function. Synthesis of complexes that selectively target zinc 
finger proteins, in turn inhibiting DNA/ZF interactions and therefore resulting in loss of protein 
function, is of great interest. Of particular interest here is the Cys3His (Cys = cysteine, His = 
histidine) HIV nucleocapsid zinc finger protein, NCp7. NCp7 is involved in multiple steps of the 
HIV life cycle, thus making it a desirable drug target. Previous studies from our group show 
platinated nucleobases such as [Pt(dien)(9-EtG)]2+ (dien = diethylenetriamine; 9-EtG = 9-
	   	  
ethylguanine) to stack effectively in a non-covalent manner with tryptophan of the C-terminal 
finger of HIV Nucleocapsid, NCp7(F2), a key residue involved in nucleic acid recognition. Due 
to the isoelectronic and isostructural relationship of Au(III) to Pt(II), we have expanded this 
system to Au(III)-(nucleobase/N-heterocycle) compounds.  
Novel Au(III)(dien)(N-heterocycle) compounds, including the first Au(III)N3(N-purine) 
examples, were synthesized. As previously reported for [AuCl(dien)]Cl2, these compounds 
exhibit pH dependency of the 1H NMR chemical shifts of the dien ligand. The acidity of the dien 
ligand is affected by the nature of the fourth ligand as a leaving group. The presence of an inert 
nitrogen donor, compared to that of the more labile Cl-, as the leaving group stabilizes the 
Au(III) metal center towards reduction, resulting in significant enhancement of π−π stacking 
interactions with tryptophan relative to platinum(II) and palladium(II) compounds. 
The presence of a more inert N-donor as the leaving group slows down the reaction with 
the sulfur-containing amino acid N-Acetylmethionine (N-AcMet); essentially no reaction was 
observed for the Au(III)-N-heterocycle compounds. All compounds react readily with N-
Acetylcysteine (N-AcCys), however lack of N-heterocycle ligand dissociation indicates, to our 
knowledge, the first long-lived N-heterocycle-Au-S species in solution.  
Electrospray ionization mass spectrometry (ESI-MS) studies with NCp7(F2) indicate 
[Au(dien)(DMAP)]3+ (DMAP = 4-dimethylaminopyridine) to be the least reactive of the Au(III) 
compounds studied, showing the presence of intact NCp7(F2) zinc finger at initial reaction 
times.  Reactivity of the Au-compounds was compared with that of Sp1(F3), a Cys2His2 ZF; in 
contrast, no intact ZF was observed for any of the compounds studied, suggesting the mode of 
action of these compounds is dependent on the nature of the zinc binding core. 
	   	  
ESI-MS studies were expanded to that of the full HIV NCp7 zinc finger. [Au(dien)(9-
EtG)]3+ reacts quickly with NCp7, resulting in immediate zinc ejection and replacement with up 
to three gold ions. Unlike with [Au(dien)(DMAP)]3+, no intact NCp7 was observed. Addition of 
[Au(dien)(9-EtG)]3+ to preformed NC-SL2 complex results in release of free RNA; based on 
EMSA (electrophoretic mobility shift assay) studies, [Au(dien)(9-EtG)]3+ disrupts the NCp7-
RNA complex with an IC50 of ~450 µM. It is possible that this HIV nucleocapsid-nucleic acid 
antagonism may result in a loss of viral activity. 
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Chapter 1. Introduction 
1.1 Gold compounds in medicine 
The earliest use of gold in medicine dates back to 2500 BC when it was used as a 
therapeutic in Chinese medicine [1,2]. It was later discovered in 1890 that gold(I) cyanide, 
[Au(CN)2]-, inhibited the growth of Tubercle bacillus, which led to the use of Au(I)-thiolate 
drugs, Figure 1.1, for the treatment of tuberculosis and rheumatoid arthritis with auranofin being 
approved for clinical use in 1985 [1,2]. Later studies suggested that gold decreases expression 
of important proinflammatory genes by inhibiting transcription mediated by the AP-1 
transcription factor protein. AP-1 DNA binding was inhibited by gold(I)-thiolates by 50% at 5 
µM concentrations of drug; the mechanism of action was hypothesized to be binding to cysteine 
residues in the DNA binding domain of AP-1 [3]. 
The discovery of the anticancer properties of cisplatin and its platinum(II) analogues and 
their clinical success in cancer treatments led to a great deal of interest in the area of metal-based 
Figure 1.1. Examples of Au(I)-thiolate drugs used for the treatment of rheumatoid arthritis. 
(1) Sodium aurothiomalate (Sodium 2-(auriosulfanyl)-3-carboxypropanoate), (2) 
Aurothioglucose ((2S,3S,4R,5S)-3,4,5-trihydroxy-6-(hydroxymethyl)-oxane-2-
thiolate)gold(I), and (3) Auranofin ((2,3,4,6-Tetra-O-acetyl-1-thio-ß-D-glucopyranosato-
S)(triethyl-phosphine)gold(I)) [ 1]. 
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antitumor agents [4,5]. The fact that gold(I) compounds were already in the clinic for the 
treatment of rheumatoid arthritis led to their consideration as possible antiproliferative agents 
[4].  Early studies showed gold(I)-phosphine compounds to be fairly active in vitro but 
practically ineffective in vivo, likely due to the inherently ‘soft’ nature and, therefore, high thiol 
affinity of Au(I) [4,6,7].  This causes inactivation of the drug through extensive binding to serum 
proteins. In the case of auranofin, the tetraacetylthioglucose ligand rapidly dissociates in vivo 
followed by slower displacement and simultaneous oxidation of the phosphine to Et3PO [8]. 
With the aim of reducing the high thiol reactivity, gold(I) complexes with chelated 
diphosphine ligands such as [Au(dppe)2]Cl were synthesized and studied, Figure 1.2 [9].  It was 
found that these compounds accumulate in the mitrochondria of tumor cells [1]. The high 
lipophilicity of these compounds, however, resulted in non-selective reactivity with both 
tumorigenic and non-tumorigenic cells, resulting in severe toxicity in the heart, liver, and lung as 
Au
R2P PR2
R2P PR2
+
Cl-
R =
Au
R2P PR2
R2P PR2
+
Cl-
N
[Au(dppe)2]Cl	  R	  =	  phenyl	   [Au(d2pypp)2]Cl	  R	  =	  2-­‐pyridyl	  
	  	  phenyl	  	  	  	  	  	  	  	  	  	  	  	  	  2-­‐pyridyl	  
Figure 1.2. Structures of (A) [Au(dppe)2]Cl  (dppe = 1,2-Bis(diphenylphosphino)ethane) and 
(B) [Au(d2pypp)2]Cl (d2pypp = 1,3-bis(di-2-pyridylphosphino)propane) [10]. 	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a result of mitochondrial dysfunction [1]. A similar compound, [Au(d2pypp)2]Cl), Figure 1.2, 
was designed with the idea to combine the two distinct features of Au(I)-phosphine drugs; the 
lipophilicity properties of the bis-chelated ligand allowing accumulation in the mitochondria, as 
well as enhancement of the reactivity towards protein thiols. This resulted in a compound that 
reacts selectively towards breast cancer cells but not normal breast cells [10]. 
Au(III) centers are isoelectronic and isostructural to those of platinum(II), both adopting 
a square planar geometry. Gold(III) compounds, therefore, looked appealing for cancer treatment 
as they might exhibit similar biological activity as previously studied platinum(II) drugs [4,5]. 
Gold (I), however, is thermodynamically more stable than gold(III); many gold(III) complexes 
are strong oxidizing agents and are easily reduced to Au(I), resulting in generally high toxicity 
[2]. Initial gold(III) compounds studied, therefore, although highly cytotoxic in vitro, 
demonstrated a poor chemical stability and, also, a rather pronounced systemic toxicity [4].  
Figure 1.3. Structures of Au(III) compounds shown to be more stable and exhibit toxic 
effects towards tumor cells. (1) [Au(en2)]Cl3, (en = ethylenediamine) (2) [Au(dien)Cl]Cl2, 
(dien = diethylentriamine) (3) [Au(cyclam)](ClO4)2Cl,(cyclam = 1,4,8,11-
tetraazacyclotetradecane) (4) [Au(terpy)Cl]Cl2, (terpy = 2,2';6',2"-terpyridine) and (5) 
[Au(phen)Cl2]Cl (phen = 1,10-phenanthroline) [5,11]. 
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Therefore, new classes of Au(III) compounds containing multidentate ligands such as 
polyamines and cylcams were synthesized to improve stability, Figure 1.3 [5,11].  All of these 
novel gold compounds turned out to be highly cytotoxic in vitro against representative human 
tumor cell lines [5].  The new cytotoxic gold compounds were often found to overcome 
resistance to cisplatin confirming the occurrence of a substantially different mode of action, 
which led researchers to speculate the existence of preferential protein targets for gold 
compounds  [4,12].   
Hard-soft acid base theory (HSAB) aids in understanding the predominant factors that 
drive chemical reactions. HSAB theory states that soft acids tend to react faster and form 
stronger bonds with soft bases. Soft acids and bases are characterized by the following 
characteristics: large atomic radius, high polarizability, low oxidation state, and low 
electronegativity [13]. Therefore, the ‘soft’ nature of gold(I) causes it to have a high preference 
for S-donors; gold drugs undergo ligand exchange with cysteine-rich peptides and proteins such 
as glutathione and albumin [14]. This reactivity with biological ligands such as cysteine may 
contribute to their pharmacological activity. The most studied targets of gold compounds are 
thioredoxin reductase (TrxR) enzymes [1]. TrxR and the thiol protein thioredoxin (Trx) play an 
integral role in intracellular redox regulation and have been implicated in chronic diseases such 
as certain cancers and rheumatoid arthritis [1,4,15]. TrxR catalyzes the NADPH-dependent 
reduction of thioredoxin, supplying electrons to a number of enzymes which rapidly regulates the 
level of hydrogen peroxide in the cell; refer to Scheme 1.1 for description of the involved 
mechanism [4,15]. Mammalian TrxRs have a conserved cysteine-rich catalytic site located in the 
flavin adenine dinucleotide (FAD) and nicotinamide adenine dinucleotide phosphate (NADPH) 
binding domain as well as a redox active selenocysteine (Sec) residue in the C-terminal active 
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site which is crucial for catalysis [1,4,15]. This high sulfur content explains the high reactivity of 
TrxR with gold compounds. 
Auranofin inhibits TrxR activity with an IC50 value of 4 nM [4]. Electrospray Ionization 
Mass Spectrometry (ESI-MS) studies of auranofin with a tetrapeptide used as a model for the 
TrxR C-terminus showed preferential binding of Au(I) to the Sec residue the C-terminal active 
site with subsequent loss of the thiosugar [16]. A variety of Au(III) drugs, including Au(III)-
dithiocarbamates, are potent inhibitors of TrxR, resulting in apoptosis [1]. Some studies suggest 
Scheme 1.1. 
1) Proposed TrxR Mechanism. First, the selenenylsulfide is reduced to the selenolate 
anion (Se-) with electrons received from NADPH via FAD. A second electron 
transfer from a second molecule of NADPH reduces the active site thiol bonds with 
one Cys residue stabilized by an interaction with FAD (Step 1). The selenolate anion 
then attacks the disulfide bonds of Trx and the resulting enzyme-Trx mixed 
selenenylsulfide (Step 2), which is then subsequently attacked by the neighboring 
Cys residue to regenerate the selenenylsulfide (Step 3). This selenenylsulfide is then 
reduced by the active-site thiolate from the other subunit (Step 4). [15] 
2) Mechanism for H2O2 reducition by TrxR. The nucleophilic selenolate is oxidized by 
H2O2, producing selenenic acid (-SeOH). One cysteine thiol reacts with the selenenic 
acid to produce water and to reform the selenenylsulfide. A second thiol then attacks 
the bridge to regenerate the selenol. [15] 
A)	   B)	  	  	  	  	  Step	  1	  
Step	  2	  	  	  	  Step	  3	  
Step	  4	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the inhibition of TrxR by Au(III) compounds is due to oxidative damage to the enzyme through 
oxidation of thiols or selenols rather than gold coordination as seen for Au(I)-drugs [4]. 
However, the Au(III) metal center may reduce to Au(I) in vivo, and therefore react similarly to 
Au(I) compounds [1]. 
Gold compounds have also been implicated as anti human immunodeficiency virus (HIV) 
agents [1,17]. The inhibition of the HIV reverse transcriptase (RT) by Au(I) aliphatic compounds 
was first shown in 1989 and the antiarthritic Au(I) drugs aurothioglucose, aurothiomalate and 
auranofin have all been investigated for their potential as drugs for treating acquired 
immunodeficiency syndrome (AIDS) [1]. AIDS patients treated with auranofin experienced an 
increase in CD4+ lymphocyte count, when normally the progression of HIV infection is marked 
by the decline of these cells [8,17]. Aurothioglucose was found to protect cells from HIV 
infection through ligand exchange with a cysteine (Cys) residue on the viral coat protein [1,8]. 
There are a few examples of Au(III) drugs that have been reported to show anti-HIV activity; 
these compounds are shown in Figure 1.4 [18].   The porphyrin complex, [Au(TMPyP)]Cl5 (Fig 
1.4) was found to successfully inhibit HIV-1 RT with an IC50 value of 0.31 µM [17,18]. 
 
[AuIII(salen)]+ [AuIII(dcbpb)]+ [AuIII(TMPyP)]5+ 
Figure 1.4. Structures of Au(III)-chelate compounds that have shown anti-HIV properties. 
[Au(salen)]+ (H2salen = N,N’-ethylene bis(salicylideneimine), [Au(dcbpb)]+ (H2dcbpb = 4,5-
dichloro-1,2-bis(2-(4-tert-butylpyridine)carboxamido) benzene), [Au(TMPyP)]5+ 
(H2TMPyP)4+ = meso-tetrakis(N-methlypyridinium-4-yl)porphyrin) [18]. 
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Inhibition by these Au(III)-porphyrin compounds has been shown to be linked to possible 
intercalation between nucleic acid base pairs of DNA, thus inhibiting the enzyme from 
converting viral ribonucleic acid (RNA) to complimentary-DNA (cDNA) [17,19].  
As described later in this chapter, the HIV-1 nucleocapsid zinc finger protein, NCp7, is 
involved in many steps throughout the HIV life-cycle and is thus a desirable drug target. The 
thiol-rich nature of zinc fingers (ZFs) merits the investigation of zinc finger proteins as specific 
targets of Au-drugs. A variety of Au(I)/(III) drugs react with zinc finger proteins, resulting in 
zinc ejection and loss of protein function; refer to Section 1.4. It is the goal of this work to 
synthesize Au(III) compounds that selectively target zinc finger proteins, one specifically being 
the NCp7 zinc finger protein. 
 
1.2 Zinc Finger Proteins 
 Zinc fingers are involved in a variety of biological functions including DNA recognition, 
transcriptional activation, regulation of apoptosis, and protein folding and assembly.  Zinc finger 
proteins comprise 2-3% of the entire human genome and are considered to be the most common 
DNA binding motifs found in human transcriptional factors [6,20].  In zinc fingers, zinc plays a 
Figure 1.5.  Representative coordination environments for zinc fingers - transcription factor 
Sp1 (Cys2His2, Finger 2); HIV nucleocapsid protein NCp7 (Cys3His, C-terminal Finger 2); 
nucleotide excision repair protein component XPA (xeroderma pigmentosum group A) (Cys4) 
[6]. 
Sp1 (F2) 
X1 - RFTRSDEL 
 
NCp7(F2) XPA 
X2 - EFMDSYLMNHFDL 
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structural role, typically coordinated to four protein derived Cys and histidine (His) residues.	    
Therefore, zinc fingers are generally classified according to the number and type of amino acids 
involved in zinc(II) coordination, such as Cys2His2, Cys3His, and Cys4 zinc fingers.  Figure 1.5 
shows the structures of these three classes of zinc fingers [6]. 
It is understood that the Zn-cysteine bonds present in zinc fingers are susceptible to 
oxidation, which may lead to Zn(II) ejection [21,22]. Modification of the zinc finger core by a 
variety of electrophilic agents, including inorganic and transition metal ions, results in eventual 
zinc ejection and therefore inhibition of the nucleic acid binding capacity of the modified peptide  
[23]. It is with this knowledge that new drugs consisting of small inorganic molecules are being 
synthesized to target such zinc fingers to cause release of zinc and loss of function. 
1.2.1  Cys2His2 (C2H2) Zinc Finger Proteins 
Many Cys2His2 zinc fingers are transcription factors, which are proteins that bind to 
specific DNA sequences thereby controlling the flow of genetic information from DNA to 
messenger-RNA (mRNA) and regulating gene expression.  Of the three zinc finger coordination 
environments shown in Figure 1.5, the Cys2His2 zinc finger motif has been shown to be the least 
nucleophilic and the least tightly packed [22].   
The human transcription factor Sp1 is an example of a Cys2His2 zinc finger protein, 
where the zinc ion is tetrahedrally bound to two cysteine and two histidine residues.  Specificity 
protein family (Sp) transcription factors regulate a variety of cancer-associated genes involved in 
cell cycle, cell proliferation and apoptosis [24]. The Sp family consists of several members that 
contain a highly conserved DNA-binding domain composed of three zinc fingers with typical 
ββα zinc finger folds at the C-terminus, Figure 1.6, and serine (Ser), threonine (Thr) and 
glutamine (Gln) rich transactivation domains at the N-terminus. Sp1 binds specifically to GC-
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rich recognition elements (GC-box) mediated by its C-terminal zinc finger domain [25].  
The overexpression of Sp1 is associated with tumor development and growth.  Recent 
studies have shown that Sp1 can regulate the expression of human telomerase reverse 
transcriptase (hTERT), a key component responsible for telomerase activity.  Inhibition of the 
Sp1 interaction with hTERT promoter DNA down regulates the expression of the telomerase 
gene, which is overexpressed in most malignant tumors [26-28]. These observations highlight the 
importance of Sp1 in tumor development and suggest that Sp1 is a potential therapeutic target.  
There is increasing evidence that indicates the proteins regulated by Sp1 are also 
involved in the mechanisms of platinum drugs. Ctr1, a copper transporter protein, facilitates the 
cell uptake of cisplatin, and low levels of Ctr1 have been detected in cisplatin resistant cells. The 
DNA-dependent protein-kinase catalytic subunit (DNA-PKcs), a key enzyme involved in 
repairing DNA double strand breaks, protects cells from toxic effects of cisplatin. In addition, the 
vacuolar ATPase (ATP = adenosine triphosphate) is often involved in the acquired cisplatin 
resistance. All these proteins are regulated by the transcription factor Sp1. Studies by Chen et al. 
Figure 1.6. Model of Sp1 zinc finger protein bound to DNA [25]. 
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show that the trans-platinum compound trans-[PtCl2(NH3)(Tz) (Tz = thaizole) exhibited high 
activity with Sp1, disrupting its structure and function both in vivo and in vitro. [26] 
1.2.2. Cys3His (C3H) Zinc Finger Proteins  
One example of a Cys3His zinc finger is PARP-1, a protein consisting of four domains 
including a DNA binding domain composed of two zinc fingers motifs, positioned upstream 
from the catalytic domain, Figure 1.7A [29]. Poly(adenosine diphosphate (ADP)-ribose) 
polymerases (PARPs) are essential proteins with roles in maintaining genome integrity, and 
regulation of transcription, and cell death signaling pathways [29-31]. The catalytic activity 
of PARP-1 is stimulated by interaction with “nicked” or damaged DNA. Once PARP detects a 
single strand break, it binds to the DNA, causing a structural change and initiating the synthesis 
of poly (ADP-ribose) (PAR) chains as a signal for other DNA-repair enzymes. Nicotinamide 
adenine dinucleotide (NAD+) acts as a substrate for generating ADP-ribose monomers. Severe 
B) 
A) 
 
Figure 1.7. (A) Schematic representation of PARP-1 domain structure [29]. (B) Crystal 
structure of ZF2 bound to DNA (PDB:  30DC) 
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DNA damage may induce hyperactivation of PARP-1, which may deplete the level of cellular 
NAD+ and induce a depletion of ATP levels, which will simultaneously lead to necrotic cell 
death [30,31].	  	  
Mutational and deletion analysis have indicated that the Zn1 binding domain plays a key 
role in PARP-1 DNA-dependent activity in vitro, whereas the Zn2 domain is not essential. 
Interestingly, studies show that the Zn1 domain has a weaker DNA binding affinity than that of 
Zn2, with Kd values of 3.43±0.86 µM and 0.034±0.010 µM respectively [30]. Both PARP-1 zinc 
fingers bind similarly to the end of duplex DNA, each forming a continuous surface interaction 
with DNA through what has been termed “phosphate backbone grip” and “base stacking loop”. 
The Zn2 domain spans the DNA minor groove, Figure 1.7B, making additional contacts with the 
phosphate backbone of the complimentary DNA strand, which could contribute to a higher DNA 
affinity [30]. 
 PARP-1 is considered an interesting drug target for the development of innovative 
therapeutic agents in diseases including cancer, inflammation, and diabetes. PARP-1 inhibitors 
have been considered as drugs for use in combinatorial therapies for cancer treatment.  It is 
thought that use of PARP-1 inhibitors would allow for synergistic enhancement of DNA 
damaging therapeutic agents such as cisplatin and carboplatin. An increasing interest and 
understanding of the polypharmacology of PARP-1 inhibitors has caused questions to arise of 
the specificity and “off-target” activities of these drugs. Therefore, it is of great interest to 
synthesize highly specific drugs to target PARP-1 [31,32]. 
The HIV nucleocapsid protein NCp7 is another example of a Cys3His zinc finger protein 
and on which this dissertation primarily focuses.  It contains two successive CysCysHisCys 
domains separated by a short linker sequence, RAPRKKG [33].  Although each of the two NCp7 
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zinc fingers shares the same retroviral zinc finger motif, the C-terminal finger (F2) is 
substantially more reactive than that of the N-terminal finger, with Cys49 being the most labile 
site of the NCp7 protein [21]. NCp7 is characterized by the presence of two aromatic residues 
crucial for its activities, the distal domain containing a phenylalanine (Phe16) and the proximal 
one containing a tryptophan residue (Trp37) [33]. NMR structures show that the recognition of 
HIV nucleocapsid protein NCp7 with DNA/RNA occurs by stacking between guanine in the 
DNA/RNA and the tryptophan in the NCp7 protein, Figure 1.8 [34-36]. Mutation of the Trp 
and/or Phe residues significantly reduces the nucleic acid chaperone activity of NCp7, which 
correlates to inhibition of viral replication [37].  
 
 The HIV-NCp7 nucleocapsid protein has a variety of functions as shown in Figure 1.9.  
As a component of the Gag precursor, the NCp7 protein promotes the packaging of viral 
genomic RNA into virions, which involves recognition of a ~120 nucleotide RNA segment 
located near the 5’ end of the genome known as the Ψ-site  [33,38]. In the precursor Gag, the 
NCp7 domain interacts with the genomic RNA to stimulate retrovirus particle assembly and 
A) B)
C) 
Figure 1.8. NMR structure (A) and sequence (B) of the full-length HIV-NCp7 protein and 
its interaction with RNA (C) [ 6, 36].	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budding [33].  NCp7 also plays a role in the early stages of infection, as shown by its in vitro 
influence to promote initiation of reverse transcription through annealing of the tRNALys,3 to the 
primer binding site [33].  Most of the known functions of NCp7 involve interactions with nucleic 
acids.  The NCp7 zinc finger protein is folded in such a way that allows specific binding to RNA.  
It has been shown that mutations that prevent zinc binding, such as Cys to alanine (Ala) or Ser, 
cause the peptide to unfold and produce disulfide bonds between Cys residues, which results in 
the production of noninfectious viruses lacking their genomic RNA [33,38]. It is clear, therefore, 
that there exists a strong relationship between the zinc finger folding and the functions of NCp7, 
thus NCp7 has become a major target in AIDS therapy. 
1.2.2.1  Small Molecule Inhibitors of HIV-1 
Numerous novel targets exist for anti-retroviral therapy, Figure 1.10 [39]. Attachment or 
entry inhibitors block the interaction between the cellular receptors and the antireceptor on the 
virus by binding to or altering the receptor sites. Chemokine receptor antagonists (examples are 
Figure 1.9.  The various functions of NCp7 during the early and late phases of the HIV-1 
replication cycle [33]. 
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maraviroc, vicriviroc, aplaviroc, AMD070) are a novel class of HIV-1 entry inhibitors that 
disrupt binding of HIV-1 to either CCR5 or CXCR4 co-receptors. Since these agents target a 
cellular receptor instead of a viral enzyme or protein, emergence of viral resistance may occur 
more slowly than with other anti-retrovirals [39].	  
In HIV, RT is used to generate complementary DNA (cDNA) from the viral RNA 
genome; this process is called reverse transcription. Reverse transcriptase inhibitors, therefore, 
inhibit reverse transcriptase from being able to function and in turn inhibiting formation of viral 
DNA. Nucleoside and nucleotide analog reverse transcriptase inhibitors (NRTIs) contain faulty 
imitations of nucleotides found in a T-cell’s cytoplasm.  Instead of incorporating a nucleotide 
into the growing chain of DNA, the imitation building blocks in NRTIs are inserted, preventing 
the double strand of DNA from becoming fully formed.  Non nucleoside reverse transcriptase 
inhibitors block reverse transcription by attaching to the enzyme in a way that prevents it from 
functioning [39]. 
Figure 1.10. Diagram of HIV life cycle showing both conventional and new targets for anti-
retroviral therapy [39]. 
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Other types of inhibitors include integrase inhibitors, drugs that inhibit the viral DNA 
from traveling to the nucleus, and protease inhibitors, which bind to the protease enzyme and 
prevent it from separating, or cleaving, the subunits. Researchers are also looking at drugs called 
maturation inhibitors, such as zinc finger inhibitors, which interfere with the packaging of the 
viral RNA into the nucleocapsid [39]. 
Owing to the importance of the two zinc fingers for the function of NCp7 in HIV-1 
replication, the first inhibitors designed to target the protein were zinc ejectors.  These consisted 
of electrophilic compounds that target the nucleophilic zinc-coordinating cysteine residues of 
NCp7 [19].  Early generation zinc ejectors showed potent antiviral activity, but suffered from 
limited selectivity and significant toxicity [40]. Figure 1.11 shows a variety of different zinc 
ejecting compounds.  3-nitrosobenzamide (NOBA) compounds are an example of a compound 
that showed good activity against NCp7 in vitro [33,41]. However, it did not show sufficient 
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   Figure 1.11.  Structures of various zinc-ejecting compounds [33,43].	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selectivity, as they reacted with cellular zinc-binding proteins such as PARP [40,42].  Further 
studies led to the development of other electrophilic compounds including azodicarbonamide 
(ADA) and disulfide bond-containing compounds such as 2,2-dithiobis(benzamide) disulfides 
(DIBA).  Thioester-based chemotypes such as S-acyl-2-mercaptobenzamide thioesters (SAMT) 
were developed from the DIBA compounds in hopes of improving selectivity and reducing 
toxicity [33,40].   
Zinc finger inhibitors have a common mechanism of reacting with a nucleophilic 
cysteine, forming a covalent adduct on the protein and leading to zinc ejection.  Such adducts 
result in formation of intra- and inter-molecular disulfide bonds before zinc can bind again [33].  
The SAMT compounds, however, acylate the cysteine residue and release a free thiol rather than 
use an oxidative mechanism, Figure 1.12 [33,40,41,43].    
 
Figure 1.12. (A) Mechanism of zinc ejection from NCp7 by disulfide compounds, (B) 
Proposed thioester reaction mechanism with NCp7 [33,43]. 
A) 
B) 
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Many problems are associated with the use of conventional antiretroviral (ARV) agents 
described at the beginning of this section including extensive drug resistance and short and long-
term side effects [39]. This has caused a great need for newer, specific agents.  Both components 
of the NC-nucleic acid chaperone activity have been targeted [44-48]. A study of approximately 
2,000 small molecules from the NCI Diversity Set suggested a possible fluoroscein-based 
pharmacore with a good correlation between tryptophan quenching and inhibition of NC-nucleic 
acid binding [44]. A second high-throughput screening of small molecules for inhibition of NC-
mediated destabilization of the stem-loop structure of cTAR DNA (a sequence complementary to 
the transactivation response element) produced only five compounds with IC50 values in the 
micromolar range from a total of 4800 compounds [45]. The inhibitory activity of 4 of the 5 
correlated with their ability to compete with the nucleic acid for binding to NC [45]. Similarly, as 
discussed throughout this dissertation, we are currently working on synthesizing Pt(II)/Au(III) 
metal complexes designed to specifically target the NCp7 zinc finger protein and therefore 
inhibit binding to RNA. 
 
1.3  Pt-nucleobase compounds act as electrophiles towards zinc finger proteins 
Two strategies, have emerged in developing zinc finger inhibitors:  the use of small 
molecule inhibitors that contain an electrophilic reactive group, and the use of metal-containing 
compounds that compete with zinc binding [33,40]. Previous studies in our group have used both 
of these strategies to develop a more selective type of zinc finger inhibitor.  Coordination 
compounds such as cis-[Pt(NH3)2(Cl)2] (Cisplatin), trans-[PtCl(9-EtG)(py)2]+ (9-EtG = 9-
ethylguanine; py = pyridine), and [PtCl(dien)]+ act as electrophiles towards zinc fingers, 
disrupting protein conformation and causing zinc ejection, Figure 1.13 [6].  To improve the 
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selectivity of these compounds, a small molecule approach using platinum-nucleobase 
compounds has been developed to target the retroviral zinc finger – DNA interaction [49-52]. As 
stated earlier, it is known that a key interaction between RNA and NCp7 is the π-stacking 
between the guanine bases of RNA and the planar aromatic amino acid Trp37 of the zinc finger 
protein, Figure 1.8.  It is thought that the nucleobase in these Pt compounds can π-stack with 
Trp37 of NCp7, therefore blocking the interaction of RNA and inhibiting the function of the 
NCp7 zinc finger protein.  
Fluorescence quenching studies have shown that metallation of nucleobase compounds 
significantly enhances the π-π stacking interactions with L-tryptophan. Metallation modifies 
HOMO-LUMO interactions, where the π-acceptor LUMO (lowest unoccupied molecular orbital) 
of the metallated nucleobase is lowered, thus improving the overlap and acceptor properties 
towards the π-donor HOMO (highest occupied molecular orbital) of the tryptophan [49,52].  
These findings were extended to a biologically relevant system, that of the C-terminal peptide of 
the HIV-NCp7 zinc finger, F2.  Upon incubation of F2 with [Pt(dien)(9-EtG)]2+ and 
[Pt(dien)(5’GMP)] (5’GMP = 5’-guanosine monophosphate), fluorescence quenching was 
observed; Eadie-Hofstee analysis gave association constants of 7.5 x 103 and 12.4 x 103 M-1, 
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Figure 1.13. Pt(II) compounds shown to act as electrophiles towards zinc finger proteins 
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   19	  
respectively [51]. Though there is little difference between their binding with free tryptophan (Ka 
values are 6.8 and 6.9 x 103 M-1 for [Pt(dien)(9-EtG)]2+ and [Pt(dien)(5’GMP)], respectively 
[49]), the extra phosphate group on the 5’GMP causes a significant increase in binding with F2. 
This may be due to enhanced binding interactions with the multiple lysine residues in the C-
terminal fingers.  
ESI-MS of [Pt(dien)(9-EtG)]2+ with F2 in a 1:1 ratio showed formation of a 1:1 adduct 
between the peptide and Pt-complex.  MS-MS of this adduct peak shows dissociation to 
reactants, indicating it is most likely that this adduct formation is facilitated by the π-π stacking 
interactions between the tryptophan and the platinated nucleobase, Figure 1.14.  Incubation of 
cis-[Pt(NH3)2(Guo)2]2+ (Guo = guanosine) with F2 showed formation of the 1:1 adduct 
[Pt(NH3)(Guo)2 / F2]3+.  The binding is weaker, however, than that of [Pt(dien)(9-EtG)]2+, most 
likely due to the steric hinderance of the cis oriented nucleosides [49].  
Figure 1.14.  ESI-MS of [Pt(dien)(9-EtG)]2+ mixed with F2 in a 1:1 ratio.  Inset shows 
proposed molecular recognition [51]. 
	   20	  
In these studies, trans-[PtCl(9-EtG)(py)2]+ was the only compound used capable of 
covalent interactions due to the presence of the substitution-labile chloride.  Due to the ‘soft’ 
nature of Pt(II), this compound has been shown to have a higher reactivity towards sulfur atoms 
(soft base) over nitrogen atoms (hard base), and it has also been shown to cause Zn ejection in 
model chelates.  In the presence of a 1:1 stoichiometric ratio of trans-[PtCl(9-EtG)(py)2]+, the 
ESI-MS of F2 showed numerous peaks pertaining to complex formation between F2 and 
[Pt(py)2].  Another peak corresponding to an adduct ([F2(Pt[py]2)2-Zn) shows two [Pt(py)]2 units 
bound to the protein with resultant loss of Zn.  Circular dichroism (CD) experiments revealed 
changes in the three-dimensional structure of the protein, which is consistent with the loss of 
tertiary structure due to Zn ejection [51].  Therefore, the proposed mechanism for attack of Pt-
nucleobase compounds on zinc fingers consists of two steps: 1) recognition through π-π stacking 
of tryptophan with platinated nucleobase and 2) covalent interaction followed by zinc ejection, 
Figure 1.15.  
 
Platinum–nucleobase compounds are also of interest as models for understanding the 
formation of DNA-zinc-finger protein crosslinks mediated by platinum compounds [6]. Relevant 
biological examples are (i) the use of transplatin to cross-link HIV-NCp7 to RNA [53] and (ii) 
Figure 1.15.  Proposed mechanism of zinc ejection from C-terminal peptide of the HIV-NCp7 
[51]. 
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ternary DNA-protein formation formed by DNA monoadducts of 2-amino-N-2-methylamino-
2,2,1-bicycloheptanedichloroplatinum(II) with the E. coli zinc finger-containing UVrAB repair 
protein [54] and (iii) ternary DNA-protein crosslinks mediated by tri- and tetrafunctional 
dinuclear platinum compounds with the UVrAB protein and Sp1 [6,55,56]. To further examine 
the covalent attachment of metal compounds to zinc finger proteins,  [PtCl(dien)]+ was reacted 
with NCp7(F2) [23]. ESI-MS studies showed formation of  {(ZF-Cl)-Pt(dien)} by substitution of 
the Pt–Cl bond by a zinc-thiolate with concomitant transfer of Cl to Zn, Figure 1.16 [23]. This is 
the first suggestion that “structural” zinc, specifically that of zinc fingers, may expand its 
coordination sphere [23].  
 
1.4  Gold complexes target zinc finger proteins 
It is of interest to expand the work of Pt(II)-nucleobase compounds to that of Au(III), as 
they are isostructural and isoelectronic. The thiol-rich nature of zinc fingers merits their 
investigation as specific targets of Au-drugs. Many studies have been reported on the reaction of 
Au(I)/Au(III) compounds with various zinc finger proteins. Franzman et al. studied the reaction 
of Et3P-Au-Cl with Cys2His2, Cys3H, and Cys4 zinc finger proteins [57]. UV/VIS spectroscopy 
Figure 1.16. Proposed structure of {(ZF-Cl)-
ML3)} adduct. ML3 = Pt(dien) [23]. 
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showed the presence of a thiolate to gold charge-transfer band and it was determined that Au(I) 
reacts with zinc finger peptides with a stoichiometry of one gold for every two cysteine residues. 
CD studies shown in Figure 1.17 show the difference in secondary structure of zinc finger, gold-
finger, and reduced/oxidized peptide. In every case, the gold-fingers have a more ordered 
structure than the corresponding apo-peptide, yet portray a less alpha-helical structure than the 
zinc finger protein, indicated by a decrease in the maximum at 190 nm and a blue shift in the 
minimum present at 205 nm [57]. It is well known that the secondary structure of these zinc 
finger proteins is integral to their ability to bind to DNA. Therefore, it is reasonable to propose 
that the loss in structure of the zinc finger protein upon zinc ejection and gold binding could lead 
to a loss of DNA binding and a loss of protein function. 
To test the hypothesis that the Au(I) drug aurothiomalate played a role in the inhibition of 
binding of certain transcription factors to regulatory elements in DNA, Handel et al. studied the 
interaction of a steroid hormone receptor, the progesterone receptor (PR), with its DNA response 
element (PRE) in the presence of aurothiomalate [58]. PR was used as a model zinc finger 
transcription factor containing two Cys4 zinc fingers. Studies showed that aurothiomalate 
inhibited binding of PR to PRE, with an IC50 of approximately 3 µM [58]. This is significant due 
Figure	  1.17.	  CD	  spectra	  of	  Et3P-Au-Cl reacted with (a) Cys2His2, (b) Cys3His, and (c) Cys4 
zinc finger proteins. Zinc fingers (n), gold-fingers (solid lines), reduced peptides (dashed 
lines), and oxidized peptides () [57].	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to the fact that 3 µM is within the range of serum concentrations achieved during treatment of 
rheumatoid arthritis. Also, 3 µM is significantly lower than Ki values reported for various 
enzymes inhibited by aurothiomalate [58]. To test the effect of aurothiomalate on PR-mediated 
transcription, the progestin-inducible expression vector pMSG-CAT was transfected into T-47D 
breast cancer cells. In the presence of 100 µM aurothiomalate there was 42±8% inhibition of 
chloramphenicol acetyl transferase activity. This shows that aurothiomalate can regulate gene 
expression and that inhibition of binding of a transcription factor to its response element is a 
likely mechanism of action [58]. 
Aurothiomalate, was shown to inhibit both TFIIIA (Transcription Factor for Polymerase 
IIIA) and Sp1 (both Cys2His2 zinc finger transcription factors) in the micromolar range [59]. 
ESI-MS studies with a peptide modeled after the third finger of Sp-1, Sp1(F3), showed release of 
Zn+2 and replacement with Au+1, Figure 1.18A, with the gold having a 4-fold higher binding 
affinity than zinc. Isotopic cluster analysis showed that the Au(I) bound to one thiol and one 
thiolate residue [58]. CD spectroscopy showed a change in secondary structure of the peptide 
A) B) 
Figure 1.18. (A) ESI-MS spectrum showing 60% gold-finger formation after addition of 
aurothiomalate to pre-formed zinc finger (2 eq. zinc) and (B) CD spectrum showing change 
in conformational structure upon formation of gold-finger [59]. 
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upon zinc ejection and concomitant gold binding. The CD spectrum of apo-Sp1(F3) showed 
features indicative of a random coil structure. Upon binding of Zn2+, the CD spectrum showed 
less negative ellipticity, a red-shift in the minimum, and a positive ellipticity between 190 and 
195 nm. The addition of aurothiomalate resulted in a slight red-shift of the minimum, however 
not to the degree caused by Zn2+; there was also a decrease in the maximum at 195 nm when 
compared to the zinc finger spectrum (Figure 1.18B). This indicates that the gold-finger has an 
ordered structure with different conformational features than zinc finger, specifically less α–
helical structure [59-61]. This is in agreement with what Franzman et al. observed with the Au(I) 
compound Et3P-Au-Cl discussed earlier.	   
Many Au(I) and Au(III) compounds have been studied with the zinc finger protein 
PARP-1 described earlier in this section. Mendes et al. studied the effects of metal-based drugs 
including platinum, ruthenium, and gold complexes [31]. The gold complexes included the Au(I) 
drug auranofin and two Au(III) compounds, [Au(phen)Cl2]+ and [Au(bipy)Cl2]+ (phen = 1,10-
phenanthroline and bipy = 2,2-bipyridine). To calculate IC50 values, PARP-1 was incubated with 
each compound at various concentrations for 24 hours before assessing its activity 
spectrophotometrically by measuring the incorporation of biotinylated poly(ADP-ribose) onto 
histone proteins. When compared to the reference PARP-1 inhibitor, 3-aminobenzamide, all Au 
compounds reported lower, more potent, IC50 values in the nanomolar range [31]. It is interesting 
to note, however, the Au(I) compound auranofin had an IC50 value one order of magnitude lower 
than both Au(III) compounds. Fourier transform ion cyclotron resonance mass spectrometry (FT-
ICRMS) studies were performed using the N-terminal domain of PARP-1 to investigate the 
nature of these compounds inhibitory effects. When reacted with apo-peptide, it was seen that the 
Au(III) compounds had a higher reactivity that any other compounds studied, binding up to three 
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Au ions. Isotope cluster analysis indicates that the first Au ion remains in the 3+ oxidation state, 
whereas the additional gold ions are reduced and bind as Au(I) [31]. Experiments were also 
performed in which the Au-compounds were added to pre-formed zinc finger protein as well as 
added simultaneously with zinc acetate to mimic competitive binding conditions. All results 
were similar; within minutes, an equilibrium between the Zn(II) and Au-bound species was 
Figure 1.19. ESI FT-ICR MS of (A) apo-ZF-PARP with zinc acetate and [Au(III)(bipy)Cl2]+ 
in a 1:2:2 ratio under competitive conditions (10 minute incubation), and (B) of pre-formed 
PARP zinc finger with subsequent addition of auranofin (24 h) in a 1:2:2 ratio. Notice the 3:1 
and 1:1 ratios of Au:Zn for Au(III) and Au(I), respectively [31].	  
A)	  
B)	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established. A ratio of Au- to Zn-bound protein was approximately 3:1 for Au(III) compounds 
and 1:1 for the reaction with auranofin, Au(I), indicating a higher binding affinity for Au ions 
than Zn(II) ions and a more efficient adduct formation for Au(III) ions than Au(I), Figure 1.19 
[31]. The lower binding affinity of Au(I) is in agreement with its lower IC50 value. This 
competition of Au for the same binding site of Zn could be reason for loss of zinc finger function 
and high inhibition of PARP-1 activity. 
Casini et al. have investigated the interaction of multiple Au(III) compounds, including 
Au(III) heterometallic compounds, as well as mono- and bi-nuclear Au(I) complexes with the 
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Figure 1.20. Au(III) and Au(I) compounds studied by Casini, et al. for their interaction with 
zinc finger PARP-1 [62,63]. 
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zinc finger protein PARP-1; the structures of these compounds are shown in Figure 1.20 [61,62]. 
All compounds studied showed interesting cytotoxicity effects in human ovarian carcinoma cell 
lines, both sensitive  (A2780) and cisplatin resistant (A2780/R), human mammary carcinoma 
cells (MCF7), and non-tumorogenic human embryonic kidney cells (HEK293). Compounds 
containing the 2-(2’-pyridyl)imidazolate ligand, compounds I and V in Figure 1.20, showed 
selectivity towards the cancer cells with respect to the non-tumorigenic cells, and the dinuclear 
and trimetallic compounds were more cytotoxic than their mononuclear counterparts [62,63].  
Interestingly, the heterometallic compounds VII and VIII were found to not react with plasmid 
DNA [62]. This, along with the fact that these Au-complexes had significantly higher 
cytotoxicity than cisplatin in the resistant A2780/R and MCF7 cell lines, supports the idea of 
different mechanisms of action than cisplatin [62].  
Further studies, therefore, were performed to investigate their interaction with the zinc 
finger protein PARP-1, due to its involvement in DNA repair and relevance to the mechanism of 
cancer cell resistance to cisplatin. The trinuclear Au-Fe compound VII (Figure 1.20) was found 
to be a potent inhibitor of PARP-1 with an IC50 value of 1±0.5 µM [62]. The active dinuclear 
compound V (Figure 1.20) was able to inhibit PARP-1 activity by 24% in A2780 cell extracts. It 
did not, however, have any effect in A2780/R cell extracts, indicating other proteins are 
competing with PARP-1 for gold binding [63]. An ESI-MS study of a 3:1 reaction of V with 
ubiquitin (Ub) after 1 hour incubation showed two main species; ubuiquitin and a gold-
containing species, Ub-AuPPh3, in which the 2[(2’-pyridyl)imidazolato ligand was completely 
dissociated [63].  
Gold(I) complexes of the formula [(PPh3)Au(L)]+ with L = substituted N-heterocycle 
pyridine have been studied by Abbehausen et al. to target the HIV nucleocapsid zinc finger 
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protein, NCp7 [64]. As stated earlier for Pt(II)-nucleobase compounds, the N-heterocycle ligand 
is used to specifically target the tryptophan residue in the C-terminal finger of NCp7. 
Fluorescence quenching studies showed the Ph3P-Au-DMAP (DMAP = 4-
dimethylaminopyridine) compound to π-stack effectively with free N-acetyltryptophan with a Ka 
of 25.0x103 M-1 [64]. ESI-MS studies of these Au(I) compounds with the C-terminal finger (F2) 
of NCp7 show the presence of a long-lived {(PPh3)Au}-S-peptide species resulting from 
dissociation of the pyridine ligand by zinc-bound cysteine followed by displacement of Zn+2, 
Scheme 1.2 [64]. Interestingly, this species is similar to that reported by Serratrice, et al. in the 
study of dinuclear Au(I) compounds with the model peptide ubiquitin described earlier [64]. 
 
The reactivity of NCp7(F2) was then compared to that of the Cys2His2 transcription 
factor, Sp1(F3) (F3 = zinc finger 3). As seen previously for the Au(I) drug aurothiomalate, 
immediate zinc ejection was observed followed by replacement of Au(I). No apoSp1F3-
{Au(PPh3 )} was observed for any of the compounds studied; however, when L = DMAP was 
used, ESI-MS peaks were present corresponding to a mass of [apoSp1F3-{(PPh3)Au2}] implying 
the presence of one coordinated Au(PPh3) unit and one Au without any starting ligands [64]. The 
reaction with the Sp1 finger is thus more ligand-specific since no evidence for any equivalent 
Au(PPh3) species is seen for any of the other Au(I) compounds studied. CD spectra show clear 
Scheme 1.2. Schematic representation of the interaction of Au(I)-N-heterocycle compounds 
with NCp7(F2) [64]. 
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differences in the conformation changes of NCp7(F2) and Sp1(F3) after reaction with the Au(I)-
N-heterocycle compounds. The results suggest the possibility of electronic and steric variations 
of “carrier” group PR3 and “leaving” group L as well as the nature of the zinc finger in 
modulation of biological activity [64]. 
 The interaction of [AuCl(dien)]Cl2 with NCp7(F2) has also been studied by ESI-MS and 
CD [23]. After 5 minutes of incubation of a 1:1 reaction, MS showed total loss of ligands and 
binding of 2 and 4 gold ions (i.e. formation of “gold-finger”) with Zn2+ ejection [23].  Whereas 
for Pt(II) direct electrophilic attack on the cysteine sites may occur, it is possible that in the 
presence of [AuCl(dien)]Cl2 a redox reaction can occur, producing Au(I) species as well as 
oxidized peptide [23].  The nature of the gold ion upon binding to the protein is unknown; 
however based on previous studies with other Au(III/I) compounds discussed above it is possible 
that Au(III) reduces to Au(I) followed by release of bound ligand and incorporation of the gold 
Figure 1.21.  CD spectra for the reaction of NCp7(F2) and [MCl(dien)]n+ (M=Pt(II), Pd(II), 
and Au(III)) [23]. 
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ion as Au(I)  [23]. The CD spectrum of NCp7(F2) is characterized by a broad band with a slight 
positive maximum at 210 nm and a stronger negative band at 200-205 nm.  In the absence of 
zinc there is an increase in the negative band as well as a slight blue shift indicative of a random 
coil.  In the presence of [AuCl(dien)]Cl2, after 15 minutes of incubation the CD spectrum 
resembles that of free peptide, Figure 1.21 [23]. This suggests complete zinc ejection, which is in 
agreement with the ESI-MS results.   
 
1.5 Chemistry of [AuCl(dien)]Cl2 
 [AuCl(dien)]Cl2 was first prepared in 1963 and the crystal structure was solved in 1986, 
Figure 1.22 [65]. Three of the four equatorial sites around the gold(III) metal center are occupied 
by the nitrogens from the dien ligand (Au-N bond length is 2.04 Å ), and the fourth site is 
occupied by a chlorine atom (Au-Cl bond length is 2.28 Å).  The two chloride counterions are 
situated in the axial positions, with an elongated Au-Cl distance of 3.15 Å [65].  The X-ray 
absorption spectrum confirmed the oxidation state of Au to be 3+ indicated by an intense peak 
Figure 1.22. ORTEP diagram showing simplified crystal structure (hydrogen atoms omitted) 
of [AuCl(dien)]Cl2 [65]. 	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attributed to the 2p to 5d electronic transition that occurs for the Au(III) d8 species, but not for 
the d10 Au(0) or Au(I) species [65].  
When in aqueous solution, [Au(dien)]3+ has been shown to lose a proton from one of the 
nitrogens on the dien with a pKa value of 4.0 in 0.5M ClO4- according to the following equation 
[66,67]: 
[AuCl(dien)]2+ ßà  [Au(dien-H)Cl]+ + H+   
Nardin et al. confirmed by single crystal x-ray diffraction of [AuCl(dien)]Cl(ClO4) and  
[AuCl(dien-H)]Cl(ClO4) that the deprotonation occurs from the central, secondary nitrogen, with 
a Au-Cl bond length of 2.33 Å, significantly longer than that of 2.273 Å  for the parent amine 
complex [68]. In the protonated complex, the four donor atoms are essentially in a plane; a 
pronounced tetrahedral distortion of the coordination geometry was observed for the dien-H 
species [63].   
The substitution reaction of -Cl by other nucleophiles has been studied for both the 
protonated and deprotonated Au(III)-dien compounds, [AuCl(dien)]2+ and [AuCl(dien-H)]+, 
respectively. Second-order rate constants for chloride exchange as well as a ring-opening 
mechanism were predicted for [Au(dien)Cl]2+ using water and strong nucleophiles, N3- and SCN-
, Scheme 1.3 [69]. For the dien-H complex, the Au-Cl bond is weaker than the Au-N2 bond due 
to its trans position to the deprotonated secondary amine, and the Au-N1,N3 bonds are also 
weaker. However, Au-Cl bond order decreases 24% compared to only 8% for the Au-N1,3 
bonds. Therefore, it is expected that the ring-opening should be less likely at pH values above the 
pKa of 4.0 due to rapid chloride exchange [69]. For the aquation reaction, which is important for 
the activation of metallodrugs, chloride exchange was found to be much faster in neutral and 
basic media, k2 ~ 0.4 M-1s-1 versus k2 ~ 10-7 M-1s-1 for pH < 4 [69]. The substitution reactions, 
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including ring-opening, were predicted to be faster in the presence of stronger nucleophiles, N3- 
and SCN-, with rate constants for chloride exchange being 10.1x101 and 5.5x103 M-1s-1, 
respectively [69]. Interestingly, the ring opening reactions were also predicted to proceed at rapid 
reaction rates for N3- and SCN- nucleophiles, however these processes are highly unfavorable 
when compared to chloride exchange [69]. 
This pH dependency of [AuCl(dien)]Cl2 can be observed by 13C and 1H NMR 
Spectroscopy.  Figure 1.23 shows NMR spectra of 10 mM [AuCl(dien)]Cl2 in D2O at various pH 
values [67].  In the 13C NMR, Figure 1.23A, both resonances were pH dependent with peak 1 
(corresponding to atoms Cc and Cb) showing a downfield shift of 4.9ppm and peak 2 
(corresponding to atoms Ca and Cd) an upfield shift of 1.5ppm upon pH increase from pH 3 to 
6.5.  These shifts were fitted to a pKa value of 4.74±0.04 and attributed to the deprotonation of 
the central secondary amine group.  Similar pH dependent results were seen for 1H NMR as 
shown in Figure 1.23B.  Peak 1 (assigned to the methylene protons of Cb and Cc) was broad over 
Scheme 1.3. Various substitution reactions of [AuCl(dien)]2+ with water and strong 
nucleophiles [69]. 
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the whole pH range and shifted 1.09 ppm upfield from pH=3 to 7.    Peak 2 (assigned to protons 
Ca and Cd) had a smaller shift difference.  This peak was broad at low pH values, but turned into 
a sharp triplet at pH 4 and above.  The pH dependent shifts of these peaks were again attributed 
to the deprotonation of the central secondary amine group [67]. 
 
The addition of methyl groups to the tridentate diethlyenetriamine ligand further adds to 
the steric hindrance of the compounds as well as decreases substitution reaction rates [70]. 
Methylated dien complexes including [AuX(Me2dien-H)]+ (Me2dien = N,N-
dimethyldiethylenetriamine), [AuX(Me4dien)-H]+ (Me4dien = 1,1,7,7-
tetramethyldiethylenetriamine), and [AuX(Et2dien)-H]+ (Et2dien = N,N-
diethyldiethylenetriamine) were synthesized by Fant et al. and the dissociation constants of their 
conjugate acids were measured, as shown in Table 1.1 [71]. Interestingly, as the number of alkyl 
AuHN
NH2
NH2
Cl
Ca
Cb
Cc
Cd
A)	   B)	  
Figure 1.23. 13C (A) and 1H (B) NMR of [AuCl(dien)]Cl2 in D2O at various pH values. The 
numbering system for the carbon atoms is shown in the center figure [67]. 	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groups increase, the pKa of the center nitrogen decreases (the acidity of the complex increases). 
The much higher acidity of the [AuCl(Et4dien)]PF6 (Et4dien = N,N,N'',N''-
tetraethyldiethylenetriamine) compared to [AuCl(dien)]Cl2 is attributed to solvation effects 
[71,72]. The more positive acid is more solvated than its conjugate base for both alkyl-
substituted and unsubstituted complexes. However, this difference, known as the energy of 
solvation, is smaller for the substituted complex because of its larger size. This results in a higher 
acidity for the alkyl-substituted ion [71,72]. 
 
 
 
 
 
 
 
 
Kinetic studies showed the methylated dien complexes [Au(Me2dien)Cl]PF6 and 
[AuCl(Me4dien)]PF6 to undergo bromide substitution by the usual two-path mechanism common 
to low-spin d8 metal complexes, a simple displacement mechanism proceeding via a trigonal-
bipyramidal-based transition state in which the entering ligand occupies an equatorial site, Figure 
1.24A [71,73]. The ligand exchange rate was found to be higher for [AuCl(Et2dien-H)]+ when 
bromide was the entering group; substitution was hypothesized to proceed via a ring-opening 
mechanism, Figure 1.24B, as described earlier [71]. It was postulated that this increase in 
substitution rate was due to either (1) the role of the higher effective positive charge on the gold 
Table 1.1. Acid dissociation constants for 
methylated Au(III)-dien complexes [71]. 
Complex pKa 
[AuCl(dien)]Cl2 4.7 [66] 
[AuCl(Me2dien)]PF6 4.2 
[AuCl(Me4dien)]PF6 3.8 
[AuCl(Et2dien)]PF6 3.6 
[AuCl(Et4dien)]PF6 2.2 
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metal center in the complex with the 1,1-Et2-dien-H ligand and/or (2) a distinct substitution 
mechanism passing through an open-ring intermediate, where the Au-N(Et)2 bond is broken [70].  
Gold(III) tetranitrogen donor complexes have previously been synthesized using 
porphyrin and cyclam-based ligands, see Figures 1.3 and 1.4 [5,6,74]. Nitrogen-donor planar 
amines are good σ-donor and π–acceptor groups, and the kinetics of L(N-heterocycle) 
substitution by Cl− in AuCl3L + Cl− à  [AuCl4 ]−  + L showed a linear relationship between the 
basicity of the leaving group and the reactivity with respect to chloride substitution, with the rate 
of displacement decreasing with an increase in ligand basicity [75]. To investigate the interaction 
of [AuCl4]- with DNA, the complex [AuCl3(9-EtG)] was synthesized and isolated. X-ray 
crystallography confirmed binding of 9-EtG to the Au(III) metal center via N7 of the purine ring 
[76]. Solution studies show that guanosine(inosine) monophosphate (5’GMP/IMP) and L-His 
bind with high affinity to gold(III) centers [77]. The reactivity of the studied nucleophiles was L-
His > 5’-GMP > 5’-IMP > inosine [77].  
 
Figure 1.24. (A) Energy diagram for synchronous bimolecular substitution of X by Y and 
(B) Scheme showing ring-opening mechanism for [Au(Et2dien-H)Cl]+ [71,75]. 
A) B) 
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1.6 Dissertation outline 
It is the goal of this dissertation to combine the chemistry of [AuCl(dien)]2+  and the 
previously mentioned [AuCl3L] compounds and to synthesize novel AuN4 species, where three 
of the nitrogen donors are from the tridentate diethylenetriamine (dien) ligand and the fourth is a 
planar amine/heterocycle ligand (Figure 1.25). The dien ligand acts as a “carrier ligand”, 
allowing for the effects of only one leaving group, either a substitution-labile Cl- or a 
substitution-inert nitrogen donor of a planar ligand, to be studied.  The [ML(dien)]n+ coordination 
sphere also allows the study of the effect of metal ion on the kinetics of the interaction. MN4 
compounds serve two purposes: 1) templates for non-covalent molecular recognition through 
tryptophan stacking, 2) serve to examine the factors involved in “activation” of the inert 
coordination sphere and covalent binding upon initial recognition. 
 
 
MR2N
NR
NR2
L
n+
M = Pt(II) or Au(III) 	  
L = Leaving group  
   = Cl or N-donor 
R = H, CH
3
 
Steric Hindrance 
R = H, CH
3
 
Figure 1.25. [ML(dien)]n+ structure allows for systematic reactivity studies. 
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This dissertation discusses the synthesis, characterization, and reactivity of novel 
AuIII(dien)(N-heterocycle) compounds designed with the goal of slowing down the reaction with 
the NCp7 zinc finger protein, aiding in improving their selectivity through targeting the π-
stacking interaction with tryptophan. The term “selectivity” is used often throughout this 
dissertation. As previously discussed, due to the high thiol affinity of gold, Au(I) and Au(III) 
compounds react rapidly with sulfur containing peptides. If our compounds are not selective, 
they can react extensively with multiple proteins containing Cys residues, for example serum 
proteins such as HSA (human serum albumin), and essentially become inactive before reaching 
the desired target. Therefore, it is important that we synthesize compounds that are selective to 
one particular protein, in our case the HIV NCp7 zinc finger protein.   
Because these compounds are the first isolated AuIIIN3(N-purine)/heterocycle 
compounds, it is necessary to study their chemistry in solution. The synthesis and pH 
dependency of these compounds is discussed in depth in Chapter 2. The enhanced stability of the 
Au(III) metal center by the addition of a more inert N-donor is also discussed.  
Chapter 3 discusses the reactivity of the Au(III)-dien-nucleobase compounds with model 
amino acids including the planar aromatic amino acid N-Acetyltryptophan and the sulfur-
containing amino acids N-Acetylmethionine and N-Acetylcysteine. As previously discussed, 
Au(I)/(III) compounds have a high thiol affinity as a result of their ‘soft’ nature. The addition of 
a more inert N-donor as a leaving group, resulting in a AuN4 coordination sphere, slows down 
this reaction. Comparison of the π-stacking ability of [Au(dien)(DMAP)]+3 with its Pt(II) and 
Pd(II) analgues is highlighted in Chapter 4.  
Study with the model amino acids gives greater insight into how the Au(III) compounds 
will interact with the zinc fingers themselves, also discussed in Chapter 3. Zinc finger cysteinates 
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vary in chemical reactivity, and nucleophilicity is very dependent on the nature of the Zn binding 
core [ 55]. Therefore, the Cys3His zinc finger NCp7(F2) and the Cys2His2 zinc finger Sp1(F3) 
were both studied to determine any difference in reactivity and possible binding selectivity. 
Lastly, studies were expanded to that with the full NCp7 zinc finger protein. Chapter 5 compares 
the reactivity of [M(dien)(9-EtG)]n+ where M = Au(III), n=3 and Pt(II), n=2. This chapter ends 
with the suggestion that the Au(III)-9-EtG compound may induce protein crosslinking. Appendix 
A is a review on cobalt- and platinum- DNA-protein crosslinks as probes for zinc finger 
conformation and reactivity. 
 The majority of the published work consists of studies performed with [Au(dien)(9-
EtG)]3+ and [Au(dien)(DMAP)]3+, however many additional Au(III)-N-heterocycle compounds 
were synthesized, as is discussed in Chapter 6. This chapter focuses on synthetic procedures as 
well as characterization techniques, both successful and unsuccessful. Experimental results are 
discussed, giving additional information about the solution behavior and reactivity of these 
compounds. 
Published work is included in a format as close as possible to that in which it was 
published. 
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2.1 Abstract: 
Novel AuIII(dien)(N-heterocycle) compounds, including the first AuIIIN3(N-purine) 
examples are reported.   The acidity of the dien ligand is affected by the nature of the fourth 
ligand as a leaving group.  The metal center of [Au(dien)(N-heterocycle)]3+ compounds was 
shown to be more stable to reduction than when Cl− is present, with consequences for reactivity 
with biomolecules: specifically significant enhancement of π-π-stacking interactions with 
tryptophan relative to isostructural and isoelectronic platinum(II) and palladium(II) compounds. 	  
2.2 Introduction: 	   We are currently exploring the use of small-molecule coordination compounds as 
electrophiles to alter zinc finger peptide structure and function [1-2]. Electrophilic attack by 
[MCl(dien)]n+ (M = PtII, PdII, AuIII; dien = diethylenetriamine) on the C-terminal finger of HIV 
Nucleocapsid NCp7(F2) results in conformational changes and ejection of Zn2+ [3]. Platinated 
nucleobases such as [Pt(dien)(9-EtG)]2+ (9-EtG = 9-ethylguanine) with a more substitution-inert 
nitrogen donor as  the “leaving group” stack effectively in a noncovalent manner with tryptophan 
of NCp7(F2) [4]. We therefore wanted to study the more reactive gold(III) system for 
comparison as well as to examine models for the interaction of [AuCl(dien)]2+ with DNA [5]. In 
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this paper we report the synthesis and characterization of [AuIII(dien)X] chelates with purines 
and nitrogen-donor heterocycles, the first isolated AuIIIN3(N-purine)/heterocycle compounds 
(Figure 2.1). The acidity of the primary and secondary amines is a long-recognized feature of 
[AuCl(dien)]2+ chemistry [6-11]. The presence of the pyridine or purine affects this acidity and 
the redox properties of the gold(III) complex as a whole. These differences further translate to 
variations in reactivity with biomolecules, where for 9-EtG, tryptophan stacking is significantly 
enhanced over that of the platinum(II) and palladium(II) analogs.  
 
Tetranitrogen donor complexes of gold(III) are known for porphyrin- [12] and cyclam-
based macrocycles [13] but the [AuIII(dien)X] species discussed herein are the first to be 
synthesized where X is a purine or planar N-heterocyclic ligand. Nitrogen-donor planar amines 
are good σ-donor and π-acceptor groups, and the kinetics of L(N-heterocycle)  substitution by 
Cl− in AuCl3L  + Cl− à [AuCl4]− + L showed a linear relationship between the basicity of the 
leaving group and the reactivity with respect to chloride substitution [14]. The complex 
[AuCl3(9-EtG)] has been isolated, confirming Au−N7 binding [15], and solution studies show 
Figure 2.1.  Structures of [AuIII(dien)L]2+/3+ chelates studied (A) and the C-terminal 
finger of HIV Nucleocapsid NCp7(F2) (B). 
A) B) 
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that guanosine(inosine) monophosphate and histidine bind with high affinity to gold(III) centers 
[16]. 
 
2.3	  Results	  and	  Discussion	  
The reaction of [AuCl(dien)]Cl2 with 9-EtG in the presence of 3 equiv. of AgNO3 
afforded orange [Au(dien)(9-EtG)](NO3)3. NMR and potentiometry show three major distinct 
species for this complex over a wide pH range (Figures 2.2-2.4). The initial pH* of a 10 mM 
Figure 2.2. 1H NMR spectra showing (A) H8 proton of 9-EtG and (B) dien region in 
[Au(dien)(9-EtG)](NO3)3 over pH range. 
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aqueous solution is 2.63, where pH* is the measurement of the pH meter. The 1H NMR spectrum 
shows that as the pH is increased the purine H8 signal first broadens and shifts upfield (Figure 
2.2A). This is followed by the appearance of sharp peaks in the intermediate pH 5-7 range and 
eventually purine dissociation at basic pH.  Potentiometric titration also showed three midpoints 
with approximate pKa values of 3.3, 5.3, and 7.5 (Figure 2.3).  
	  
The  pKa for deprotonation of the secondary central amine in [AuCl(dien)]2+ is in the 
range of 4.0-4.7 depending on conditions [7,11]. The dien region of the 1H and 13C NMR spectra 
for [Au(dien)(9-EtG)](NO3)3 was similar to that reported for [AuCl(dien)]Cl2 (Scheme 2.1 and 
Figures 2.2B and 2.4) [11].  The 13C chemical shifts are a sensitive diagnostic of chelate 
deprotonation [11] and were fitted in this case to a pKa of 3.3 for the central nitrogen on the dien.  
At pH* > 6.3, new signals appear, attributed, as for [AuCl(dien)]Cl2, to hydrolysis of the 
gold(III) species [11], also supported by dissociation of 9-EtG at basic pH. A reasonable 
explanation for the three species observed is therefore a “fully” protonated species, a species 
with dien-H but N1 protonated, and a fully “deprotonated” species. The pKa of the N1H of 9-EtG 
Figure	  2.3.	  pH titration curve of [Au(dien)(9-EtG)](NO3)3 shows three 
distinct equivalence points over broad pH range.	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(9.57) is reduced to 8.17 in [Pt(dien)(9-EtG)]2+ [17]. Binding to gold(III) further decreases this 
value to 5.3.   
	  
	  
 To confirm these interpretations, analogous [AuIII(N-Medien)X] (N-Medien = 2,2’-
diamino-N-methyldiethylamine) compounds were prepared. In comparison to the free ligand, the 
1H NMR N-Me peak shifts significantly downfield by approximately 1.35 ppm for both Cl− and 
9-EtG. The pH dependency of the 1H NMR spectrum shows only two major peaks, as expected 
(Figure 2.5).  At pH* 2.96, one peak is present, likely representing the fully protonated species.  
Figure	   2.4.	   13C NMR spectrum showing dien region of [Au(dien)(9-EtG)](NO3)3 over a 
broad pH range.  Peak 1 corresponds to Cb and Cc and peak 2 corresponds to Ca and Cd.  	  
Scheme 2.1.  Proposed structures for [Au(dien)(9-EtG)](NO3)3 over broad pH range 
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At pH* 4.05, an additional upfield peak appears, indicating the N1H deprotonation.  At pH* > 
5.6, the 9-EtG ligand is completely dissociated. A pKa of 5.7-6.8 has been assigned for 
deprotonation of the primary amine in [AuCl(N-Medien)]2+ [18]. Such deprotonation may 
destabilize the Au-9EtG bond. 
 
 
Figure	  2.5.	  1H NMR spectra of [Au(N-Medien)(9-EtG)](NO3)3 at various pH values	  	  
Figure	   2.6.	   Absorption spectra of [Au(dien)(DMAP)]Cl3 over pH range showing one 
isosbestic point for deprotonation of the chelate ligand dienàdien-H. 	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We further prepared [Au(dien)(DMAP)]3+ [DMAP = 4-(dimethylamino)pyridine)] 
because the more basic DMAP (4-Me2Npyr) has a pKa of 9.1, compared to that of 2.7 for 9-EtG 
[17]. The UV/Vis spectra in the 3-5 pH range shows one isosbestic point (Figure 2.6).  In the 13C 
NMR spectrum at pH* up to 6.4, two 13C signals were observed, assigned to Cb and Cc (Peak 1) 
and Ca and Cd (Peak 2) (Figure 2.7).  The pH dependence of the peak shifts were fitted to a pKa 
of 4.7 for the secondary central amine of the dien, higher than that for 9-EtG but similar to 
[AuCl(dien)]2+ [7,11]. Additional peaks appear at pH* > 6, peaks 1a and 2a in Figure 2.7, but the 
DMAP ligand remains bound, thus protecting the compound from hydrolysis (Figure 2.8).  The 
extra peaks may be due to deprotonation of the primary amines.  
 
The contrast between X = Cl− and the N-heterocycle as the fourth ligand is clearly seen in 
the [Au(N-Medien)X]n+ case. The 1H NMR N-Me peak in the DMAP complex is shifted 
downfield similar to Cl− and 9-EtG. In excess Cl−, chelate displacement occurs for [AuCl(N-
Figure 2.7. 13C NMR chemical shift values of dien C’s versus pH for 50 mM 
[Au(dien)(DMAP)]Cl3 in D2O and proposed structures over pH range shown.  	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Medien)]2+ by a ring-opening mechanism with a large absorption band at 317 nm indicative of 
production of [AuCl4]− [18]. A similar trend is seen at low pH even in absence of Cl-, with a large 
absorption band at 310 nm (Figure 2.9A).  The development of this band is not seen for the 
DMAP case, suggesting that no ring opening occurs and that the N-Medien ligand is stabilized 
Figure 2.8.  1H NMR spectra of [Au(dien)(DMAP)]Cl3 over broad pH range.  The chelate 
dien region is shown in (A) and DMAP ligand region is shown in (B) giving evidence that 
DMAP does not dissociate at high pH.   	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by the DMAP ligand (Figure 2.9B). At low pH*, one dien N-Me peak is present in the 1H NMR 
spectrum of both compounds, with a new peak appearing 0.15 ppm upfield at higher pH* (Figure 
2.10).  At pH* 6.1, these peaks are present at 50:50 integration, suggesting that the pKa of both 
compounds is ~6.1 under these conditions and indicating deprotonation of the primary amines on 
Figure 2.9.  Absorption spectra of 1 mM [AuCl(N-Medien)]Cl2 (A) and 1 mM [Au(N-
Medien)(DMAP)]Cl3 (B) at various pH values. 	  
	   53	  
Figure 2.10. 1H NMR Spectra of [AuCl(N-Medien)]Cl2 (A) and [Au(N-Medien)(DMAP)]Cl3 
(B) over broad pH range. Upon further expansion of aromatic region of DMAP ligand (C), 
additional peaks can be seen at pH*>6.5 (inset). Red circles indicate free DMAP. 	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the N-Medien ligand, as reported [18]. At high pH*, the DMAP ligand remains bound to the 
gold(III) center (Figure 2.10C). 
The basic and more substitution-inert N-donor stabilizes the gold(III) metal center.  
Cyclic Voltammetry (CV) of [AuIII(dien)X] (X = Cl−, 9-EtG and DMAP)  in phosphate buffer (to 
maintain a constant pH for all compounds) showed only one peak indicating a one-step reduction 
of AuIII/Au0 but with more negative reduction potentials for the nitrogen-donors when compared 
to the AuN3Cl species, indicating a more stable metal center (Table 2.1). CV in water gave two 
reduction peaks for separated AuIII/AuI and AuI/Au0 steps. Stabilization was not observed for 
[Au(N-Medien)(9-EtG)]3+ attributed to the observed dissociation of the purine ligand, while the 
low peak potential for [Au(N-Medien)(DMAP)]3+ at pH 7.4 may suggest that deprotonation of 
the primary amines affects the stability of the metal center.   
 
 
 
 
 
 
 
 
A primary reason for the synthesis of these compounds has been to compare their 
potential biological properties with those of their isoelectronic and isostructural platinum 
analogs. Fluorescence studies with tryptophan, a planar amino acid present in the C-terminal 
Table 2.1. Peak Potential Values (vs. Ag/AgCl) for the 
reduction of Au(III) complexes at a Platinum Electrode 
Complexa Ep b (V) Ep1 c (V) Ep2 c (V) 
[AuCl(dien)]2+ -0.280 0.1 -0.418 
[Au(dien)(9-EtG)]3+ -0.349 0.064 -0.446 
[Au(dien)(DMAP)]3+ -0.328 N/A -0.563 
[AuCl(N-Medien)]2+ -0.232 0.043 -0.407 
[Au(N-Medien)(9-EtG)]3+ -0.263 0.047 -0.358 
[Au(N-Medien)(DMAP)]3+ -0.238 0.0482 -0.5504 
a Anions omitted for clarity. b 50 mM Phosphate Buffer, 4mM 
NaCl pH=7.4. c H2O, 0.1M NaCl  
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finger of the NCp7-HIV Zn finger (Table 2.2) shows that the π-stacking affinity of the 
AuIII(9EtG) compounds is increased over their platinum(II) and palladium(II) analogs [19-20].  
All DMAP compounds give Ka values significantly higher than those for their direct 9-EtG 
analogs, reflecting the greater basicity of the  DMAP ligand [21]. The low Ka for [Au(N-
Medien)(9EtG)]3+ in Tris buffer, pH 7.4 (but not in water) may be explained again by the 
dissociation of the 9EtG at biological pH.   
 
 
 
 
 
 
 
 
 
 
 
2.4 Experimental  
Materials and Reagents:  N-Medien was obtained from TCI America; all other materials were 
obtained from Sigma Aldrich, USA. Purity of all compounds was confirmed by 1H NMR 
Spectroscopy and Elemental Analysis (performed by QTI Laboratory, USA). 
NMR Spectroscopy:   
1H NMR spectra were obtained on a Varian Mercury-300MHz Spectrometer. 13C NMR spectra 
Table 2.2. Association Constants Obtained from Eadie-Hofstee 
Plots of N-AcTrp with different Au(III) quenchersa 
Compound Ka x 103 M-1 SD 
free 9-EtG 3.319 0.119 
[Pt(dien)(9-EtG)]2+ 719,20 0.119 
[Pd(dien)(9-EtG)]2+ 5.119 0.319 
[Au(dien)(9-EtG)]3+ 16.7 (16.6)b 1.5 (1.9) 
[Au(N-Medien)(9-EtG)]3+ 10.0 (16.7) 0.4 (0.5) 
free DMAP 29.0 1.1 
[Pt(dien)(DMAP)]2+ 25.020 0.920 
[Au(dien)(DMAP)]3+ 25.5 (26.5) 0.3 (0.9) 
[Au(N-Medien)(DMAP)]3+ 31.2(26.1) 0.8 (0.3) 
a In Tris HCl buffer, pH=7.4. Anions omitted for clarity.  
b Values in parenthesis were obtained in water.  
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were obtained on a Bruker AVANCEIII 600MHz instrument. Chemical shifts were referenced to 
the residual signal in D2O (4.80ppm). For pH dependency experiments, 10-12 mM and 50 mM 
solutions were prepared in D2O for 1H and 13C NMR respectively. pH was adjusted using 1 M 
DNO3 and 1 M NaOD; 0.1 M solutions were used for tighter pH ranges. Readings of the pH 
meter for D2O solutions were not corrected for deuterium isotope effects and are designated as 
pH* values.  
UV/VIS Spectroscopy:  Experiments were carried out on a JASCO V-550 UV/VIS 
Spectrophotometer. For pH dependency experiments, 1 mM solutions were used and pH was 
adjusted using 0.1 M NaOH and 0.1 M HNO3/HCl. 
Fluorescence Spectroscopy:  Methods were adapted from those previously published [19]. A 3 
mL solution of N-AcTrp (5 µM) in 20 mM Tris-HCl buffer was titrated with aliquots of the 
corresponding quenching compound (7.5 mM) in the range [quencher]/[N-AcTrp]) 1-10, rather 
than 10-100 as previously reported.   
Potentiometric Titration:  Potentiometric titrations were performed using a Metrohm 798 MPT 
Titrino Autotitrator with Tiamo v 2.2 software. A 1mM solution of each compound in water was 
prepared.  25mL of water was added to allow the electrode to be fully submerged in solution.  
Aliquots of 0.01M NaOH was used as titrant.  
Cyclic Voltammetry:  Cyclic voltammetry experiments were conducted with a CH Instruments 
Potentiostat using a three-electrode cell having a platinum disk working electrode (1.7 mm in 
diameter), a platinum mesh counter electrode, and a Ag/AgCl (0.1 M KCl) reference electrode. 
All measurements were performed on solutions degassed with nitrogen for 10-15 minutes.  
Measurements were run in both 50 mM phosphate buffer (4 mM NaCl, pH=7.4) and water (0.1 
M NaCl). 
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[AuCl(dien)]Cl2 was prepared as previously reported [23].  Ep (50mM Phosphate buffer, 4mM 
NaCl pH=7.4) = -0.280 V; EP (water, 0.1M NaCl) = 0.1, -0.418 V. 
[Au(dien)(9-EtG)](NO3)32H2O was prepared by reacting [AuCl(dien)]Cl2 with 0.98 
equivalents of 9-EtG and 2.8 equivalents of AgNO3 in water in the dark at room temperature for 
3 days.  The reaction mixture was filtered to remove precipitated AgCl, and the orange filtrate 
was evaporated to dryness.  Acetone was added to precipitate the orange product (78% yield) 
which may be crystallized from H2O/acetone. Anal.	   Calcd.	   for	   C11H26O12N11Au:	   	   C,	   18.84;	  H,	  3.74;	  N,	  21.97%.	  	  Found:	  	  C,	  19.01;	  H,	  3.32;	  N,	  21.77%.	  At 1mM (pH=3.54): λmax1=204 nm, log 
ε1=4.79; λmax2=248 nm, log ε2=4.25; λmax3=279 nm, log ε3=4.04; λmax4=362 nm, log ε4=3.06. Ep 
(50mM Phosphate buffer, 4mM NaCl pH=7.4) = -0.349 V; EP (water, 0.1M NaCl) = 0.064 V, -
0.446 V. 
[Au(dien)(DMAP)]Cl3H2O was prepared by reacting [AuCl(dien)]Cl2 with 0.98 equivalents of 
DMAP  in water at room temperature for 1 hour.  Reaction mixture was evaporated to 
dryness.  Acetone was added to precipitate orange product (85% yield) which may be 
crystallized from H2O/acetone.  Anal.	   Calcd.	   for	  C11H25AuCl3N5O:	  	   C,	   23.78;	   H,	   4.72;	   N,	  12.60%.	  	   Found:	  	   C,	   23.79;	   H,	   4.65;	   N,	   12.74%.	    At 1mM (pH=5.19): λmax1=195 nm, log 
ε1=4.31; λmax2=211 nm, log ε2=4.3; λmax3=278 nm, log ε3=4.33; λmax4=380 nm, log ε4=3.19. Ep 
(50mM Phosphate buffer, 4mM NaCl pH=7.4) = -0.328 V; EP (water, 0.1M NaCl) = -0.563 V. 
[AuCl(N-Medien)]Cl2 was prepared as previously reported [18]. Ep (50mM Phosphate buffer, 
4mM NaCl pH=7.4) = -0.232 V; EP (water, 0.1M NaCl) = 0.043 V, -0.407 V. 
[Au(N-Medien)(9-EtG)](NO3)32H2O was prepared analogously to [Au(dien)(9-
EtG)](NO3)32H2O, using [Au(N-Medien)Cl]Cl2 as the starting material (61% yield).  Anal. 
Calcd. for C12H28AuN11O12:  C, 20.15; H, 3.95; N, 21.54%.  Found:  C, 19.88; H, 3.62; N, 
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21.82%. At 1mM (pH=4.03): λmax1=204 nm, log ε1=4.69; λmax2=249 nm, log ε2=4.14; λmax3=260 
nm, log ε3=4.04. Ep (50mM Phosphate buffer, 4mM NaCl pH=7.4) = -0.263 V; EP (water, 0.1M 
NaCl) = 0.047 V, -0.358 V. 
[Au(N-Medien)(DMAP)]Cl32H2O was prepared analogously to [Au(dien)(DMAP)](Cl3)H2O, 
using [Au(N-Medien)Cl]Cl2 as the starting material (80% yield).   Anal. Calcd. 
for C12H29AuCl3N5O2:  C, 24.9; H, 5.05; N, 12.1%.  Found:  C, 24.9; H, 4.72; N, 12.12%. At 
1mM (pH=5.87): λmax1=195 nm, log ε1=4.21; λmax2=212 nm, log ε2=4.22; λmax3=281 nm, log 
ε3=4.16. Ep (50mM Phosphate buffer, 4mM NaCl pH=7.4) = -0.248 V; EP (water, 0.1M NaCl) = 
0.0482 V, -0.5504 V. 
 
2.5 Conclusion 
In summary, use of N-heterocycle ligands allows for manipulation of metal-ligand 
electronic communication leading to new insights into well-known chemistry including (i) the 
first isolated AuIIIN3(N-purine)/heterocycle compounds, (ii) recognition of the effect of the N-
heterocycle on the acidity of the Au(dien) ligands, (iii) stabilization of the gold(III) center, and 
(iv) enhancement of π-π stacking interactions relative to isostructural and isoelectronic 
platinum(II) and palladium(II) compounds. While many diverse gold(III) complexes have been 
reported with interesting cytotoxicity, information on speciation and stability at physiological pH 
is lacking. The use of more substitution-inert ligands within the MN4 chemotype allows for 
greater control and more specific interactions with biomolecules, especially those with strongly 
nucleophilic thiolates [22]. 
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Chapter 3. Au(III)-dien-N-heterocycles: reactivity with biomolecules and 
Cys3His HIV-NCp7(F2) and Cys2His2 Sp1(F3) zinc finger peptides 
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3.1 Abstract:  
The reaction of novel Au(III)-dien-N-heterocycle compounds with model amino acids 
and zinc finger proteins is reported.  NMR studies show the presence of a more inert N-donor as 
the leaving group slows down the reaction with the sulfur-containing amino acids N-
acetylmethionine (N-AcMet) and N-acetylcysteine (N-AcCys). Lack of ligand dissociation upon 
reaction with N-AcCys indicates, to our knowledge, the first long-lived N-heterocycle-Au-S 
species in solution. Reactions with zinc finger proteins show a higher reactivity with the Cys3His 
zinc finger than the Cys2His2 zinc finger, likely due to the presence of fewer reactive cysteines. 
Of the Au(III) compounds studied, [Au(dien)(DMAP)]3+ appears to be the least reactive, with 
ESI-MS studies showing the presence of intact zinc finger at initial reaction times.  Though these 
compounds are still too reactive to result in any binding specificity, these results in combination 
with previous reported characterization and pH dependency will further aid in optimizing the 
structure of these AuN4 species to obtain a reactive yet selective compound for targeting zinc 
finger proteins. 	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3.2 Introduction: 
Zinc finger (ZF) domains are made up of amino acids with a combination of cysteine and 
histidine residues coordinated to a tetrahedral zinc ion core [1-4]. ZF proteins are critical for a 
variety of biological functions, including transcription, DNA repair, and apoptosis. Displacement 
of the central zinc ion, along with mutation of coordinated amino acids can result in a loss of 
biological function [5]. There has been an increasing interest to synthesize complexes that 
selectively target zinc finger proteins, in turn inhibiting DNA/ZF interactions and therefore 
resulting in loss of protein function. A zinc finger of special interest is the HIV nucleocapsid 
NCp7 protein, a significant target for HIV intervention [6,7]. A key interaction between RNA and 
NCp7 is the π-stacking between the guanine bases of RNA and the planar aromatic amino acid 
Tryptophan37 (Trp37) of the zinc finger protein [8,9]. Mutation and/or deletion of this residue 
from the zinc finger significantly decreases the chaperone activity of HIV NCp7 and inhibits 
viral replication [10].  
Coordination compounds such as cis-[Pt(NH3)2(Cl)2]  (Cisplatin), trans-[PtCl(9-
EtG)(py)2]+ (9-EtG = 9-ethylguanine; py = pyridine), and [PtCl(dien)]+ (dien = 
diethylenetriamine)  act as electrophiles towards zinc fingers, disrupting protein conformation 
with zinc ejection [5,11-13]. An approach to target specifically the C-terminal finger of HIV-
NCp7, F2, is to use platinated nucleobases as in [Pt(dien)(Nucleobase)]2+ as electrophiles 
capable of tryptophan molecular recognition and eventual attack on the highly nucleophilic zinc-
cysteinate residues [12,14-16]. Pt(II)-N-heterocycle compounds with, for example 4-NMe2pyr 
(DMAP) may also interact with the HIV-NCp7 C-terminal zinc finger through non-covalent 
interactions between tryptophan in the zinc finger and the nucleobase ligand [17].   
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Given the isoelectronic and isostructural relationship of Pt(II) and Au(III) we have been 
exploring analogous Au(III) chemistry. The properties of [Au(III)(dien)(Nucleobase/N-
heterocycle)]3+ show that the N-donor ligand stabilizes the Au(III) oxidation state, the N-donor 
ligand affects the acidity of the central secondary amine proton of the dien ligand and that π-π 
stacking with the simple amino acid tryptophan is significantly enhanced over their Pt(II) 
analogs [18].  
The “parent” [AuCl(dien)]Cl2 reacts rapidly with the C-terminal finger of the HIV 
nucleocapsid protein NCp7 with Zn2+ ejection and formation of AuF/Au2F/Au4F  “gold fingers” 
[13]. The Au(III) compound also reacts much  faster than its Pt(II) analog, attributed to the ‘soft’ 
nature and high thiol affinity of Au(III) [5,13]. The presence of a more substitution-inert ligand 
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such as a nucleobase or planar amine may allow tuning of the Au(III) reactivity aiding in the 
overall selectivity of the reaction with peptides. Following our description of the basic chemistry 
of [Au(III)(dien)(Nucleobase/N-heterocycle)]3+ [18], we now report on their reactivity with 
relevant biomolecules, specifically toward the sulfur containing amino acids N-AcMet (N-
Acetylmethionine) and N-AcCys (N-Acetylcysteine) and zinc finger peptides differing in zinc 
coordination sphere: the Cys2His2 finger-3 of the Sp1 transcription factor (Sp1(F3)) and the 
Cys3His C-terminal finger of HIVNCp7 nucleocapsid protein (NCp7(F2)), Figure 3.1. The 
Au(III)-N-heterocycle compounds reacted slower than [AuCl(dien)]Cl2 with both N-AcMet and 
N-AcCys, the latter producing a N-heterocycle-Au-S species, unlike previous results seen for 
Au(I)-N-heterocycle compounds [19]. Differences in reactivity of Cys3His and Cys2His2 ZF are 
also discussed. 
 
3.3 Results and Discussion 
3.3.1 Reactivity with Biomolecules 
Competition assays of the DNA-Ethidium Bromide (EtBr) interaction showed little 
fluorescence quenching of the intercalator in the presence of Au(III)-compounds I-V, Figure 3.2, 
confirming that  DNA is unlikely to be the principal target for these compounds.  [Au(dien)(4-
picoline)]3+, compound IV, appears to bind to DNA slightly, resulting in a loss of fluorescence 
intensity. Based on these results, it is likely that there will be little competitive binding between 
the drug and DNA, a necessary prerequisite if we are to target zinc finger proteins.  	   The soft nature of Au(III) predicts reactivity with sulfur-containing amino acids.   The 
reactions of [AuCl4]- with L-Methionine (L-Met) and L-Cys and the influence of tridentate N-
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donors varying in π-donor ability on stability of the Au(III) oxidation state have been reported  
[20-21]. The dien chelate affords the least reactive compounds of those studied. Given that the 
MN4 compounds stabilize further the Au(III) oxidation state relative to [AuN3Cl] [18], we 
compared the reactivity of the AuN4 species with both N-AcMet and N-AcCys to verify whether 
this stabilization will further slow down the reaction. 
  The reaction of [AuCl4]- with L-Met results in oxidation of the thioether and concomitant 
Au(III) -> Au(I) reduction [20-21]. Little or no reaction has been reported for [AuCl(dien)]2+ and 
L-Met based on UV-VIS spectra. In this study, we used a 2.5 fold excess of N-AcMet and 1H 
NMR spectral changes were noticed over time (Figure 3.3). The initial pH of the solutions was 
approximately 3.0.  Clear downfield shifts of the S-CH3 Ha and S-CH2 Hb, indicate binding of N-
AcMet to gold (Figure 3.3). Multiple peaks appear for the S-CH3 singlet shifted downfield from 
the free ligand at δ = 2.13 ppm. In the case of [AuCl(dien)]2+, a second singlet appears at 2.7 
Figure 3.2. EtBr assay with Au(III)-dien-N-heterocycle compounds showing DNA is not a 
target. 
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ppm and increases slightly in intensity over time; these shifts may be due to different Au-
Met(SCH3) species or, as has been suggested [21], reflect the presence of oxidized methionine 
sulfone or sulfoxide. The dien ligand dissociates as indicated by both a loss of the broad singlet 
at 3.65ppm indicative of [AuCl(dien)]2+ and by the appearance of a multiplet centered at ~ 3.46 
ppm (Figure 3.3A). This multiplet is similar in shape and chemical shift when compared to the 
free dien salt. For [AuCl(N-Medien)]2+, the situation is somewhat different with up to three S-
A)	  
B)	  
Figure 3.3. NMR spectra of [AuCl(dien)]Cl2 (A) and [AuCl(N-Medien)]Cl2 (B) reacted with 
2.5 equivalents of N-AcMet. 	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CH3 species clearly distinguishable (Figure 3.3B). In this case, the singlet of the N-Medien 
ligand suffers an upfield shift to shielding, consistent with the formation of Au-Met trans to the 
Au-NMe bond. No evidence for production of free N-Medien was seen throughout the reaction 
but it is possible that deprotonation of the primary amines on the N-Medien occurs allowing 
further ligand substitution, as noted previously in the solution behavior of [AuCl(N-Medien)]2+ 
[18]. These complex highly pH-dependent reactions were not investigated further since our 
primary goal was to compare the reactivity of the Cl versus N-heterocycle compounds. A 
summary of chemical shifts is reported in Table 3.1.  
 
Table 3.1 Chemical	  shifts	  of	  N-­‐AcMet	  and	  N-­‐Me	  peaks	  upon	  reaction	  with	  AuN3Cl	  species.	  
 
Compound S-CH3 1 (ppm) S-CH3 2 (ppm) S-CH3 3 (ppm) S-CH2 (ppm) N-Me (ppm) 
I + NAcMet 2.45 (+0.32) 2.72 (+0.59) N/A 2.93 (+0.31) N/A 
II + NAcMet 2.64 (+0.51) 2.69 (+0.24) 2.8 (+0.67) 2.93 (+0.31) 3.37 (-0.25) 
 
** Values in parenthesis refer to change in chemical shift from free, unreacted ligand (S-CH3 = 
2.13 ppm, S-CH2 = 2.62 ppm, N-Me = 3.62 ppm) 
  
NMR studies showed that the presence of the more inert N-donor ligand does results in 
slower reactivity and the absence of downfield shifts for the S-CH3 protons indicated no 
significant reaction with N-AcMet.  Further, no evidence for significant loss of dien ligand or 
release of the N-heterocycle was observed. For [Au(N-Medien)(DMAP]3+ small peaks 
corresponding to N-AcMet substitution can be observed after 15 h. (Figure 3.4).  
The thiol-containing amino acid L-cysteine quickly reduces Au(III) in aqueous solution, 
the reaction being complete in the first minute [20-21]. The initial rapid substitution reaction 
results in an unstable Au(III)-S complex that is quickly reduced to Au(I/0) in a slower electron-
transfer process [21]. The addition of a tridentate ligand, dien, stabilizes the Au(III) metal center 
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somewhat [21-22], and the addition of the more inert N-donor leaving group is expected to 
stabilize it even further [18]. Both Au(III) N3Cl compounds are very reactive with N-AcCys, due 
to its greater nucleophilicity. Both AuN3Cl species show similar results to that of the N-AcMet 
reaction, resulting in loss of dien/NMedien ligands and precipitation of white solids as has been 
A)	  
B)	  
Figure 3.4. NMR spectra of [Au(dien)(9-EtG) (A) and [Au(dien)(DMAP)]3+ (B) +  2.5 
equivalents N-AcMet over time.  	  
	   69	  
observed previously [21] (Figure 3.5). The final pH of all reaction mixtures upon addition of N-
AcCys is approximately 3. In the case of the reaction with AuN4 compounds, the dien ligand also 
dissociates, however there is no evidence for concomitant release of the DMAP N-heterocycle 
ligand, as indicated by no ligand peak shifts in the NMR spectra, Figure 3.6. The pH of 
[Au(dien)(DMAP)]3+ decreases from 5.2 to 3.3. The broad peak at ~ 3.6 ppm (Figure 3.6) 
A)	  
B)	  
Figure 3.5. NMR spectra of (A) [AuCl(dien)]Cl2 and (B) [AuCl(N-Medien)]Cl2 with 1 eq. N-
AcCys over time. 
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represents the dien protons when bound to Au. This broad peak decreases over time, while the 
multiplet at 3.4ppm (free dien) increases, again showing the loss of dien over time. As shown in 
Figure 3.6 the DMAP ligand does not dissociate over time; the presence of free DMAP would be 
indicated by peaks at 8.15 and 6.7ppm. This situation is in contrast to that of Au(I) where the 
reaction of [(Ph3P)Au(I)(DMAP)]1+ with  1 equivalent of N-AcCys, results in DMAP 
displacement and formation of a P-Au-S coordination unit [19]. 
Similar spectra are seen in the case of 9-EtG. The pH of [Au(dien)(9-EtG)]3+ increases 
from 2.7 to 3.0. The H8 peaks of the 9-EtG ligand shift upfield upon addition of NAcCys a result 
of the change in pH of the reaction mixture (Figure 3.7). This is not due to ligand dissociation as 
the spectrum is identical to that of III alone at pH ~3.0 [18].   The fact that the dien ligand 
dissociates but the N-heterocycle remains bound is an interesting result. The spectra could reflect 
the slower substitution kinetics of the [Au(dien)(N-heterocycle)] species or the presence of 
Figure 3.6. NMR spectra of [Au(dien)(DMAP)]3+, V, and N-AcCys over time. Spectra of 
free DMAP and [Au(dien)(DMAP)]3+ alone are shown for reference. 8.2-6.8 ppm refers to 
aromatic region and 3.8-3.0 ppm refers to dien region of NMR spectra. 	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mixed Au/N-AcCys/DMAP(9-EtG) products. Despite the complexity of the reaction it does 
appear that the stabilization of the Au(III) oxidation state in [Au(dien)(N-heterocycle)]3+ does 
extend to reactions with biomolecules  and overall the results suggest that [AuN4] systems might 
be capable of fine-tuning to distinguish substitution from redox reactions. 
3.3.2. Reactivity with Zinc Finger Proteins: 
Reaction of [AuCl(dien)]Cl2 with NCp7(F2) results in immediate Zn ejection and 
formation of gold fingers [13].  It was our goal to slow down this interaction by replacing the 
labile -Cl with a more inert N-donor. As seen for Pt(II) species, it is expected that the planar 
amine will π-stack with the tryptophan residue in the C-terminal finger of HIV-NCp7. 
Fluorescence studies with free N-AcTrp show that Au(III) compounds exhibit a greater 
stacking interaction when compared to Pt(II) analogs, Table 3.2 [18].  Compounds containing 
DMAP as the leaving group have Ka values significantly higher than those of their 9-EtG 
Figure 3.7. NMR spectra of [Au(dien)(9-EtG)]3+ (III) at initial pH*, pH*=3.05, and upon 
initial reaction with N-AcCys . 
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analogues, reflecting the greater basicity of the DMAP ligand [14,17-18]. It was hypothesized 
that [Au(dien)(4-picoline)]3+ would stack more efficiently than [Au(dien)(9-EtG)]3+ due to the 
higher pKa of the ligand; pKa of 4-picoline is 6.05 whereas the pKa of N7 of 9-EtG is 2.7 [23-24]. 
The Ka values for all 4-picoline compounds, however, are much lower than all other compounds 
studied, with a Ka of the free ligand being too low to determine. Though the Ka values are lower 
than expected, it is still important to note the more than 2-fold increase of Au(III) vs. Pt(II) as 
similarly seen for the [M(dien)(9-EtG)]n+ compounds. It is also interesting to note the large effect 
of the N-dimethyl group of the DMAP ligand on the π-stacking ability of the complex.  
 
Table 3.2. Association Constants of N-AcTrp with Au(III)-N-
heterocycle compounds and their Pt(II) analogues. 
Compound Ka   (x103 M-1) SD Ref. 
[Pt(dien)(9-EtG)]2+ 6.8 0.1 14 
[Au(dien)(9-EtG)]3+ 16.7 1.5 18 
[Pt(dien)(4-pic)]2+ 1.34 0.48 -- 
[Au(dien)(4-pic)]3+ 3.61 0.58 -- 
[Pt(dien)(DMAP)]2+ 25 0.9 17 
[Au(dien)(DMAP)]3+ 25.5 0.3 18 
 
A fluorescence quenching assay is typically performed to calculate a Ka value for the 
compounds with the C-terminal finger of NCp7, due to the presence of a tryptophan residue. In 
the case for the Au(III) compounds studied, the fluorescence decreased significantly over time 
indicating loss of zinc and change in peptide structure (Figure 3.8A). Therefore, a representative 
Ka value could not be calculated. Both planar amine compounds exhibited a slightly larger 
decrease in fluorescence upon addition of drug, which could be due to their π-stacking ability. 
CD experiments show that all Au(III) compounds studied result in some degree of zinc 
ejection when reacted with the C-terminal finger of the NCp7 zinc finger protein. The CD 
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spectrum of NCp7(F2) is characterized by a positive band at ~220 nm. The Au compounds cause 
a decrease in intensity of this band and a significant increase in the negative ellipticity with a 
slight blue shift of the 195-200 nm band, which are indicative of conformational changes from 
ordered structure to random coil [25-27]. After 15 minutes incubation, [AuCl(dien)]2+ resembles 
the free peptide spectrum. [Au(dien)(9-EtG)]3+, III, and [Au(dien)(DMAP)]3+, V, both result in 
zinc ejection and loss of ordered structure, however to a lesser degree than [AuCl(dien)]2+, 
Figure 3.8B. After 1 hour incubation, the spectrum of III + NCp7(F2) resembles that of free 
A) 
B) 
Figure 3.8 (A) Fluorescence quenching over time upon addition of I, III, and V. (B) CD 
spectrum of I, III, and V with NCp7(F2) after 15 minutes incubation. 	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peptide, however the spectrum of V + NCp7(F2) does not change over time, indicating  
[Au(dien)(DMAP)]3+ is the least reactive of the three gold compounds studied.  
 The ESI-MS of [AuCl(dien)]2+ with NCp7(F2) shows loss of ligand and complete zinc 
ejection, with incorporation of two or four Au ions [13]. ESI-MS spectra of both [Au(dien)(9-
EtG)]3+ and [Au(dien)(DMAP)]3+, Figure 3.9, show that both N-heterocycle compounds stay 
Figure 3.9. Initial ESI-MS spectra of (A) [Au(dien)(9-EtG)]3+ and (B) [Au(dien)(DMAP)]3+ 
with NCp7(F2). 	  
A) 
B) 
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intact upon initial reaction with NCp7(F2) indicating the AuN4 species are more stable to 
reduction. Interestingly, both compounds exhibit fragmentation resulting in partial loss of the 
dien ligand.  This was also seen in ESI-MS recorded of the compounds alone. The most 
prominent peaks for the reaction between [Au(dien)(9-EtG)]3+ (III) and NCp7(F2) are 740.9927 
(3+) and 1110.9861 m/z (2+) corresponding to apo-peptide. Smaller peaks at 872.3034 (3+) and 
1307.9520 m/z (2+) represent Au2/F.  Therefore, like the -Cl complex, compound III results in 
formation of gold fingers, however incorporation of four Au ions was not observed. The ESI-MS 
spectrum of [Au(dien)(DMAP)]3+ (V) and NCp7(F2), however, shows peaks corresponding 
primarily to intact zinc finger, 571.7282 (4+) and 762.6356  m/z (3+).  There is some zinc 
ejection, as indicated by a peak at 1111.4963 m/z (2+), which represents oxidized apo-peptide. 
This is in agreement with the CD data, which shows compound III to react the slowest. The CD 
spectrum results from a sum of different conformations in solution; therefore the negative 
ellipticity may be due to the presence of some apo-peptide in solution. At 4 hours reaction time, 
these zinc finger m/z peaks are no longer present. It is difficult to interpret the spectra at later 
time points; however, it does not appear that Au2/F is present as is the case for the 9-EtG 
analogue.  
Zinc finger cysteinates vary in chemical reactivity; the Zn-Cys49 thiolate of NCp7 is 
most susceptible to electrophilic attack. The Cys2His2 zinc finger motif has also been shown to 
be less nucleophilic and less tightly packed [28] and therefore it is expected that it would be less 
reactive with the Au(III) compounds. To examine this point further, we compared the reactivity 
of ZF NCp7 with that of Sp1(F3), the third zinc finger of the Sp1 transcription factor. As 
indicated by CD spectroscopy (Figure 3.10) there is a difference in the rate of reactivity between 
the Cys3His and Cys2His2 ZFs, the latter taking ~ 5 hours for complete loss of ordered structure, 
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whereas the Cys3His ZF shows similar results at 15 minutes (Figure 3.8A). Compounds I and III 
appear to react similarly, resulting in complete Zn ejection and loss of structure at 5 hours. 
Compound V, [Au(dien)(DMAP)]3+, appears to react slower than compounds I and III; though a 
slight blue shift occurs at ~200nm compared to that of zinc finger, an increase in negative 
ellipticity does not, indicating less zinc ejection. However, upon further examination, the CD 
spectrum in Figure 3.10C is similar to that of oxidized Cys2His2 peptide (See Figure 1.17 in 
Chapter 1), which indicates zinc is in fact being ejected and disulfide bonds are being formed. 
 
A) B) 
C) 
Figure 3.10. CD spcectra of (A) [AuCl(dien)]2+, I (B) [Au(dien)(9-EtG)]3+ , III and (C) 
[Au(dien)(DMAP)]3+, V, with Sp1(F3) at 15 min, 1 hr, and 5 hr incubation times. 	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ESI-MS of [AuCl(dien)]2+ and Sp1(F3) show prominent peaks for apo-peptide (674.3635 
m/z, 5+) and Au/F (713.7566 m/z, 5+), Figure 3.11A.  Unlike the reaction with NCp7(F2), 
incorporation of more than one gold ion was not observed initially. However, small peaks 
representing Au2/F appeared after 1 hour incubation. Unlike the Cys3His zinc finger, the 
[Au(dien)(9-EtG)]3+ does not stay intact upon reaction with the Sp1(F3) Cys2His2 zinc finger 
indicated by a large peak at 180.0883 m/z representing free 9-EtG ligand. Immediately after 
adding the drug, the prominent peaks in the mass spectrum are apo-peptide (842.4415 m/z, 4+) 
A) B) 
C) 
Figure 3.11. ESI-MS of (A) [AuCl(dien)]2+ (B) [Au(dien)(9-EtG)]3+ and (C) 
[Au(dien)(DMAP)]3+ with Sp1(F3) at initial time points. 
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and Au/F (891.9345 m/z, 4+), Figure 3.11B. Over time the Au/F peaks increase in intensity; 
however, Au2/F is not present as seen for the Cl species. Unlike both the –Cl and –9-EtG species, 
the Au-DMAP species does not result in immediate formation of Au/F.  The initial ESI-MS 
shows a small peak at 391.1222 m/z indicating a fragment of [Au(dien)(DMAP)]3+; loss of 
CH2NH2 from the dien ligand. Other peaks present represent apo-peptide (561.9996 m/z, 6+), 
Figure 3.11C. This peak refers to the mass of apo-peptide minus two protons, indicating the 
formation of a disfulide bond, which agrees with the CD data. After 1 hour, Au/F begins to 
appear at 713.3511 m/z, 5+, increasing in intensity over 24 hours, however apo-peptide remains 
the prominent species. An equimolar reaction of the Au(I) drug aurothiomalate and pre-formed 
Sp1 zinc finger (excess Zn present) resulted in 60% Au/F and 40% zinc finger [27]. Similar to 
our results, binding of more than one metal ion was not observed. [Au(dien)(DMAP)]3+, V, 
appears to be the least reactive of the Au(III) compounds studied for both the Cys2His2 and 
Cys3His zinc finger proteins.  Though zinc ejection and formation of gold-finger still occurs, the 
rate of the reaction has decreased with the presence of DMAP as the leaving group.  
Upon binding to the peptide, the gold ions may remain Au(III) and bind in a square 
planar fashion or reduce to Au(I) and bind linearly. Table 3.3 shows the expected and observed 
m/z values for the reaction of the Au(III) compounds with Sp1. To calculate the expected values, 
it was assumed the Au would bind in a 4-coordinate geometry, similar to that of Zn2+. When the 
expected and observed m/z values are compared, we observe m/z values within 0.1 of what is 
expected, suggesting that when bound to the Cys2His2 zinc finger, Sp1, the Au remains in the 3+ 
charge state. CD spectra of Au/F formed from the reaction of aurothiomalate (Au+1) and Sp1 
showed a slight red shift in the minimum, however not to the same degree of ZF, indicating a 
difference in conformational features such as less α–helix [27]. Based on the difference in CD 
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spectra between the Au(III) compounds (large increase in negative ellipticity) studied here and 
various Au(I) compounds (decrease in negative ellipticity) in the  literature [19,27], it is likely 
that Au(III) binding results in a different conformational changes than either Au(I) or Zn(II). This 
change in conformation can then, presumably, result in inhibition of DNA binding and therefore 
loss of function. 
 
It is slightly more complicated to determine how the Au atoms are binding in the Cys3His 
zinc finger, NCp7(F2), due to the fact that multiple gold ions bind. Expected values match 
closest to those observed when it is assumed the first gold binds as 3+ and the second gold atom 
binds minus a proton, perhaps binding in a linear geometry as Au(I) (Table 3.4). This is similar to 
what was observed for Au(III) compounds when reacted with the Cys3His zinc finger PARP-1 
[29]. 
Table 3.4 Observed vs. Expected m/z values for Au2/F in reaction of Au(III) 
compounds with the NCp7(F2) zinc finger. 
Charge state Observed m/z Calculated m/z * Delta m/z 
2+ 1307.952 1307.964 -0.012 
3+ 872.303 872.309 -0.006 
 
 
Table 3.3 Observed vs. Expected m/z values for Au/F in reaction of Au(III) compounds with 
the  Sp1(F3) zinc finger. 
Charge state Observed m/z Calculated m/z * Delta m/z 
3+ 1188.255 1188.240 0.015 
4+ 891.432 891.430 0.002 
5+ 713.347 713.344 0.003 
6+ 594.624 594.620 0.004 
7+ 509.679 509.817 -0.138 
* Calculated values assume Au binds in same 4-coordinate geometry as Zn 
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3.4 Experimental  
Materials: HAuCl4 was purchased from Strem Chemicals; N-Medien was purchased from TCI 
America; all other reagents were purchased form Sigma Aldrich, USA. Both NC and Sp1 
peptides were purchased from GenScript Corporation. 
Synthesis: Synthesis of [AuCl(dien)]Cl2 (I), [AuCl(N-Medien)]Cl2  (II), [Au(dien)(9-
EtG)](NO3)3•2H2O (III), [Au(dien)(DMAP)]Cl3•1.5H2O (V), have been previously published 
[18,30]. 
Synthesis of [Au(dien)(4-pic)](NO3)3•H2O (IV).  0.98 equivalents of 4-picoline (4-pic) and 
2.98 equivalents of AgNO3 were added to a solution of [AuCl(dien)]Cl2 in water. The reaction 
mixture was stirred at room temperature in the dark for 1 hour.  The solution was filtered to 
remove AgCl and the yellow filtrate was evaporated to dryness. Acetone was added to precipitate 
orange product. Anal. Calcd. for C10H21AuCl3N5:  C, 20.11; H, 3.71; N, 16.42%.  Found:  C, 
19.67; H, 3.25; N, 16.01%. At 1 mM: λmax1=206 nm, log ε1=4.63; λmax2=247 nm, log ε2=3.92; 
λmax3=357 nm, log ε1=2.87.  
Ethidium Bromide (EtBr) Assay: CT-DNA (calf-thymus DNA) was prepared in 1 mM 
phosphate buffer (50 mM NaCl, pH=7.4). The concentration of both DNA and EtBr were 
determined by absorption measurements at 260 nm and 338 nm, respectively. Stock solutions of 
the CT-DNA incubated with the gold(III) compounds at a ri of 0.1 were prepared and incubated 
at 37ºC for 24 hours for I-II (covalent binding) and 1 hour for III - V (non-covalent binding). 
Varying amounts of ethidium bromide in the range of ri = 0 – 0.25 was added to CT-DNA (100 
µM) and CT-DNA (100 µM) treated with I-V. Fluorescence emission spectra were recorded on a 
Cary Eclipse (Varian) fluorometer at 25ºC. Fluorescence was excited at λex= 525 nm and 
registered at λem= 600 nm. Spectra were recorded in triplicate and averaged. 
	   81	  
NMR Spectroscopy with N-AcMet and N-AcCys: 0.006-0.009 mmol solutions of compounds 
I-V were added to a solution containing 2.5 equivalents N-AcMet or 1 equivalent of N-AcCys.  
The reaction was followed over time by NMR.  NMR spectra were referenced to the residual 
signal of D2O (1H, 4.80ppm).   
Zinc finger preparation: Free peptide was dissolved in water (concentration was dependent on 
experiment/techinique being performed).  The pH was adjusted to 7.2-7.4 with a concentrated 
solution of NH4OH.  1.3 equivalents of Zn was added using a concentrated solution of zinc 
acetate. In both cases, the ZF formed immediately and no incubation was necessary.  ZF 
formation was confirmed by both CD and MS. The data obtained were in agreement with values 
previously reported in the literature [25-27].  
Tryptophan Quenching by Fluorescence Spectroscopy: For fluorescence quenching studies, 
methods were adapted from those previously published [15]. A 3 mL solution of N-AcTrp (N-
acetyltryptophan) or NCp7(F2) (5 µM) was titrated with aliquots of the corresponding quenching 
compound (7.5 mM) in the range [quencher]/[N-AcTrp]) 1-10. For time studies performed with 
zinc finger proteins, 1 equivalent of Au-compound was added to 5µM NCp7 and fluorescence 
was monitored over time. 
Circular Dichroism Spectroscopy: Methods were adapted from those previously published 
[13]. A 0.2 mg/mL solution of peptide in water was prepared.  CD was run before and after 
adding zinc (1.3 eq.) to ensure correct formation of zinc finger. The reaction of ZF:drug was 
performed in a 1:1.3 eq ratio and followed over time. 
Mass Spectrometry: ESI-MS experiments were performed on an Orbitrap Velos from Thermo 
Electron Corporation. Instrument parameters were as follows: electrospray voltage = 2.3 kV; 
capillary temperature = 230 °C; flow rate = 0.7 µL/min. A concentrated ZF solution was 
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prepared in water (450 µM) and 1 equivalent of Au(III) compound was added.  Samples were 
diluted as follows for analysis by mass spectrometry: 20 µL sample, 20 µL methanol, 200 µL of 
20 µM acetic acid.  
 
3.5 Conclusions  
 The Au(III) compounds studied are the first isolated Au(III)-dien-N-heterocycle 
compounds. We have recently shown the effect of the nature of the N-heterocycle on the acidity 
of the Au-dien ligand, stabilization of the Au(III) metal center, and the π-stacking ability with 
free N-Acetyltryptophan when compared to their Pt(II) analogs [18]. Expanding on that work, 
we report here the reactivity of these compounds with model amino acids and Cys3His and 
Cys2His2 zinc finger protein cores. NMR studies show a decrease in reaction rate for AuN4 
species with both N-AcMet and N-AcCys when compared to AuClN3 species. Upon reaction 
with N-AcCys, the dien ligand completely dissociates. In the case of the AuN4 species, the N-
heterocycle ligand remains bound, suggesting formation of a N-heterocycle – Au – S species. 
Interestingly, this was not the case for Au(I)-N-heterocycle compounds with N-AcCys, which 
resulted in loss of the N-heterocycle ligand and formation of a P—Au—S species [19].  
Many studies have been reported on the reaction of Au(I)/Au(III) compounds with 
various zinc finger proteins. Such reactions result in rapid displacement of Zn2+ with 
concomitant replacement of Au(I)/(III) in which all gold-coordinated ligands are lost 
[13,27,29,31]. Though this zinc ejection may result in loss of ZF function, it is necessary to 
develop drugs with selectivity. The Au(III) drugs discussed herein were designed to selectively 
target the NCp7 ZF through π-stacking interactions with the planar amino acid tryptophan. 
Though fluorescence experiments show a significant enhancement of π-stacking with free 
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NAcTrp for Au(III) compounds over their Pt(II) analogues, studies with NCp7(F2) resulted in 
quenching over time suggesting rapid zinc ejection. The initial mode of recognition may result 
from the non-covalent interaction of the N-heterocycle ligand with the tryptophan residue, 
however the reaction is still too fast to observe any intermediate species. 
In agreement with small-scale NMR reactions with model amino acids, ESI-MS and CD 
experiments with zinc finger proteins also showed a decrease in the rate of reactivity for AuN4 
species. ESI-MS studies showed both Au(III)-N-heterocycle compounds remained intact at initial 
timepoints when reacted with NCp7(F2), unlike that observed for [AuCl(dien)]2+ [13]. CD and 
ESI-MS studies showed [Au(dien)(DMAP)]3+ to react the slowest, with evidence of intact zinc 
finger present at early time points. CD showed the Cys2His2 zinc finger, Sp1(F3), to react slower 
than the Cys3His zinc finger, NCp7(F2), taking 5 hours to result in complete zinc ejection for 
[AuCl(dien)]2+ and [Au(dien)(9-EtG)]3+. [Au(dien)(DMAP)]3+ was the only compound studied 
that did not result in formation of Au/F. When calculated m/z values were compared to those 
observed, it was determined that the gold remains in the 3+ oxidation state upon binding to Sp1. 
In the case of NCp7(F2), the primary gold-finger species observed in NCp7(F2) reactions was 
Au2/F. Based on calculations, it was determined that the first gold remains Au(III) upon binding 
and the second gold binds Au(I). 
 Previous pH dependency studies show [Au(dien)(DMAP)]3+ to be the most stable of the 
Au(III)-N-heterocycle compounds studied [18].  The DMAP ligand stabilizes the dien ligand and 
does not dissociate at low or high pH values [18]. The studies reported herein support the fact 
that the Au-DMAP species is the most stable, resulting in the least amount of zinc ejection and 
gold-finger formation for both zinc finger peptides studied. Though these compounds are sill 
	   84	  
relatively reactive and unlikely to bind with selectivity, the loss in ordered structure indicated by 
CD suggests DNA would not bind and therefore would result in a loss of function. 
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**As supporting author for the following work, I have contributed all work pertaining to 
[Au(dien)(DMAP]3+ including synthesis and fluorescence quenching data with N-
Acetyltryptophan (N-AcTrp).  I also played a significant role in understanding the inner filter 
effect in regards to the fluorescence quenching assay.  At concentrations above 50 µM, 
[Au(dien)(DMAP)]3+  absorbs at the wavelength at which the fluorophore, NAcTrp, emits, thus 
resulting in more quenching than actually present and a higher Ka value.  Therefore, it was 
necessary to titrate 1-10 molar equivalents of drug : NAcTrp, rather than 10-100 as previously 
reported for platinum(II) compounds in the literature. The absorbance of [Au(dien)(DMAP]3+ at 
or below10 molar equivalents (50 µM) was <0.05 absorbance units. 
 
4.1 Abstract 
A survey of selected N-heterocycle ligands showed that platination of 4-N-
dimethylaminopyridine (DMAP) in [Pt(dien)L]2+ (dien = diethylenetriamine) gave especially 
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strong π–π stacking interactions with tryptophan and the tryptophan-containing C-terminal zinc 
finger (ZF) of the HIV (human immunodeficiency virus) nucleocapsid protein NCp7. The 
association constants (all at 103 M−1) were significantly stronger (25.0 and 28.1 for tryptophan 
and ZF respectively) than those previously measured for the purine nucleobase 9-ethylguanine 
(9EtG) in [Pt(dien)(9EtG)]2+ (6.88 and 7.55 for tryptophan and ZF, respectively). Extension to 
Pd and Au complexes also confirmed the utility of DMAP in assisting stacking interactions. The 
results confirm the utility of a “bioinorganic” approach to targeting and inactivation of medicinal 
chemistry targets using the dual approach of target recognition (non-covalent) followed by target 
fixation (covalent). 
 
4.2. Introduction 
Zinc finger (ZF) proteins constitute 2–3% of the human genome and play a diverse role 
in many cell processes, such as transcription, DNA repair, cellular signaling and apoptosis. Their 
structures are characterized by zinc coordination to four amino acids, typically cysteine and 
histidine. Elimination of zinc from zinc finger proteins causes a loss of 3-dimensional structure 
leading to loss of protein function [1–3]. The 2-zinc finger nucleocapsid protein human 
immunodeficiency virus (HIV1) NCp7 remains an interesting drug target, complementary to the 
current therapies aimed at inhibiting HIV reverse transcriptase and protease. While this approach 
has been successful in reducing the viral loads of many patients, there are problems of resistance, 
drug toxicity and latent viral reservoirs that are contained in long-lived cell populations. NCp7 is 
an attractive target because it is highly conserved in all viral strains and mutations in the 
sequence have been shown to render the virus non-infectious [4,5].  
The C-terminal finger of NCp7 (ZF) contains a tryptophan residue while the N-terminal 
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finger contains a phenylalanine. A critical feature in NCp7-DNA/RNA recognition is the 
stacking of these aromatic residues with purine and pyrimidine bases (guanine, cytosine) on 
DNA/RNA [6,7]. N-quaternization of nucleobases enhances the stacking interaction, in part by 
lowering the energy of the lowest unoccupied molecular orbital (LUMO) of the nucleobase, 
making it closer in energy to the highest occupied molecular orbital (HOMO) of the Trp [8,9]. N-
quaternization may be achieved by protonation, alkylation or metallation and it is possible that 
the lowering of the energy of the LUMO may be due in part to the removal of the lone pair of 
electrons on the nitrogen of the nucleobase [8,9]. We have been systematically examining the 
coordination chemistry of NCp7 with platinum–metal compounds based on the 
[M(dien)(nucleobase)]n+ (MN4) motif (dien=diethylenetriamine). On average, free 9-
ethylguanine (9EtG), GMP, and CMP have Ka values for association with tryptophan of 3x103 
M−1 whereas platination increases the Ka for the three species to 6.8, 6.9, and 7.0x103 M−1, 
respectively [9–12]. Extension to the Trp-containing C-terminal finger of NCp7 with 
[Pt(dien)(9EtG)]2+ and [Pt(dien)(GMP)] gave Ka values of 7.5 and 12.4x103 M−1, respectively 
[13]. 
The design of [M(dien)(nucleobase]n+ as a peptide-specific drug may be envisaged as a 
classic “two-step” approach — target recognition through tryptophan stacking followed by  
fixation” through zinc ejection and/or covalent binding to the peptide. Recently, we have shown 
that the incorporation of a Trp residue increases the rate of reaction, and perhaps specificity, 
between [Pt(dien)(9EtG)]2+ and a short 4-amino acid peptide [14].While it is attractive to 
modulate drug–target interactions based on nature's motif, it is important to examine whether we 
are restricted to purine and pyrimidine motifs for targeting and how to improve these association 
constants in order to more effectively recognize NCp7. In this contribution, we explore the 
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manipulation of the π-stacking interaction between tryptophan, both free in solution and as part 
of a peptide sequence, and metal complexes containing non-natural (N-heterocycle pyridine and 
thiazole) aromatic ligands to mimic the Trp/Gua interaction. The strong donor 4-Me2N-pyridine 
gives significantly enhanced stacking over the 9EtGua analog; these results were extended to the 
isostructural Pd and Au systems. 
 
4.3 Results and Discussion 
 
To examine the π-stacking potential of platinated N-heterocycle ligands an initial 
systematic survey was performed; Fig. 4.1 shows the structures of the synthesized complexes. 
Pyridine was used as the comparison point when referring to the effects of electron donating or 
withdrawing groups.  
Fig. 4.2 shows the % quenching of tryptophan fluorescence by the various platinum 
compounds. The previously reported [Pt(dien)(9EtG)]2+ displayed a fluorescence quenching of 
Figure 4.1. Structures of the metal (M= Pt, Pd, Au) N-heterocycle 
complexes studied. 
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94.34%. The pyr, MeOpyr, and 4-pic and thiazole complexes gave less than 10% fluorescence 
quenching.  
 
Three complexes displaying high quenching – containing bztz, CNpyr and DMAP 
ligands – were evaluated to determine an association constant (Table 4.1). While the bztz and 
CNpyr compounds showed significant decrease in florescence intensity, the calculated Kas, 3.32 
and 6.73x103 M−1 respectively, are similar to that of the 9EtG complex (6.88x103 M−1 [9]). In 
contrast, the presence of the DMAP ligand results in a compound with a significant increase in 
Ka (25.0x103 M−1) over that of 9EtG. 
There is no clear trend in this series with respect to the simple quenching except that all 
ligands represent potentially delocalized systems. This trend is reinforced by the observation that 
the addition of a delocalized π system in quinoline increased the fluorescence quenching over 
pyridine, albeit not to as significant an extent as that of DMAP and benzothiazole, and no Ka was  
Figure 4.2. Percent fluorescence quenching of N-acetyltryptophan by platinum-N-
heterocycle, [Pt(dien)L]2+, complexes. **The percent fluorescence quenching for 
[Pt(dien)(DMAP)]2+ refers to the quenching at 10 molar equivalents. The value for all 
other compounds refers to the percent fluorescence quenching at 100 molar 
equivalents. 
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Table 4.1. Association constants for metal-N-heterocycle complexes with 
N-acetyltryptophan and the C-terminal zinc finger of HIVNCp7. Published 
values for the 9-ethylguanine complex were taken from a — Ref. [10] and b 
— Ref. [13] and for [Au(dien)(DMAP)]3+ was taken from c — Ref. [19]. 
 
Compound Ka (x 103) M-1  
N-AcTrp ZF 
[Pt(dien)(9EtG)]2+ 6.88 ± 0.3 a 7.5 b 
[Pt(dien)(bztz)]2+ 3.32 ± 0.36 3.20 ± 0.39 
[Pt(dien)(CNpyr)]2+ 6.73 ± 0.26 7.72 ± 0.79 
[Pt(dien)(DMAP)]2+ 25.0 ± 0.90 28.1 ± 1.76 
[Pd(dien)(DMAP)]2+ 23.2 ± 0.31 N/A 
[Au(dien)(DMAP)]3+ 25.5 ± 0.30 c N/A 
 
measureable. The pKa for the platinated nitrogen may also give an indication of the strength of 
the stacking interaction between platinum complexes and Trp. The pKas under similar conditions 
for 9EtG, CNpyr, bztz and DMAP are 1.2 [15], 1.9 [16], 3.1 [16], and 9.6 [17], respectively. 
Clearly the strong donor DMAP has the most profound effect, even though the platinated 
compound is actually slightly lower than free ligand, in contrast to the situation for free 9EtG. 
Basicity considerations and use of electrondonating substituents would seem important for 
identification of a wider group of improved N-heterocycle ligands. 
The [M(dien)] structure allows for systematic study of electronic and steric effects 
(substitution on the dien ligand) and substitution effects where the isoelectronic M=Pt(II), Pd(II) 
and Au(III) compounds can be studied for effects of substitution lability of the central metal ion. 
We have contrasted the reaction products of C-terminal HIV NCp7 with [MCl(dien)]n+ where 
M=Pt, Pd and Au [18]. It was therefore of interest to extend the DMAP findings to Pd(II) and 
Au(III) because of the strong stacking interaction the Pt-DMAP complex displays. In both cases, 
the calculated association constants confirmed the utility of the DMAP ligand, being 
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25.5x103M−1 for [Au(dien)(DMAP)]3+ [19], and 23.2x103M−1 for [Pd(dien)(DMAP)]2+ (Fig. 4.3).  
Both values are significantly higher than the corresponding 9-EtG complexes [10,19]. No 
reaction was seen between [Pd(dien)(DMAP)]2+ with N-AcTrp at pH* 7.52 when followed by 
1H NMR over 2.5 h (data not shown). This implies improved complex stability over 
[Pd(dien)(9EtG)]2+, which has been shown to react with N-AcTrp through displacement of the 
9EtG ligand at increasing pH [11]. Interestingly, the changes in the chemical shifts for the 
DMAP protons are largest for Au(III) over that of the Pd(II) and Pt(II) complexes, Table 4.2. 
This may reflect the short central M\N bond observed in [AuCl(dien)]2+ and the demonstrated 
acidity of the dien ligand when bound to Au(III) [19]. 
Table	  4.2.	  Major NMR ligand chemical shifts for [M(dien)(DMAP)]n+ complexes. 
Values in parentheses are the difference in chemical shift (ppm) from free ligand 
followed by the 3JH–coupling constants (Hz). 
 
Compound 
δ1H(Δδ1H) ppm, 3JH-HHz 
δ195Pt(ppm) H2/H6 H3/H4 N-Me2 
[Pt(dien)(DMAP)]2+ 6.64 (0.15), 5 8.02 (-0.20), 7.5 3.06 (0.06) -2816 
[Pd(dien)(DMAP)]2+ 6.66 (0.17), 7.5 7.92 (-0.31), 5 3.04 (0.04) N/A 
[Au(dien)(DMAP)]3+ 6.90 (0.41), 5 8.02 (-0.21), 5 3.22 (0.22) N/A 
Figure 4.3. The association constants for [M(dien)L]n+ complexes with N-acetyltryptophan as 
determined by fluorescence spectroscopy. 
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These results were then extended to the C-terminal ZF of NCp7, which contains a single 
tryptophan in its sequence (Fig. 4.4). Generally, the association constants for the nucleobase 
complexes increase for the ZF of NCp7 when compared to N-AcTrp [9]. This trend is not 
followed for all N-heterocycles. The Kas for [Pt(dien)(bztz)]2+ and [Pt(dien)(CNpyr)]2+ are 
approximately the same for the ZF when compared to N-AcTrp and the Ka for 
[Pt(dien)(DMAP)]2+ increases slightly. The interaction of the Au(III) and Pd(II) compounds with 
HIV NCp7 resulted in rapid displacement of the central Zn2+ ion; no association constant could 
be measured for this interaction [Spell and Farrell, unpublished results].  
 
The results show that a limited number of N-heterocycle ligands, when metallated, also 
effectively engage in π-stacking interactions with tryptophan and tryptophan-containing 
peptides. These findings further expand the structural variation of the MN4 chemotype where we 
have suggested that use of a substitution-inert ligand such as an N-heterocycle group instead of 
the substitution-labile Cl−, in for example [PtN3X], where X = leaving group, is an approach to 
selectivity for specific peptide-substitution reactions and templates for design of specific protein 
inhibitors [14]. The DMAP complexes all bind very strongly with Trp and the C-terminal ZF of 
NCp7, suggesting that they are suitable for further study with zinc finger proteins 
Figure 4.4. A — structure of the HIVNCp7 zinc finger peptide and B — a model of the π-
stacking interaction between [Pt(dien)(9EtG)]2+ and N-acetyltryptophan 
	   95	  
complementary to our studies with metallated natural nucleobases.  
 
4.4 Experimental 
Materials and reagents  
The complexes [MCl(dien)]Cl (M = Pt, Pd, Au; dien = diethylenetriamine) were prepared by 
literature methods [20,12,21]; purity was confirmed by 1H and 195Pt NMR Spectroscopy, and 
Elemental Analysis (performed by QTI Laboratory, USA). All reagents were purchased from 
Sigma Aldrich, USA and used without further purification. The NCp7 C-terminal peptide 
sequence (KGCWKCGKQEHQMKDCTER) was purchased from GenScript Corporation. 
Synthesis of N-heterocycle platinum complexes 
Complexes of general formula [Pt(dien)L](NO3)2 for L = quin, MeOpyr, pyr, 4-pic, CNpyr, tz 
and bztz were prepared by standard procedures [10] and characterized by 1H and 195Pt NMR 
Spectroscopy and Elemental Analysis (performed by QTI Laboratory, USA).  
[Pt(dien)(quin)](NO3)2: [PtCl(dien]Cl was stirred overnight in DMF with 1.98 
equivalents of AgNO3 in the dark. The solution was filtered through celite to remove the 
precipitated AgCl. Quinoline (3 eq.) was added to the filtrate and the solution was stirred 
overnight. The volume was reduced by rotary evaporation to near dryness, methanol and 
ether were added. The final product was obtained upon centrifugation and dried in vacuo 
(50% yield). Anal. Calcd for C13H20N6O6Pt: C, 28.32; H, 3.66; N, 15.24. Found: C, 
27.76; H, 3.45; N, 14.88. 1H NMR (D2O): 3.00 (8H, m), 7.60 (1H, m), 7.90 (1H, m), 8.10 
(2H, m), 8.50 (1H, m), 9.50 (2H, m). 195Pt NMR: -2837 ppm. 
[Pt(dien)(bztz)](NO3)2  0.75H2O: [Pt(dien)(bztz)](NO3)2 was synthesized in a similar 
manner as [Pt(dien)(quin)](NO3)2 using benzothiazole as the planar amine ligand and 
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water as the solvent (29% yield). Anal. Cald for C11H19.5N6O6.75Pt: C, 23.14; H, 3.44; N, 
14.72. Found: C, 23.14; H, 3.29; N, 14.26. 1H NMR (D2O): 3.00 (8H, m), 7.70 (1H, m), 
7.80 (1H, m), 8.10 (1H, m), 8.80 (1H, m), 9.70 (1H, s). 195Pt NMR: -2861 ppm. 
[Pt(dien)(pyr)](NO3)2: [Pt(dien)(pyr)](NO3)2 was synthesized in a similar manner as 
[Pt(dien)(bztz)](NO3)2 using pyridine as the planar amine ligand (62% yield). Anal. Cald 
for C9.75H19.5N6O6.75Pt: C, 20.99; H, 3.82; N, 16.32. Found: C, 21.28; H, 3.34; N, 15.86. 
1H NMR (D2O): 3.00 (8H, m), 7.50 (2H, m), 8.00 (1H, m), 8.70 (2H, m). 195Pt NMR: -
2833 ppm. 
[Pt(dien)(MeOpyr)](NO3)2  H2O: [Pt(dien)(4-mopyr)](NO3)2 was synthesized in a 
similar manner as [Pt(dien)(bztz)](NO3)2 using 4-methoxypyridine as the planar amine 
ligand (24% yield). Anal. Cald for C11H22N6O8Pt: C, 21.86; H, 4.04; N, 15.30. Found: C, 
21.31; H, 3.91; N, 15.41. 1H NMR (D2O): 3.00 (8H, m), 3.90 (3H, s), 7.10 (2H, d), 8.40 
(2H, d). 195Pt NMR: -2824 ppm. 
[Pt(dien)(4-pic)](NO3)2  0.75H2O: [Pt(dien)(4-pic)](NO3)2 was synthesized in a 
similar manner as [Pt(dien)(bztz)](NO3)2 using picoline as the planar amine ligand (48% 
yield). Anal. Cald for C10.75H21.5N6O7.5Pt: C, 22.71; H, 4.10; N, 15.89. Found: C, 22.82; 
H, 3.69; N, 15.39. 1H NMR (D2O): 2.4 ppm (3H, s), 3.00 (8H, m), 7.40 (2H, d), 8.50 (2H, 
m). 195Pt NMR: -2835 ppm. 
[Pt(dien)(tz)](NO3)2: [Pt(dien)(tz)](NO3)2 was synthesized in a similar manner as 
[Pt(dien)(bztz)](NO3)2 using thiazole as the planar amine ligand (39% yield). Anal. Cald 
for C7H16N6O8SPt: C, 16.57; H, 3.17; N, 16.56. Found: C, 16.74; H, 2.67; N, 16.07. 1H 
NMR (D2O): 3.00 (8H, m), 7.75 (1H, d), 7.94 (1H, d), 9.20 (1H, s). 195Pt NMR: -2820 
ppm. 
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[Pt(dien)(CNpyr)](NO3)2: [Pt(dien)(CNpyr)](NO3)2 was synthesized in a similar manner 
as [Pt(dien)(bztz)](NO3)2 using 4-cyanopyridine as the planar amine ligand (23% yield). 
Anal. Cald for C7H16N6O8SPt: C, 22.25; H, 3.45; N, 18.16. Found: C, 21.93; H, 3.19; N, 
18.11. 1H NMR (D2O): 3.00 (8H, m), 7.94 (1H, d), 9.00 (1H, d). 195Pt NMR: -2839 ppm. 
Synthesis of [Pt(dien)(DMAP)](NO3)2 (DMAP=4-dimethyaminopyridine) 
[PtCl(dien)]Cl was stirred overnight in water with 1.98 equivalents of AgNO3 in the dark. The 
solution was filtered through celite to remove the precipitated AgCl. DMAP (1 eq.) was added to 
the reaction and the solution was stirred at room temperature overnight. The volume was reduced 
by rotary evaporation to near dryness. The final product was precipitated using acetone, filtered 
and washed with acetone and ether, and dried in vacuo (26% yield). 1H NMR (D2O): 3.0 (8H, br, 
m), 3.06 (6H, s), 6.64 (2H, d), 8.02 (2H, d). 195Pt NMR: −2816ppm. 
Synthesis of [Au(dien)(DMAP)]Cl3  H2O 
[AuCl(dien)]Cl2 was stirred with 0.98 equivalents of DMAP in water at room temperature for 1 
h. The solvent was removed by rotary evaporation and acetone was added to precipitate the 
orange product (85% yield). Anal. Calcd. for C11H25AuCl3N5O: C, 24.17; H, 4.61; N, 12.81. 
Found: C, 23.96; H, 4.21; N, 12.68.  
Synthesis of [Pd(dien)(DMAP)]Cl2  1.1H2O 
[PdCl(dien)]Cl was stirred in water with 1eq. of DMAP at room temperature overnight. The 
solvent was removed by rotary evaporation and acetone was added to the resulting solid. The 
solution was stirred overnight, the acetone was decanted and the solid dried in vacuo (60% 
yield). Anal. Calcd. for C11H25.2N5O1.1Cl2Pt: C, 31.27; H, 6.01; N, 16.58. Found: C, 31.53; 
H, 6.11; N, 16.10. 1H NMR (D2O): 3.0 (8H, br, m), 3.04 (6H, s), 6.6 (2H, d), 8.0 (2H, d). 
Preparation of the zinc finger 
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The peptide was dissolved in deionized water at a concentration of 1 mg/mL. The pH was 
adjusted to 7.2 using NH4OH and zinc acetate (1.3molar eq.) was added to the solution. For 
fluorescence experiments, a 5µM solution of ZF was prepared by diluting the concentrated stock 
solution [13]. 
Nuclear magnetic resonance spectroscopy 
All samples were prepared in D2O at a concentration of ~4mg/mLfor 1H NMR and ~15 mg/mL 
for 195Pt NMR. For 1H NMR, the solvent peak (D2O) was referenced to 4.80 ppm. 195Pt NMR 
samples were measured using Na2PtCl6 as an external reference. 
Fluorescence spectroscopy 
Fluorescence studies were recorded on a Varian Cary Eclipse fluorometer with a single-cell 
Peltier accessory. Samples were irradiated with 280 nm light and spectra were recorded from 300 
to 450 nm with a scan rate of 600 nm/min at 25 °C. The experiments were carried out in 20 
mMTris buffer with 50 mM NaCl at pH 7.4. 5 µM N-acetyl tryptophan or zinc finger was titrated 
with [M(dien)L]n+ at molar ratios of drug from 1 to 10 for DMAP complexes and 10 to 100 for 
all other complexes. The absorbance for the DMAP compounds at 362 nm at 10 molar 
equivalents and all other compounds at 100 molar equivalents was <0.05; therefore, the inner 
filter effect was disregarded [22]. The emission maximum (362 nm) was measured after each 
titration. The Ka was determined from Eadie–Hofstee plots from an average of 3 trials using the 
equation: ΔF = (Ka)−1 ∗ΔF / [quencher]+ΔFc. 
 
4.5 Conclusions 
With respect to zinc proteins in general, target selectivity is a major issue for specific 
inhibition using small molecules. In the case of zinc fingers, the results here extend the concept 
	   99	  
of “weak electrophiles” from organic chemistry to substitution-inert MN4 platinum compounds 
in attempts to gain selectivity and distinguish between the cysteine nucleophilicity of the various 
coordination spheres Cys2His2, Cys3His, and Cys4 [23,24]. The notable increase in association 
constant of [M(dien)(DMAP)]n+ on the zinc finger through the “non-covalent” π–π stacking 
interaction allows further avenues for design of specifically targeted inhibitors and further 
confirms the viability of the medicinal chemistry dual approach of target recognition (non-
covalent) followed by target fixation (covalent) [14]. 
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5.1 Abstract 
The zinc finger HIV nucleocapsid protein HIV NCp7 (NC) is a nucleic acid chaperone 
involved in both the early and late steps of the HIV-1 cycle. Development of NC-nucleic acid 
antagonists is an attractive strategy for AIDS treatment. We report a new class of potential NC-
nucleic acid antagonists, based on the intrinsic ability of metallated nucleobases to mimic the 
reaction of nature. The formally substitution-inert [MN3(Nucleobase)]n+ systems are capable of 
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(i) NC molecular recognition through tryptophan-nucleobase stacking and (ii) subsequent peptide 
covalent bond formation through manipulation of the reactivity of the coordination sphere. They 
represent the first class of inorganic molecules capable of systematic study on the HIV zinc 
finger and may be the only set of compounds with intrinsic selectivity. 
 
5.2 Introduction 
Identification of novel targets and development of new agents for the management of 
HIV-AIDS is a global priority. The nucleocapsid protein HIV NCp7 (NC) is a small basic protein 
containing two zinc finger (or zinc knuckle) CysCysHisCys motifs [1,2]. This motif is highly 
conserved in all known retroviruses, and mutation of the zinc-chelating residues results in 
noninfectious viruses. NC is critically involved in both the early and late steps of the HIV-1 
cycle, mainly through its ability to chaperone nucleic acids toward their most stable 
conformation [1,2].  The chaperone activity includes control of nucleic acid aggregation, 
destabilization and modulation of the kinetics of protein-nucleic acid interactions. The 
rearrangement of nucleic acids is essential for many viral replication processes including reverse 
transcription and recombination. For these reasons, development of NC-nucleic acid antagonists 
is an attractive strategy for AIDS treatment complementary to HAART (Highly Active 
Antiretroviral Therapy)  [3,4]. Further, the high conservation in all HIV-1 strains raises the 
possibility that drugs targeted against NC may be effective in those strains resistant to anti-
reverse transcription and anti-protease drugs [5].  
Zinc proteins in general are important targets for inhibition and drug development [6, 7]. 
Zinc protein sites are generally divided according to function into catalytic, where there is 
usually one substitution-labile aqua ligand, and structural with four strongly-bound donors, 
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usually N (histidine) and S(cysteinate). Zinc finger thiolates constitute soft nucleophilic sites and 
a corollary of zinc thiolate alkylation in nature is that such a process – alkylation or oxidation of 
the liganding moieties - will inactivate the zinc finger and inhibit target (DNA/RNA) 
recognition. On the basis of the physical properties of structural and catalytic Zn-binding sites in 
proteins, it has been suggested that the target for drug design should be the metal ion (chelation) 
for coordination sites with < 1 Cys and the Zn(II) ligands (electrophilic attack) for sites with > 2 
Cys [8]. The underlying principle is that the increase in Cys ligands renders the Zn(II) a weaker 
Lewis acid with concomitant weakening toward chelation.  In general, cysteine modification is 
accompanied by conformational changes and zinc ejection. The report of the use of aromatic C-
nitroso compounds to inhibit HIV-1 infectivity ushered in an intensive search for suitable drug 
candidates based on modification of the zinc-binding ligands [9,10]. The sparse clinical trials on 
zinc finger inhibitors as putative NC-interacting drugs for HIV treatment have been summarized 
[4].  S-acyl 2-mercaptobenzamide thioesters (SAMTs) reduce infectious virus in a transgenic 
mouse model [11]. In a proof-of-concept study using simian immunodeficiency virus 
SIV/DeltaB670 in cyanomolgus macaques SAMT-19 decreased infectious virions in peripheral 
blood mononuclear cells (PBMCs) [12].  
Assessment of protein packing, steric accessibility and electrostatic screening of zinc 
finger cores has recognized the enhanced reactivity of Zn-Cys3His coordination spheres over 
their Cys2His2 counterparts [13,14]. Selectivity for the former, and the ability to distinguish 
between different zinc finger-coordination spheres, can be found in nucleophilic discrimination 
through reaction of weak “organic” electrophiles with the highly nucleophilic zinc-cysteine 
residues [13,14]. In coordination chemistry the equivalent of weak “inorganic” electrophiles has 
been suggested by us to be formally substitution-inert MN4 compounds with four strong M-N 
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bonds typical of the quintessential soft electrophiles Pt(II) and Au(III) [15]. Compounds 
containing a Pt(Au)-Cl bond are likely to be far too reactive for protein selectivity – exemplified 
by the often quoted statement that < 5% of the administered dose of the anticancer drug cisplatin, 
cis-[PtCl2(NH3)2], is considered to get to its cellular target DNA.   
 A significant source of selectivity for HIV-1 inhibition lies in identification of 
nucleocapsid NC-nucleic acid antagonists [9,16,17].  Agents which interrupt the interaction with 
‘natural’ substrate combined with either electrophilic attack or covalent modification may be 
classed as a discrete approach to zinc finger inhibition. The aromatic amino acids tryptophan 
(Trp) and phenylalanine (Phe) are critical for the NC-nucleic acid molecular recognition.  The 
mutation of even one of these residues significantly decreases NC’s nucleic acid chaperone 
activity, and correlates with inhibition of viral replication [18].  Trp interacts with nucleobases 
through both H-bonding and π-stacking with the indole ring of the W37 residue inserted between 
adjacent C and G bases and stacked on the latter [19-22]. Metallation of nucleobases, as with 
protonation and alkylation, enhances π-π stacking interactions with tryptophan, in part due to 
lowering of the HOMO-LUMO gap [23]. Using the C-terminal finger of the HIVNCp7 (F2, 
residues 34-52) we have demonstrated the targeting of the critical tryptophan residue with 
metallated nucleobases [24,25].  
We have now extended these studies to the ‘full” two-zinc finger NC and its complex 
with SL2 RNA (SL2). In the presence of the metallated nucleobases [M(dien)(9-EtG)]n+ (M=Au, 
n=3, I; M=Pt, n=2, II); 9-EtG = 9-ethylguanine) the NCSL2 interaction is inhibited in an 
antagonist fashion and expands the chemistry of this important HIV target in hitherto 
unrecognized directions. Incorporation of a functionalized nucleobase within the MN4 structure 
as in [M(dien)(Nucleobase)]n+ gives agents capable in principle of (i) molecular recognition 
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through the non-covalent tryptophan-nucleobase interaction and (ii) subsequent peptide covalent 
bond formation through manipulation of the reactivity of the coordination sphere. The contrast in 
substitution kinetics between the isoelectronic and isostructural Au(III) and Pt(II) compounds 
provides valuable insights into the antagonist mechanism, allowing for further systematic 
enhancement of this new biological role for platinum metal complexes. The proposed chemistry 
represents the first class of inorganic molecules capable of systematic study on the HIV zinc 
finger with the potential for intrinsic selectivity. The structures of the complexes and 
biomolecules are shown in Figure 5.1. 
 
5.3 Results and Discussion 
Incubation of [Au(dien)(9-EtG)]3+ (I) with intact NC resulted in the detection of species 
produced by ejection of both Zn2+ ions and incorporation of up to 3 Au ions – AuF, Au2F and 
Au3F (Figure 5.2). There was no evidence for intermediate Au-ligand-peptide species, in contrast 
to the reaction of the C-terminal finger of NC with [Au(I)(PPh3)(L)]+ [26].  
Figure 5.1. Structures of A) [M(dien)(9-EtG)]n+(M=Au, I, n= 3; Pt, II, n=2); B) SL2RNA 
(SL2)  and C) NCp7 (NC). 
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 The CD spectrum of NC is characterized by a positive maximum observed at ~215 nm. 
The Au compound caused a decrease in intensity of this band and a significant increase in the 
negative ellipticity with a slight blue shift of the 195-200 nm band, which are indicative of 
conformational changes from ordered structure to random coil (Figure 5.3A) [27,28].  The 
pronounced changes are consistent with a loss of structural integrity in NC upon treatment with I. 
The effects of these conformational changes on the NCSL2 interaction were investigated 
by FT-ICRMS by adding SL2 to an NC sample that was pre-incubated with I for 30 min, or by 
adding I to preformed NCSL2 complex. In the former case, only free unbound SL2 was 
observed, thus indicating that the major structural changes induced by Zn2+-Au3+ replacement 
abrogated the binding capabilities of NC (Figure 5.4). In the latter case, a direct comparison of 
data obtained from NCSL2 in the presence/absence of I showed a significant increase of free 
SL2 in solution (Figures 5.5 and 5.6A), thus suggesting that the gold compound is capable of 
inducing dissociation of the peptide from its cognate RNA. In addition, minor signals 
Figure 5.2.  ESI-FTICRMS spectra (positive ion mode) of a 1:1 reaction of NC: [Au(dien)(9-
EtG)]3+.   
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corresponding to [(Au,ZnNC)SL2] and [(Au2NC)SL2] were detected, which are consistent 
with direct displacement of Zn2+ from the intact NCSL2complex (Figure 6B).	  	  
An advantage of the [M(dien)(9-EtG)]n+ system is that both isostructural and 
isoelectronic systems can be studied. The CD spectrum in the presence of [Pt(dien)(9-EtG)]2+ (II) 
case shows that there is little disruption of the 3D structure in the presence of the Pt(II) complex, 
as evidenced by the maintenance of the positive ellipticity, (Figure 5.3A). Incubation of the intact 
NC with II results in a concentration-dependent decrease in fluorescence from which an 
A)	  
B)	  
Figure 5.3. A. CD spectra of the reaction of NC and [M(dien)(9-EtG)]n+ at 15 minutes 
incubation. B. NC Fluorescence quenching upon addition of [Pt(dien)(9-EtG)]2+ from 10-100 
molar ratios. 	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Figure 5.4. FT-ICRMS spectrum (negative ion mode) of 1:1 [Au(dien)(9-EtG)]3+ / NC 
mixture (incubated for 30 minutes) followed by addition of SL2 RNA.   
 
Figure 5.5. FT-ICRMS spectrum (negative ion mode) of NC:SL2 RNA complex in a 2:1 
ratio.  Note that under these MS conditions, no free RNA is present and the complex remains 
intact. These conditions were used before addition of any metallated nucleobase. 
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Figure 5.6. (A) FT-ICRMS spectra (negative ion mode) of 2:1 NCSL2 complex upon 
addition of 1 eq. [Au(dien)(9-EtG)]3+ (top t=0, run immediately; bottom after 15 mins 
reaction). (B) Expanded region of 2:1 NC/RNA complex reacted with 1 eq. [Au(dien)(9-
EtG)]3+ showing presence of possible RNA-Au-NC crosslinking. 
  	  
A) 
B) 
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association constant (Ka) of 2.0 x 104 M-1 was calculated, compared to 7.5 x 103 M-1 for the C-
terminal finger alone, [24], Figure 5.3B.  
In the case of the Pt complex, analysis under identical experimental conditions as the 
Au(III) case revealed only weak association between II and NC. Nevertheless, pre-incubation 
significantly retarded the kinetics of formation of the NCSL2 complex. Furthermore, addition of 
II to preformed NCSL2 complex induced the release of free SL2, similar to the observations 
afforded by the gold compound (Figure 5.7). In this case, the release of nucleic acid was also 
accompanied by the detection of a relatively abundant species corresponding to a [Pt(dien)(9-
EtG)]2+-SL2 adduct. Biophysical studies on the interaction of II with Calf Thymus DNA 
indicated little or no reaction [15], but the tertiary structure of RNA may enhance association. 
 
Figure	  5.7.	  ESI-MS Spectrum (negative ion mode) of NC-SL2 (2:1) in presence of 2.5 eq. 
of [Pt(dien)(9EtG)]2+ showing liberation of SL2 with decrease in intensity of NC-SL2 
species and observation of  SL2-[Pt(dien)(9EtG)] species.	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Electrophoretic mobility shift assays (EMSA) confirm the general trend of these results 
(Figure 5.8). Increasing concentrations of [Pt(dien)(9-EtG)]2+ results in a decrease in intensity of 
the NCSL2 band. Concomitantly, the free SL2 band changes to an upward smear, which again 
may indicate interaction of the compound itself with the RNA. In contrast, there is no diminution 
of the NCSL2 band in the presence of the Au compound, which could be explained by the 
absence of any interaction, in contradiction to the MS and CD results. An alternative explanation 
is the possible cross-linking of the two biomolecules by the gold compound, or metabolite or 
substitution product thereof. In this case, EMSA analysis may be precluded from properly 
resolving the cross-linked adduct by the large size of the NCSL2 complex. 
 
The cross-linking hypothesis was further investigated by fluorescence polarization 
experiments using labelled SL2-[Flc] (Flc = fluorescein). A control sample consisting of NC and 
Figure 5.8. Effect of Metal-Nucleobase Compounds on SL2 RNA -NCp7 protein 
interaction. See SI for full experimental conditions.  
A: Control Experiment. 32P end-labeled SL2 RNA (2nM) incubated with varying 
concentrations of NCp7 in binding. Lane 1 contains SL2; Lanes 2-8 1µM, 500, 250, 125, 
62.5, 31.3, and 15.6 nM NCp7 respectively.  
B: 250nM NCp7 is Incubation of NC (250 nM) with [Pt(dien)(9-EtG)]2+ for 1hr followed 
by addition of SL2 (2 nM) in binding buffer and further incubation for 1 h. Lane 1 
contains SL2 only, Lane 2 SL2 and NCp7 only; Lanes 3-9 contain NC, SL2 and 500, 250, 
125, 62.5, 31.3, 15.6, and 7.8 µM of I respectively.   
C: Identical to B in all respects but Lanes 3-9 contain 7.8, 15.6, 31.3, 62.5, 125, 250, and 
500 µM [Au(dien)(9-EtG)]3+ respectively. 	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SL2-[Flc] afforded results consistent with formation of the NCSL2 complex (Table 5.1). Upon 
incubation of NC for 1 hour with increasing concentrations of [Au(dien)(9-EtG)]3+ addition of 
SL2-RNA-[Flc] gave polarization values that were higher than those obtained from the control  
 
sample. Although it would be tempting to explain the strengthening of the RNA-protein 
interaction with the formation of a stable [NC-Au-SL2] species, the fluorescent anisotropy 
experiments cannot per se provide direct proof of its formation. Nevertheless, the minor products 
observed in the MS spectra (Figure 5.6B) are consistent with such a hypothesis. The gold 
compound does not interact with RNA itself, as indicated by the values of polarization afforded 
by this control (Table 5.1). In agreement, no [Au(dien)(9-EtG)]-SL2 adducts were observed from 
the MS analysis of Figure 5.6. The “parent” [AuCl(dien)]2+ also has only weak affinity for DNA. 
[29] These results can be rationalized by considering that upon NC interaction, the Au ligands 
are lost (confirmed by MS and CD studies, Figures 5.2 and 5.3A) and it is possible that 
coordinatively unsaturated Au-S or Au-OH(H2O) species could then bind to nucleotides. Of 
relevance, trans-[PtCl2(NH3)2] (trans-DDP) produces cross-links between NC and HIV-1 RNA 
[30], presumably by taking advantage of the long-lived nature of monofunctional trans-DDP-
biomolecule adducts [31].  
 
 
 
Table 5.1. Fluorescence Polarization (mP) of NC (100 nM) incubated with indicated 
concentrations of [Au(dien)(9-EtG)]3+ (I) followed by addition of SL2-[Flc] (10 nM). See 
Experimental.  
SL2                
(-) I 
SL2             
(+) I 
SL2 + NC       
(-) I 
SL2 + NC                
(+) 0.01 µM I 
SL2 + NC              
(+) 0.08 µM I 
SL2 + NC             
(+) 1.25 µM I 
SL2 + NC             
(+) 10 µM I 
106 101 173.5 169 175 191.5 203 
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5.4 Experimental 
Synthesis and Biomolecule Preparation:  The Pt and Au compounds were prepared as 
described previously [14,22]. For the MS studies the NC was prepared in the Fabris lab. Briefly, 
Nucleocapsid (NC) protein of HIV-1 was obtained by in vitro expression in E. coli, subsequently 
purified under non-denaturing conditions to preserve the coordination of Zn2+ by its 
characteristic zinc-finger domains. For the gel shift and biophysical studies, the NC (identical 
sequence) was a generous gift of Dr. R.J. Gorelick, NIH. RNA oligonucleotides corresponding to 
the SL2  stemloop domain of the HIV-1 genome packaging signal (Ψ-RNA) were purchased 
from IDT (Coralville, IA) and desalted using ultrafiltration against 150 mM ammonium acetate. 
Mass Spectrometry: 
Experiments were conducted on a modified Bruker Daltonics (Billerica, MA) SolariX FTICR-
MS equipped with a 12T superconducting magnet.  Analyses were carried out by direct infusion 
using tapered quartz nanospray emitters loaded with 5-10 µL of sample with a spray voltage 
between 800-1100 V relative to the capillary inlet supplied by an inserted stainless steel wire.   
Solutions were prepared as follows: 
A. 1:1 reaction of NC with [Au(dien)(9-EtG)]3+ 
A solution of [Au(dien)(9-EtG)]3+ (7.5 µM in 1 µL H2O)  was added to a solution of NC (7.5 
µM in 1 µL H2O) and volume was brought up to 10 µL with 7µL 150 µM ammonium acetate 
and 1 µL isopropyl alcohol.  The solution was analyzed immediately in positive ion mode. 
B. 1:1:1 reaction of NCp7/[Au(dien)(9-EtG)]3+ with SL2-RNA, Figure S1. 
A solution of NC (7.5 µM in 1 µL H2O) and [Au(dien)(9-EtG)]3+ (7.5 µM in 1 µL) was 
incubated for 30 minutes at room temperature.  SL2-RNA (7.5 µM in 1 µL), 6 µL 150 mM 
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ammonium acetate, and 1 µL isopropyl alcohol were added and the mixture was analyzed 
immediately in negative ion mode. 
C. Control experiment showing formation of NC/SL2 (2:1) complex, Figure S2  
A solution of NC (7.5 µM in 4 µL H2O) was added to a solution of SL2 (7.5 µM in 2 µL 
H2O) and volume was brought up to 10 µL with 3 µL 150 mM ammonium acetate, and 1 µL 
isopropyl alcohol. The solution was analyzed immediately.  No significant incubation was 
necessary. 
D. 2:1:1 reaction of NC/RNA complex with [Au(dien)(9-EtG)]3+ 
A solution of NC (7.5 µM in 4 µL H2O) was added to a solution of SL2 (7.5 µM in 2 µL 
H2O) to form the 2:1 NC/RNA complex. The complex formed immediately; no significant 
incubation was necessary.  A solution of [Au(dien)(9-EtG)]3+ (7.5 µM in 2 µL) was added 
and volume was brought up to 10 µL with 1 µL 150 mM ammonium acetate and 1 µL 
isopropyl alcohol. The mixture was analyzed in negative ion mode immediately (time = 0) 
and after 15 minutes incubation. 
E. 2:1:2.5 reaction of NCp7/RNA complex with [Pt(dien)(9-EtG)]2+, Figure S4. 
A solution of NC (7.5 µM in 4 µL H2O) was added to a solution of SL2 (7.5 µM in 2 µL 
H2O) to form the 2:1 NC/RNA complex. Complex formed immediately; no significant 
incubation was necessary.  A solution of [Pt(dien)(9-EtG)]2+ (37.5 µM in 1 µL) was added 
and volume was brought up to 10 µL with 2 µL 150 mM ammonium acetate and 1 µL 
isopropyl alcohol.  The mixture was analyzed immediately in negative ion mode. 
Circular Dichroism: 
Methods were adapted from those previously published [14,29]. 
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Fluorescence Spectroscopy: 
Methods were adapted from those previously published [14].  A 3 mL solution of NC (5 µM) in 
water was titrated with aliquots of the corresponding quenching compound (7.5 mM) in the 
range [quencher]/[N-AcTrp]) 10-100. 
Gel Shift Assays: 
As a control experiment, 32P end-labeled SL2 RNA (2 nM) was incubated with varying 
concentrations of NC in binding buffer (50 mM Tris-HCl, 40 mM MgCl2, 200 mM NaCl, 0.1 
mM ZnCl2, 5% glycerol, and 1% BME) for 1 hr at 30°C.  In all subsequent reactions, 250 nM 
NC was incubated with increasing concentrations of [Au(dien)(9-EtG)]3+ or [Pt(dien)(9-EtG)]2+ 
for 1 hr in binding buffer. Subsequently, 2 nM SL2 was added to the buffer and the mixture 
incubated for an additional hour.  
Fluorescence Polarization: 
In 250 µl total volume, increasing concentrations of NC were incubated with 10 nM fluorescein-
labeled SL2 RNA for 4 hrs in minimal buffer (25 µM phosphate buffer, pH 7.2 and 225 mM 
NaCl) at room temperature to afford control values. In all subsequent experiments, in 250 µl total 
volume, 100 nM of NC was incubated in minimal buffer (25 µM phosphate buffer, pH 7.2 and 
225 mM NaCl) with varying concentration of drug before addition of 10 nM SL2-
RNA[Flc].  The reactions were incubated 4hrs at room temperature and analyzed on 
a  SynergyTM NEO HTS multi-mode microplate reader system. 
 
5.5 Conclusions 
In summary, the results are consistent with the ability of the chemotype [M(dien)(9-
EtG)]n+ to act as antagonist of the NCSL2 interaction, with significant potential for optimization 
	   116	  
as a structurally discrete new class of agents capable of disrupting the chaperone activity of NC, 
Figure 5.9. The differences in profile between the two metallated nucleobases reflect the 
different substitution kinetics of the central metal ions. Thus, we see immediate displacement of 
Zn2+ by Au3+ (MS, CD) whereas with the kinetically inert Pt2+ an association constant can be 
measured and there is no evidence of Zn2+ dislocation from the NC under these conditions – the 
stacking reaction is observed by fluorescence and CD. In this case, purely non-covalent 
approaches appear to allow physical blocking of the interaction. It is reasonable to expect the Au 
compound to react in the same way – the subsequent loss of ligands upon covalent reaction with 
peptide is just too fast. Model studies with N-AcTrp confirm the greater stacking of the Au(III) 
species relative to Pt(II) [32]. Thus, a classical “two-step’ approach of molecular recognition 
followed by target fixation (electrophilic attack on the zinc finger core) is suggested [24]. The 
greater reactivity of the Au(III) species is also reflected in the possible formation of the higher-
order aggregates.  
Both components of the NC-nucleic acid chaperone activity have been targeted [33-37]. 
A study of approximately 2,000 small molecules from the NCI Diversity Set suggested a 
possible fluoroscein-based pharmacore with a good correlation between tryptophan quenching 
Figure 5.9. Metal-nucleobase compounds as potential HIVNCp7-Nucleic Acid Antagonists. 
n+
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and inhibition of NC-nucleic acid binding [33]. A second high-throughput screening of small 
molecules for inhibition of NC-mediated destabilization of the stem-loop structure of cTAR 
DNA (a sequence complementary to the transactivation response element) produced five selected 
hits from a total of 4800 compounds [34]. The inhibitory activity of 4 of the 5 correlated with 
their ability to compete with the nucleic acid for binding to NC [24].  Along with platinum 
compounds, [9,24], gold drug binding to single zinc fingers has been reported by a number of 
authors, [26, 38-40] but this report is the first of coordination compounds reacting on a “multiple 
(>1)” zinc finger peptide. The chemotype has the potential for intrinsic selectivity for this 
important target over other zinc fingers – the formally substitution-inert species are the 
equivalent of ‘weak’ electrophiles proposed as one approach to selectivity [14,15]. 
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Chapter 6: Synthesis and characterization of additional Au(III) compounds 
designed to target zinc finger proteins (unpublished data) 
 
6.1 Introduction 
The following is an account of additional, unpublished work completed on the synthesis 
and characterization of Au(III)  compounds (Figure 6.1). This chapter will focus on synthetic 
procedures as well as characterization techniques, both successful and unsuccessful. Ongoing 
and suggested future work is also discussed. 
 
Figure 6.1.  Structures of Au(III) compounds discussed in this chapter.  
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6.2  Synthesis and Characterization: 
 The following compounds are additional [Au(dien)(N-heterocycle)]3+ compounds that 
were successfully synthesized.  These compounds have not yet been published in the literature. 
Synthesis of [Au(dien)(9-EtG)]3+ and [Au(dien)(DMAP)]3+, compounds 10 and 11 in Figure 6.1 
respectively, is reported in Chapter 2.  
[Au(dien)(2-amino-4-picoline)]Cl3 (1): A solution containing 0.98 equiv. of 2-amino-4-picoline 
(7.8mg, 0.072mmol) in 1 mL H2O was added to a solution of [AuCl(dien)]Cl2 (30.0mg, 0.074 
mmol) in 3mL H2O. Reaction mixture was stirred at room temperature for approximately 1 hour.  
Upon addition of 2-amino-4-picoline, solution changed from yellow to orange in color.  After 
stirring for 1 hour, solution was evaporated to dryness, resulting in an orange solid.  Solid was 
dried in the dessicator and analyzed by NMR. 1H-NMR in D2O: δ 7.65 (d, 1H), 6.81 (s, 0.92H), 
6.77 (d, 1.04H), 3.40 (t, 4.74H), 2.44 (broad s, 2.92H), 2.37 (s, 3.70H).  Anal. Calcd. for 
C10H21AuCl3N5:  C, 23.34; H, 4.11; N, 13.61%.  Found:  C, 23.02; H, 4.04; N, 13.37%. ε200nm = 
37344 M-1 cm-1, ε230nm = 12690 M-1 cm-1 , ε294nm = 7354 M-1 cm-1.  
[Au(dien)(4-aminoquinaldine)]Cl3  H2O (2): A solution containing 0.98 equiv. of 4-
aminoquinaldine (35.0mg, 0.221 mmol) in 1 mL H2O (not completely soluble) was added to a 
solution of [AuCl(dien)]Cl2 (91.9mg, 0.226 mmol) in 2mL H2O. The reaction mixture was 
stirred at room temperature until all solid was dissolved, approximately 4 hours.  Upon addition 
of 4-aminoquinaldine, solution changed from yellow to orange in color.  After all solid was 
dissolved, solution was evaporated to dryness, resulting in an orange solid.  Solid was dried in 
the dessicator and analyzed by NMR.  1H-NMR in D2O: δ 7.94 (d, 1.07H), 7.81 (t, 1.11H), 7.55 
(m, 2.16H), 6.48 (s, 1.00H), 3.38 (t, 2.87H), 2.51 (s, 3.27H), 2.41 (broad s, 2.03H).  Anal. Calcd. 
for C14H25AuCl3N5O:  C, 23.86; H, 4.32; N, 12.02%.  Found:  C, 28.93; H, 3.91; N, 11.91%. 
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ε191nm = 9661 M-1 cm-1, ε198nm = 11034 M-1 cm-1 , ε214nm = 23905 M-1 cm-1, ε235nm = 27132 M-1 cm-
1, ε319nm = 10244 M-1 cm-1, ε329nm = 9101 M-1 cm-1. 
[Au(dien)(guanosine)](NO3)3  HCl (3): A mixture of [AuCl(dien)]Cl2 with 0.98 equivalents of 
guanosine and 2.8 equivalents of AgNO3 in water was stirred in the dark at room temperature for 
3 days.  Reaction mixture was filtered to remove precipitated AgCl, and orange filtrate was 
rotovapped to dryness.  Acetone was added to precipitate orange product (75% yield). Anal. 
Calcd for C14H27O14N11ClAu:  C, 20.87; H, 3.38; N, 19.12%.  Found:  C, 20.96; H, 3.02; N, 
18.57%.  ε201nm = 54554 M-1 cm-1, ε250nm = 15846 M-1 cm-1 , ε366nm = 884 M-1 cm-1.   1H-NMR in 
D2O: δ 8.70 (s, 1H), 8.37 (s, 0.59H), 6.01 (d, 0.96H), 5.95 (d, 0.34H), 4.71 (t, 1.75H), 4.39 (t, 
1.37H), 4.26 (m, 1.51H), 3.88 (m, 3.51H), 3.70 (s, 1.05H), 3.60 (t, 4.15H), 2.99 (broad s, 4.13H). 
[Au(dien)(5’GMP)](NO3)2    (H2O)3 (4): A solution of [AuCl(dien)]Cl2 (103.0mg, 
0.253mmol) was activated with 2.8 equiv. of AgNO3 (120.7mg, 0.711mmol) in 3mL water 
overnight in the dark while stirring at room temperature. The solution was filtered to remove 
precipitated AgCl; the resulting solution was colorless.  0.98 equivalents of 5’GMP (90.4mg, 
0.249mmol) in 2mL H2O was slowly added and the reaction mixture was left to stir at room 
temperature for one day.  The solution turned light orange.  At the end of day, a small amount of 
solid precipitated.  The reaction mixture was filtered and the remaining solution was lyophilized.  
NMR showed 13% free 5’GMP present.  The solid was re-dissolved in 5mL D2O and solution 
was left to stir for two days, after which free 5’GMP was still present (analyzed by NMR). The 
reaction mixture was heated overnight at 40-45°C. The solution was evaporated to dryness and 
the solid was dried in the dessicator.  No free ligand was present. 1H-NMR in D2O: δ  8.76 (s, 
1H), 6.06 (d, 1.06H), 4.39 (m, 6.91H), 3.54 (t, 1.2H), 3.45 (t, 2.64H), 2.44 (broad s, 3.34H). 
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Anal. Calcd. for C14H32AuN10O17P:  C, 20.01; H, 3.84; N, 16.67%.  Found:  C, 20.18; H, 3.5; N, 
16.24%. 
 **This synthesis was difficult to reproduce.  Though NMR did not show any impurities, 
elemental analysis showed C, H, and N% to be very low (could be presence of salts such as 
NaCl, HCl, etc). For the majority of attempts, however, there was always an excess of free 
5’GMP present and it was difficult to separate the ligand from the product because both are 
extremely soluble in water. It is likely that the 5’GMP ligand acquired H2O over time, which 
would alter the molecular weight.  
 Size exclusion chromatography was performed in an attempt to separate the product from 
free ligand based on size/molecular weight. In theory, the larger Au-complex should exit the 
column first and the smaller components such as free ligand and other impurities should move 
through the column slower allowing separation. The column was prepared using Sephadex G-10 
medium (40-120 µ particle size) and packed with water.  A 10 mL solution of the crude product 
(approx. 18 mM) was passed through the column and collected in fractions.  All fractions were 
lyophilized and analyzed by NMR.  The third fraction contained no free 5’GMP ligand, however 
the amount of solid was very small.   
 The Sephadex G-10 has an exclusion limit of 700 MW. The exclusion limit is defined as 
the molecular weight at which molecules are too large to be trapped in the stationary phase. The 
molecular weight of [Au(dien)(5’GMP)]2+ is ~660 g/mol, suggesting that the Sephadex G-10 was 
not the optimal medium to use. In order to obtain better separation, a medium with a smaller 
exclusion limit should be used. Water was the only eluent used in the initial attempt. In order to 
provide better separation, a mixed solvent system may need to be used. 
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 The following compounds are additional [Au(dien)(N-heterocycle)]3+ compounds that 
were either not successful, have not yet received suitable elemental analysis, or were only 
performed on a small NMR scale and have yet to be scaled up and isolated.   
[Au(dien)(5’CMP)](NO3)3 (5): A solution of [AuCl(dien)]Cl2 was prepared in 10 mL H2O. 0.98 
equivalents of 5’CMP and 2.8 equivalents of AgNO3 were added and reaction mixture was 
stirred at room temperature in the dark for 3 days.  Precipitated AgCl was removed via vacuum 
filtration and the remaining filtrate was rotovapped to dryness, resulting in an orange film on the 
glass.  Acetone was added to precipitate orange solid.  1H-NMR in D2O: δ  8.14 (d, 0.50H), 8.09 
(d, 1.00H), 6.28 (d, 0.86H), 6.22 (d, 0.59H), 5.98 (t, 1.08H), 4.19 (broad m, 8.47H), 3.51 (broad 
m, 10.88H), 2.96 (broad s, 2.30H), 2.42 (broad s, 3.77H).  Anal. Calcd. for C13H27AuN9O17P: C, 
19.29; H, 3.36; N, 15.58%.  Found:  C, 16.48; H, 2.64; N, 14.44%.  
[Au(dien)(1-MetCyt)](NO3)3 (6a): A solution of [AuCl(dien)]Cl2 (33.6mg, 0.083mmol) was 
dissolved in 2mL H2O.  0.98 equivalents of 1-MetCyt (10.3mg, 0.082mmol) was dissolved in 
1mL H2O and added to the [AuCl(dien)]Cl2 solution.  The solution changed from yellow to 
orange.  2.8 equivalents of AgNO3 (40.0mg, 0.236mmol) was added to the reaction mixture.  The 
reaction was left to stir at room temperature in the dark for 3 days.  The mixture was filtered to 
remove AgCl, and the remaining light yellow solution was rotovapped to dryness, resulting in a 
nearly invisible film.  Acetone was added and sides of flask were scratched to remove a light 
yellow solid.  Acetone was decanted and solid was dried in dessicator.  1H-NMR in D2O: δ  7.81 
(d, 0.80H), 7.70 (d, 0.75H), 6.13 (d, 1.00H), 3.61 (broad s, 7.38H), 3.44 (s, 0.62H), 3.43 (s, 
0.90H), 3.11 (broad s, 3.19H).  Anal. Calcd. for C9H20AuN9O10: C, 17.68; H, 3.3; N, 20.62%.  
Found:  C, 17.37; H, 3.41; N, 13.51%. The presence of a broad peak at 3.61ppm and the fact that 
the final product is yellow indicates the presence of free [AuCl(dien)]Cl2.  
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 Elemental analysis of the free 1-MetCyt ligand and a AgCl test both show that excess 
chloride is present.  If the 1-MetCyt ligand is in fact a chloride salt, it is likely that the N3 site, 
that to with gold(III) will bind, is protonated.  It was thought that adding 1 equvalent of NaOH 
would neutralize the ligand and deprotonate this site.  The initial results are promising; the final 
product is orange, similar to all other AuN4 compounds and the NMR contains a triplet in the 
dien region rather than a broad singlet so it is thought that there is no free dien present. 
Elemental analysis of this product indicates the produce is very impure, most likely due to the 
presence of salt impurities in the free ligand.  To obtain a pure final product, the 1-
methylcytosine ligand must first be purified. A new graduate student in the lab, James Beaton, is 
taking over the project and is currently working on ligand purification/synthesis.  
[Au(dien)(1-MetCyt)]Cl3 (6b): A solution of [AuCl(dien)]Cl2 (107.6mg, 0.265mmol) was 
dissolved in 2mL H2O.  0.98 equivalents of 1-MetCyt (32.5mg, 0.260mmol) was dissolved in 
2mL H2O.  The solution of 1-MetCyt was added to the [AuCl(dien)]Cl2 solution and the reaction 
mixture was left to stir overnight at room temperature.  Solution immediately turned from yellow 
to dark orange.  Overnight a small amount of black solid precipitated.  Solution was filtered and 
rotovapped to dryness, resulting in an orange solid.  Solid was dried in dessicator and analyzed 
by NMR. 1H-NMR in D2O: δ 7.78 (d, 1.00H), 6.10 (d, 1.00H), 3.79 (broad d, 1.38H), 3.57 (t, 
4.63H), 3.43 (s, 2.60H), 3.41 (s, 0.40H), 3.27 (m, 1.64H), 3.05 (broad s, 4.25). Anal. Calcd. for 
C9H20AuN9O10: C, 20.33; H, 3.79; N, 15.81%.  Found:  C, 15.52; H, 3.08; N, 18.57%.  
 It is possible that the [Au(dien)(1-MetCyt)]Cl3 synthesis was successful with a few 
impurities (peaks at 3.79 and 3.27ppm), as indicated by elemental analysis.  The absence of free 
1-MetCyt and the presence of the sharp triplet at 3.57ppm are also indicative of a successful 
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reaction. This reaction should be attempted again with an extra purification step, perhaps 
recrystallization with water/acetone.  
[Au(dien)(quinolone)]Cl3 (7): 0.98 equivalents of quinolone (10.68 µL) was added to a solution 
of [AuCl(dien)]Cl2 (37.5mg in 1 mL H2O).  The reaction was stirred at room temperature for 30 
minutes.  Reaction turned light orange over time.  Reaction was evaporated to dryness. 1H-NMR 
in D2O: δ 8.95 (d, 1.00H), 8.83 (d, 1.11H), 8.12 (m, 2.16H), 8.01 (t, 1.07H), 7.82 (m, 2.20H), 
3.46 (t, 4.12H), 2.66 (broad s, 3.56H). 
[Au(dien)(isoquinoline)]Cl3 (8): Reaction was performed on a small scale and followed by 
NMR. A solution of [AuCl(dien)]Cl2 (4.8mg in 700 µL D2O) was prepared. 0.98 equivalents 
(1.36 µL) isoquinonline was added and reaction was followed by NMR. 1H-NMR in D2O: δ 9.57 
(s, 1.00H), 8.42 (m, 2.99H), 8.17 (m, 2.15H), 7.98 (m, 1.09H), 3.48 (t, 6.52H), 2.78 (broad s, 
5.12H), 2.39 (broad s, 0.59H). 
 ** The NMR spectra of the Au(III)-quinoline and iso-quinoline species suggest that the 
reactions were successful.  It would be interesting to scale-up the reaction and isolate a product 
and determine the Ka with free N-acetyletrypophan.  Though the pKa’s of the free ligand are are 
5.0 and 5.4 respectively (both lower than DMAP), it is still expected that they would pi-stack 
efficiently with N-AcTrp due to the extended π-system into another 6-membered ring. This 
could, however, also aid in binding to DNA, therefore it would also be necessary to perform an 
EtBr assay. 
[Au(dien)(pyridine)](NO3)3 (9): 0.98 equivalents of pyridine (5.69 µL) was added to a solution 
of [AuCl(dien)]Cl2 (29.3 mg in 1 mL H2O). Solution immediately turned from yellow to orange.  
2.8 equivalents of AgNO3 (34.1 mg) was added to the reaction mixture.  Reaction was stirred at 
room temperature in the dark overnight. Solution was filtered to remove AgCl; filtrate was 
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yellow. Reaction mixture was evaporated to dryness and acetone was added to precipitate a 
sticky yellow solid.  1H-NMR in D2O: δ  8.79 (t, 2.00H), 8.64 (t, 0.73H), 8.29 (t, 0.29H), 8.09 (t, 
1.52H), 7.87 (t, 0.56H), 3.60 (broad s/t, 7.30H), 3.10 (broad s, 1.64H), 2.60 (broad s, 1.02H).   
 
To add both steric hindrance and lipophilicity to the Au(III) compounds, Me4dien 
(1,1,7,7-tetramethyldiethylenetriamine) was used in place of dien. In theory, this would allow for 
a decrease in the rate of reactivity, as well as aid in the drugs’ entrance into cells. It is still of 
interest to synthesize this on a larger scale and expand the series of Au(III)-N-heterocycle 
compounds. 
[Au(Me4dien)Cl]PF6 : This procedure was adapted from the literature [1]. One hundred µL of 
Me4 dien was added to 300 µL of ice cold ether and left to stir. HAuCl4, 34.5 mg, was dissolved 
in 100 µL ice cold ether.  While stirring on ice, the HAuCl4 solution was slowly added dropwise 
to the Me4dien solution.  An orange paste immediately formed.  (The paper being followed did 
not specify how long to leave reaction stirring on ice.  It was noticed that if the reaction mixture 
was left to stir for a long period of time that the orange paste turned brown, therefore, reaction 
was left to stir for only one minute. Ether was immediately decanted.  The orange paste was 
washed three times with 200 µL ether. Cold water, 300 µL, was added to the orange paste; solid 
did not completely dissolve.  Extraction was performed with ten 600 µL portions of cold ether.  
Aqueous solution was frozen with liquid nitrogen and subsequently thawed under running water 
with “vigorous agitation”. NH4PF6, 21.1 mg,  was added and mixture was re-frozen.  Solid 
immediately formed upon addition of salt.  Once thawed, the solid was isolated and dried in 
dessicator.  The resulting solid was orange in color.  1H-NMR in D2O: δ 3.50 (t, 3.98H), 3.21 (s, 
12H), 2.92 (broad s, 4.70H ).  Anal. Calcd. for C8H21AuClF6N3P : C, 17.94; H, 3.76; N, 7.84%. 
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Found: C, 15.41; H, 3.12; N, 7.28%.  If two –Cl’s are present, the elemental analysis fits better: 
Anal. Calcd. for C8H21AuCl3F6N3P (%): C, 15.81; H, 3.48; N, 6.92%. Found (%):C, 15.41 (-
0.40%); H, 3.12 (-0.36%); N, 7.28 (+0.36%). 
 
2,2’,2”-terpyridine (terpy) is another well known chelating ligand used for Au(III) 
compounds.  [AuCl(terpy)]Cl2 was initially synthesized to compare to that of [AuCl(dien)]2+, 
however it was decided not to continue any further due to the increased binding to DNA (see 
Table 7.1).   
[AuCl(terpy)]Cl2  2H2O: This compound was synthesized using a previously reported method 
[2].  The yield was 73%.  NMR and elemental analysis results were consistent with previous 
reports. 1H-NMR in D2O: δ 9.28 (d, 2.00H), 8.88 (m, 1.11H), 8.72 (m, 6.47H ), 8.15 (m, 2.25H).  
Anal. Calcd. for AuCl15N3H11Cl3•2H20:  C, 31.46; H, 2.64; N, 7.34%.  Found:  C, 31.46; H, 2.35; 
N, 7.11%  
 
 **Crystallization was attempted for many of the compounds above using water/acetone, 
however crystals were never obtained.  For most attempts, no solid ever precipitated and if any 
solid did come out of solution it was a very small amount and sticky; never crystals.  As noted 
above, most compounds seem to have one or two waters present.  These waters could be a key 
part to their crystal structure, which could be why it is difficult to precipitate.   
Crystallization should, however, continue to be attempted.  We could try other solvents 
such as methanol and ether.  There are also other techniques we could use. We could simply 
dissolve the solids in minimal amount of water or any other suitable solvent and place in the 
fridge undisturbed. It is best to do this in an NMR tube or a type of vial with a large surface area 
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for the crystals to form/grow. We could also use a slow cooling technique in which we suspend 
the solid in a solvent with a boiling point of 30-90 °C, such as methanol.  The heat should aid in 
dissolving the compound.  Once the compound is fully dissolved, the solution is then cooled 
slowly with the hope of precipitating crystals. Solvent diffusion is another technique in which a 
solution is placed in a sample vial and a second less dense solvent is carefully dripped down the 
side of the vial. Crystals form at the boundary where the solvents slowly diffuse [3]. 
 
6.3 Experimental 
IR: For all IR measurements, KBr pellets were used.  To prepare a KBr pellet, approximately 
100 mg KBr was weighed and placed in a mortar.  2% of the sample was added and the 
KBr/sample mixture was ground to a fine powder.  It is important to work fast as KBr is 
hygroscopic, absorbing water in the air, which can result in a high background in the IR 
spectrum. Once the mixture was ground to a fine power, a pellet was formed using a pellet press, 
and the pellet was quickly analyzed by both far and near IR. 
Melting point experiments: DNA melting point experiments were carried out on a JASCO V-
550 UV/VIS spectrophotometer.  All measurements were carried out in 10 mM NaClO4 buffer, 
pH 7.5.  Calf thymus DNA was dissolved in the buffer and the DNA concentration was 
determined by absorption measurements at 260nm.  A titration of DNA was performed to 
evaluate the effects of increasing drug concentration on the melting point of the DNA.  DNA was 
incubated for 1 hour with ri (ratio of drug to DNA) values of 0.01, 0.03, 0.05, 0.075, and 0.1, the 
DNA concentration always being 100 µM.  The temperature ranged from 41.5 to 95°C.   Each 
experiment was done in duplicate.  
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Fluorescence Spectroscopy:  
• Basic fluorescence spectra of compounds: A 5 µM solution was prepared in water and the 
samples were excited at 280 nm.   
• Fluorescence quenching assay: Methods were adapted from those previously published 
[4]. A 3 mL solution of N-AcTrp (5 µM) in water was titrated with aliquots of the 
corresponding quenching Au-compound (7.5 mM) in the range [quencher]/[N-AcTrp]) 1-
10. 
NMR Spectroscopy: 1H NMR spectra were obtained on a Varian Mercury-300MHz 
Spectrometer; chemical shifts were referenced to the residual D2O peak at 4.8 ppm. 2D NMR 
spectra were obtained on a Bruker AVANCEIII 600MHz instrument.  
• Reactions with small molecules: 0.006-0.009 mmol solutions of Au-compounds were 
added to a solution containing 1 equivalent of N-Acetylcysteine or N-Acetylmethionine.  
The reaction was followed hourly by NMR.  
• pH dependency: 10-12 mM solutions of Au-compounds were prepared in D2O. pH was 
adjusted using 1M DNO3 and 1M NaOD; 0.1M solutions were used for tighter pH 
ranges. Readings of the pH meter for D2O solutions were not corrected for deuterium 
isotope effects and are designated as pH* values.  
• Temperature dependency: 10-12 mM solutions of Au-compounds were prepared in D2O. 
Temperature was adjusted every ~10 °C and the 1H NMR spectra was recorded. 
• 2D NMR: [Au(dien)(9-EtG)](NO3)3 was analyzed by 2D COSY NMR and [AuCl(N-
Medien)]Cl2 was analyzed by 2D HMBC NMR. Both samples were prepared in D2O at 
approximately 50 mM concentration.  
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Zinc Finger Preparation: All proteins were purchased from GenScript.  Each peptide was 
dissolved in degassed deionized water to a final concentration of 0.2 mg/mL.  pH was adjusted to 
7.2-7.4 using a NH4OH solution.  1.3 equivalents of zinc acetate was added to free peptide 
solution to make zinc finger.  For both mutant peptides, the zinc finger was incubated at 37 °C 
for 2 hours to ensure complete formation of zinc finger.  Other peptides, Cys3His HIV NCp7(F2) 
and Sp1(F3), form zinc finger immediately; no incubation was necessary. 
CD: CD spectra were obtained using a JASCO J-600 Spectropolarimeter (Jasco Corp., Tokyo, 
Japan). Each spectrum was recorded in the wavelength range of 190–240 nm in a 1 mm cuvette 
path length at room temperature under N2 gas. Spectra were baseline-corrected and smoothed. 
A CD spectrum of both free peptide and zinc finger were run before drug was added.  1.3 
equivalents of drug was added to zinc finger and CD was recorded at various time points. 
PAR Assay: To obtain a calibration curve, a 50 µM PAR solution was titrated with 0.1, 0.5, 1, 
and 2 molar equivalents of zinc (from 10 mM Zinc Acetate solution) and the intensity at 500 nm 
was measured. For the ZF/PAR/Au reaction, a solution containing 30 µM ZF (mutant Cys3His) 
and 50 µM PAR was prepared.  1.3 equivalents of [Au(dien)(9-EtG)](NO3)3 was added and the 
reaction was followed by UV/VIS every 10 minutes for 1 hour. 
Mass Spectrometry with NCp7(F2) and Sp1(F3): Experiments were performed using the same 
parameters and procedures outlined in Chapter 3. Experiments performed using apo-peptide, 
however, were run without ammonium acetate. Apo-peptide samples were diluted as follows: 20 
µL concentrated sample in 200 µL methanol. 
Mass Spectrometry with full NCp7 Zinc Finger: Experiments were performed using the same 
instrumentation and parameters as described in Chapter 5. 
A. Reaction of NC with [Au(dien)(DMAP)]3+ and [Au(dien)(9-EtG)]3+ 
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1:1 drug:ZF reaction: A solution of Au(III) complex (7.5 µM in 1 µL H2O)  was added to 
a solution of NC (7.5 µM in 1 µL H2O) and volume was brought up to 10 µL with 7µL 
150 µM ammonium acetate and 1 µL isopropyl alcohol.  The solution was analyzed 
immediately in positive ion mode. 
0.5:1 drug:ZF reaction: A solution of Au(III) complex (7.5 µM in 1 µL H2O)  was added 
to a solution of NC (7.5 µM in 2 µL H2O) and volume was brought up to 10 µL with 6µL 
150 µM ammonium acetate and 1 µL isopropyl alcohol.  The solution was analyzed 
immediately in positive ion mode. 
B. Competitive binding studies  
SL2-RNA (7.5 µM in 1µL H2O) and either [Au(dien)(9-EtG)]3+ or [Au(dien)(DMAP)]3+ 
(7.5 µM in 1 µL H2O) were added simultaneously to a solution of NCp7 (7.5 µM in 2 µL 
H2O). Volume was brought up to 10 µL with 5 µL 150 µM ammonium acetate and 1 µL 
isopropyl alcohol. The solution was analyzed initially and after 15 minutes incubation at 
room temperature in negative ion mode. 
EMSA Gel Shift Assay: As a control experiment, 32P end-labeled SL2 RNA (2 nM) was 
incubated with varying concentrations of NCp7 in binding buffer (50 mM Tris-HCl, 40 mM 
MgCl2, 200 mM NaCl, 0.1 mM ZnCl2, 5% glycerol, and 1% BME) for 1 hr at 30°C. In all 
subsequent reactions, 250 nM NCp7 was incubated with 2 nM SL2/SL3 for 30 minutes in 
binding buffer, followed by the addition of increasing concentrations of Au(III)-metal complex 
with an addition 1 hr incubation period. Experiments performed in low zinc buffer were 
performed in the same manner. Low zinc buffer components are: 50 mM Tris-HCl, 40 mM 
MgCl2, 200 mM NaCl, 5% glycerol, and 1% BME (There is still 10 µM zinc in the final reaction 
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because the protein itself is diluted in 10 mM Tris-HCl (pH8.0), 25 mM NaCl, 5 mM MgCl2, 1 
mM ZnCl2, 1 mM BME, and 0.01% PEG).  
MTT Assay: Human colon carcinoma cells HCT116 and human ovarian carcinoma cells A2780 
were cultured in RPMI 1640 medium with 10% fetal bovine serum (FBS).  Cells were routinely 
passaged at 80-90% confluency.  For the MTT assay, cells were plated at a density of 5,000 cells 
per well in a 96-well plate and incubated overnight at 37°C in a 5 % CO2 atmosphere. Cells were 
treated with varying drug concentrations (50, 25, 12.5, 6.25, 3.125, 1.5625, and 0.78125 µM) for 
72 hours.  After drug removal, cells were incubated with MTT (3-(4,5-Dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide) (0.5 mg/ml in media) for 3 hours.  The excess MTT was 
removed, the dye dissolved in 100 µl of DMSO, and absorbance was read on a Bio-Tek uQuant 
Microplate Spectrophotometer at 570nm. 
Au recovery: [5] Due to the high cost of HAuCl4 it is useful to be able to recycle the Au waste 
we produce in the lab and synthesize chloroauric acid ourselves. To do so, all gold waste was 
evaporated down to dryness.  The resulting solid (51.57 g) was dissolved in aqua regia (200 mL 
of 3:1 HCl:HNO3). Solution was heated at 70 °C for ~15 minutes followed by stirring at room 
temperature for ~1 hour.  The solution was filtered and filtrate was reduced to ~50 mL. The 
filtrate was diluted with H2O, and HAuCl4 was extracted with butyl diglyme.  The extract was 
washed with 1.5 M HCl three times. Oxalic acid, 5 wt%, was added and solution was heated at 
70-80 °C for 4-5 hours; brown/black solid immediately formed.  The solution was filtered to 
remove solid. Ether was added to the filtrate and the mixture was placed in the fridge to 
precipitate solid.  The mixture was filtered and the solid was washed with 4M HCl, water, and 
methanol.  At this point, the solid is metallic gold.  This is where gold recovery stopped, 
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however in order to produce HAuCl4 we would simply need to dissolve the metallic gold in aqua 
regia (see equation 1 below) and carefully evaporate the solution. 
Au + HNO3 + 4 HCl → HAuCl4 + NO + 2 H2O        (1) 
 
6.4 Results and Discussion: 
6.4.1 Characterization of select Au(III) compounds: 
6.4.1.1 IR Characterization  
The main purpose for performing IR was to observe the absence of the distinct Au-Cl 
band upon binding of N-donors. IR was performed for [Au(dien)(9-EtG)](NO3)3, 
[Au(dien)(guanosine)](NO3)3, and [AuCl(dien)]Cl2 (See Figure 6.1 for structures). The far IR 
spectra (500 – 100 nm) is shown in Figure 6.2.  The strong band at 360 nm indicates the presence 
of a Au-Cl bond, which is not present in either the 9-EtG or guanosine compound. This is a 
Figure 6.2.  Far-IR spectra of [AuCl(dien)]Cl2, [Au(dien)(gua)](NO3)3, [Au(dien)(9-
EtG)](NO3)3. 
[AuCl(dien)]2+ 
[Au(dien)(gua)]3+ 
[Au(dien)(9-EtG)]3+ 
Au-­‐Cl	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useful technique, in addition to NMR, to determine the presence of free starting material, 
[AuCl(dien)]Cl2. 
6.4.1.2  Structural information using 2D NMR 
The two-dimensional COSY (correlation spectroscopy) NMR spectrum of [Au(dien)(9-
EtG)]3+ shows the 1H spectra along both axes (Figure 6.3).  The peaks on the diagonal 
correspond to the peaks in a regular 1D-1H-NMR experiment, while the cross peaks indicate 
couplings between pairs of nuclei. Unfortunately, from this spectrum, we do not gain any 
structural information we did not already know; the protons on the ethyl group of the 9-EtG 
ligand couple with each other, as do those on the tridentate dien ligand. 
 
An HMBC (heteronuclear multiple-bond correlation) 2D NMR was performed for  
[AuCl(N-Medien)]Cl2 (Figure 6.4). This type of NMR detects correlations between different 
nuclei, in this case 1H and 13C, over 2-4 bond lengths. This experiment was performed not 
necessarily to learn more about the structure of the compound, but to aid in identifying which 
Figure 6.3. 2D COSY NMR spectrum of [Au(dien)(9-EtG)](NO3)3. 
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hydrogens each peak represented on the 1H NMR spectrum. The 13C NMR spectrum has three 
distinct peaks, which one would expect based on the structure.  The 1H NMR spectrum, however, 
has 4 peaks, and it is unclear which N-Medien hydrogens are which peaks. Due to integration, it 
is clear which peak is the methyl group in both the 13C and 1H spectra. The cross-peaks indicate 
that the 1H NMR peaks farthest downfield represent the “B” hydrogens in the labeled structure in 
Figure 6.4. This multiplet integrates as 4 so all “B” protons are in a similar environment. The 
“A” protons, however, are split into two 2H multiplets differing by ~ 0.45 ppm. The 2D HMBC 
spectrum does not show any coupling to these protons, other than the corresponding 13C peak, so 
it is still difficult to determine which peaks are which hydrogens specifically. 
 
 
Figure 6.4. 2D HMBC spectrum of [AuCl(N-Medien)]Cl2. 	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6.4.1.3 Temperature and pH dependency experiments with [Au(dien)(5’CMP)]3+ and 
[Au(dien)(1-MetCyt)]3+ compounds 
Temperature dependency experiments by NMR are a useful technique in determining if 
rotamers are present in solution.  For example, where at 20°C two peaks are present in the 195Pt 
NMR spectrum for [Pt(dien)(1MetCyt)]2+, only one broad peak is present at 80°C. This 
coalescence of peaks indicates rotamers are present in solution due to hindered rotation around 
the Pt-N3 axis [6]. Similarly, the low field 1H NMR spectrum in d7-DMF showed coalescence of 
the secondary dien-NH amine protons at 40°C.  The X-ray crystal structure of 
[Pd(dien)(cytosine)]2+ provides evidence for the presence of rotomers, with the cytosine ligand 
being perpendicular to the dien [6].  
1H NMR temperature dependency studies were performed for both [Au(dien)(5’CMP)]3+ 
Figure 6.5. Temperature dependency experiment of [Au(dien)(5’CMP)]3+. Peaks marked with 
* indicate those that coalesce upon increase of temperature. 	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and [Au(dien)(1-MetCyt)]3+. Though both compounds are impure according to their elemental 
analysis results, both NMR spectra appeared to show no evident impurities. NMR	   of	   
[Au(dien)(5’CMP)]3+ showed splitting of the H6 doublets, similar to what is seen for the H8 
singlet in [Au(dien)(9-EtG)](NO3)3.  Unlike for the 9-EtG complex, upon heating the sample 
these peaks coalesce (Figure 6.5), indicating this is not due to pH dependency as is the case for 
[Au(dien)(9-EtG)]2+ , but rather due to the presence of rotamers in solution.  Upon cooling the 
solution, the NMR spectrum returned to its initial state.	  	  
Similar results were expected for the [Au(dien)(1-MetCyt)]3+ complex due to the 
similarities in the cytosine structures. However, unlike the 5’CMP complex, there was no peak 
coalescence upon temperature increase, rather the doublet furthest upfield decreased in intensity, 
until the peak was no longer present at 70°C (Figure 6.6). It is unclear as to why increasing the 
temperature would cause peaks to disappear, as the typical result is peak coalescence. However, 
the fact that the peaks did not coalesce indicates the peak splitting is likely not due to rotamers in 
solution, but more likely a result of pH dependency.  
Figure 6.7 shows the change in NMR spectra over a pH range for [Au(dien)(1-
MetCyt)]3+. As the pH* is increased from 3.0 to 4.8, the H6 doublet most downfield (most likely 
pertaining to the protonated compound) disappears, and one doublet is present (most likely the 
deprotonated form). As pH* is increased to 7.4, a new doublet appears upfield, which may 
represent the deprotonated form of the NH2 on the 1-methylcytosine ligand. H5 appears to show 
some pH dependency as well, but it is not as clear as the H6.  
Lippert et al. have previously reported pKa studies with Pt(II)-1-MetCyt compounds.  
Under extremely basic conditions, the exocyclic amino group of [Pt(dien)(1-MetCyt)]2+ becomes 
deprotonated with a pKa of 13.5 in D2O [7, 8]. If the upfield doublet that appears at pH*>6.5 in 
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fact represents the deprotonation of the NH2 on the Au-complex, the pKa can roughly be 
estimated to be ~7.4. This extreme reduction in pKa values between Au and Pt is also seen for the 
Figure 6.6. NMR spectra of [Au(dien)(1-MetCyt)]3+ at varying temperatures. 
Figure 6.7. NMR spectra of [Au(dien)(1-MetCyt)]3+ at varying pH* values. 
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9-EtG complex, where the pKa of N1H of 9-EtG is reduced from 9.57 for Pt-dien to 8.17 for Au-
dien [9]. Lippert et al. have also reported that at alkaline pH values, Pt(II)-1-MetCyt complexes 
can undergo cytosine deamination, forming the 1-methyluracilate complex.  With the dien 
complex, specifically, a competing reaction also takes place where Pt(II) migrates from the N3 
position to the exocyclic N4 position, thus producing syn and ani rotamers (Figure 6.8A) [7, 8]. 
These rotamers, however, were distinguished by significant shifts in the H5 NMR peaks, which 
in the case of the [Au(dien)(1-MetCyt)]3+ complex, the H5 peaks do not shift a lot.  However, the 
NMR spectra in Figure 6.7 appear to be very similar to an experiment by Lippert et al. where a 
solution of [Pt(NH3)3(1-MetCyt)] was monitored at alkaline pH over time, showing the shift 
from the 1-MetCyt to 1-MetUracilate complex (Figure 6.8B) [7].  Due to this similarity, it would 
be worth while to investigate this further once a pure [Au(dien)(1-MetCyt)]3+ compound is 
synthesized.	  	  
	  
Figure 6.8. (A) Scheme showing both deamination and metal migration for 
[Pt(dien)(1-MetCyt)]2+ and (B) NMR spectra of [Pt(NH3)3(1-MetCyt)]2+ at pD=12.7 
taken at different time points. [7] 
A) B) 
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6.4.2 Reactivity with biomolecules 
6.4.2.1 DNA Melting Point Experiments 
 The primary goal of this thesis is to synthesize Au-metal complexes that interact with 
zinc fingers, in turn inhibiting DNA binding. Because our primary target is the zinc finger itself, 
it is important that our compounds do not favor binding with DNA. To analyze the degree of 
binding to DNA, melting point studies of Calf Thymus (CT) DNA in the presence of metal-
complex were performed. Table 6.1 shows the ΔTm relative to the calf thymus DNA titrations 
for both the activated and non-activated forms of [AuCl(dien)]3+ and [AuCl(terpy)]3+ as well as 
various other Au(III) compounds synthesized. 
 
Though all compounds induce stabilization of DNA, some induce less than others. The 
compounds showing the least amount of stabilization are those where X = 2-amino-4-picoline, 
5’GMP and 9-EtG. When compared to the ΔTm values of Triplatin NC, a known Pt-compound 
that binds strongly to DNA, all values for [Au(dien)X]3+ are not very significant which suggests 
DNA is not the primary target for these compounds and there will be little competitive binding 
Table 6.1. ΔTm values relative to the CT-DNA titrations for various Au(III)-
complexes. 
ri = 0.01 0.03 0.05 0.075 0.1 
[AuCl(dien)]Cl2 2.2 0.3 2 4.45 6.6 
[Au(NO3)(dien)](NO3)2 1.8 3.8 2.85 6.35 6.1 
[AuCl(terpy)]Cl2 2.8 4.3 7.9 10.35 12.6 
[Au(NO3)(terpy)](NO3)2 3.7 5.3 11.2 N/A N/A 
[Au(dien)(DMAP)]Cl3 2.226 2.856 4.704 5.922 7.014 
[Au(dien)(2amino4picoline)]Cl3 0.294 3.528 1.596 1.344 1.848 
[Au(dien)(4aminoquinaldine)]Cl3 0.882 2.856 3.738 6.804 7.014 
[Au(dien)(5’GMP)](NO3)2 -0.05 0.35 1.4 2.7 4 
[Au(dien)(9-EtG)](NO3)3 0.882 1.932 2.106 4.116 3.906 
Triplatin NC 3.8 12.1 17.8 --- --- 
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between the drug and DNA.  Both the activated and non-activated forms of [AuCl(terpy)]2+ bind 
strongly to DNA; ri values of 0.075 and 0.1 for the activated species did not cause any DNA 
denaturation. This suggests that the terpy ligand is intercalating with the DNA base pairs and 
binding very strongly.  Because DNA seems to be a target for the Au(III)-terpy compounds, 
synthesis of [Au(terpy)(N-nucleobase)]3+ compounds was not continued.  
6.4.2.2 Fluorescence quenching assay with N-AcTrp  
 Fluorescence spectroscopy can be used to monitor changes in the π-cloud of the indole 
ring of the N-AcTrp due to noncovalent interactions with the planar metallated ligand. Changes 
in the emission intensity of N-AcTrp upon complex formation with ligand can be used to 
calculate binding constants for the binding of the small molecules.  
Fluorescence studies were performed to observe the π-π stacking interactions between N-
AcTrp and [Au(dien)(5’GMP)]2+ and [Au(dien)(guanosine)]3+, Table 6.2 (Ka values for other 
Au(III) complexes reported in Chapter 2).  For the 5’GMP compounds, the typical trend is 
observed.  Both the Pt(II) and Au(III) complexes have a higher Ka value than that of free ligand, 
and the Au(III) complex π-stacks more efficiently than the Pt(II) complex.  The Ka of free 
guanosine could not be calculated due to its insolubility in the aqueous buffer.  Unlike all the 
other complexes studied, in the case of guanosine, the Pt(II) complex π-stacks better than the 
Au(III) complex.  It is interesting to compare the differences in Ka values between the 9-EtG, 
guanosine, and 5’GMP complexes.  The Ka values of Au(III) metal complexes are 16.7, 11.0, 
and 19.7 x 103 M-1, respectively. All three ligands are very similar in structure, with guanosine 
adding a pentose sugar ribose, and the 5’GMP adding both the ribose sugar and a phosphate 
group.  It is evident that the presence of a phosphate group enhances the π-stacking, whereas 
when only the sugar is present the stacking is decreased.  A Ka value for [Au(dien)(5’GMP)]2+ 
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was calculated to be almost 4 times that of free N-AcTrp.  This assay should be repeated, 
however, because only one trial was performed and the fluorescence was performed by titrating 
10-100 equivalents of drug, resulting in extremely low intensity values. It is likely that these low 
values resulted in an inaccurate Ka value and 1-10 molar equivalents should be used. 
Nonetheless, it is likely that the Au(III)-5’GMP compound has a significantly higher Ka for the 
ZF when compared to that of free NAcTrp. This large enhancement in π-stacking due to the 
phosphate group was also seen for the Pt(II) complex when reacted with the Cys3His HIV-
NCp7(F2) zinc finger protein [10].  
Table 6.2. Association Constants Obtained from 
Eadie-Hofstee Plots of N-AcTrp with Different 
Au(III) Quenchers 
Compound Ka x 103 M-1 St. Dev. 
free 5'GMP 3.1 0.3 
[Pt(dien)(5'GMP)] 6.9 (12.4) 0.2 
[Au(dien)(5'GMP)]2+ 19.7 (74.6) 0.1 
free guanosine N/A N/A 
[Pt(dien)(guanosine)] 13.1 1.29 
[Au(dien)(guansoine)]3+ 11.0 0.6 
* Values in parenthesis are Ka values calculated 
for the C-terminal finger of HIV-NCp7 
 
Calculation of Ka values was attempted for both the 2-amino-4-picoline and 4-
aminoquinaldine compounds, however when excited at 280 nm, both of these compounds 
fluoresce in the same region as that of N-AcTrp, Figure 6.9. Therefore, when the Au(III) 
compounds were titrated into the solution of N-AcTrp, rather than solely observing a quenching 
effect from π-stacking, the fluorescence intensity was altered from the fluorescence of the Au 
compounds themselves. Various methods were attempted to correct for this increase in 
fluorescence from the Au compounds, such as exciting at another wavelength or trying to 
subtract out the fluorescence of the Au compounds so the only quenching observed would be 
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from the π-stacking, however none proved to be successful.  
6.4.2.3 Reactivity with amino acids by NMR 
The reaction between [Pd(dien)(nucleobase)]2+ complexes and N-Acetyltryptophan is pH 
dependent; at pH values above 5, the nucleobase ligand is substituted by the amino acid [4].  It 
was of interest to see if this same trend occurred for Au(III) complexes. [Au(dien)(9-EtG)]3+ was 
reacted with N-AcTrp in a 1:1 ratio; if this reaction were to take place, this would mean the Ka 
values calculated for [Au(dien)(9-EtG)]3+ with free N-AcTrp would be inaccurate.  A 1:1 
reaction was followed over time at room temperature, resulting in no apparent reaction between 
the two compounds (Figure 6.10).  It is important to note that the Pd(II) complex only reacted 
with N-AcTrp at pH values above 5. The pH of the Au(III) reaction was not recorded, and must 
further be investigated in order to definitively say that [Au(dien)(9-EtG]3+ does not react with N-
AcTrp. 
Figure 6.9. Fluroescence spectra of [Au(dien)(2-amino-4-picoline)]Cl3 and [Au(dien)(4-
aminoquinaldine)]Cl3 (excitation wavelength = 280nm, emission scan = 300-450 nm). 
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[Au(dien)(5’GMP)]2+ was reacted with 1 equivalent of N-Acetyltryptophan and NMR 
spectra were recorded at various pH* values (pH* refers to the reading of the pH meter in 
deuterated solvent). pH* ranged from approximately 3.7 (the initial pH*) up to 12.64 (Figure 
6.11). At initial pH* 4.76 there was no reaction between the Au(III)5’GMP complex and the N-
AcTrp. At pH* 5.99, however, there are new peaks seen	  slightly upfield from those representing 
bound 5’GMP, suggesting that the 5’GMP ligand may begin to dissociate at pH*>6.  As the pH* 
increases to 8.23 these upfield peaks become more prominent, and at pH* 12.64, the 5’GMP 
ligand is completely free; no Au-bound 5’GMP is present.  It does not seem, however, that the 
N-Acetyltryptophan is replacing the 5’GMP as is the case for Pd-nucleobase compounds, as 
there is no clear shift in the N-AcTrp peaks on the NMR spectra. 
It is possible that this trend is a property of the [Au(dien)GMP]2+ complex, and not in fact 
due to the reaction with N-Acetyltryptophan, therefore a pH dependency experiment was 
performed with only [Au(dien)(GMP)]2+ (Figure 6.12).  Similar peaks for the aromatic region of 
Figure 6.10. NMR spectra of a 1:1 reaction of [Au(dien)(9-EtG)]3+ and N-AcTrp over time. 
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[Au(dien)(GMP)]2+ were seen as those observed in the reaction with N-AcTrp (Figure 6.11).  
Most likely, the shift in peaks that is seen when the Au-complex is reacted with N-
Acetyltryptophan is not evidence of the nucleobase being substituted by the amino acid but 
Figure 6.11. NMR spectra of a 1:1 reaction of [Au(dien)(5’GMP)]2+ and N-AcTrp at various 
pH* values. Peaks in red boxes indicate N-AcTrp and peaks in blue box indicate free 5’GMP. 
Figure 6.12. NMR spectra of [Au(dien)(5’GMP)]2+ at various pH* values.  Peaks in blue 
boxes indicate free 5’GMP.	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rather due to the pH dependency of the compound itself.  Similar pH dependency was later seen 
for [Au(dien)(9-EtG)]3+ and [Au(dien)(DMAP)]3+ compounds, where at low pH* values the 
center nitrogen on the dien ligand was protonated, and as the pH* was increased, it became 
deprotonated [9].  Like the 9-EtG, the 5’GMP ligand appears to dissociate at high pH* values. 
 
A) 
B) 
Figure 6.13. NMR spectra of 1:1 reaction of [Au(dien)(5’GMP)]2+ with N-AcMet (A) 
and N-AcCys (B) over time. Only the aromatic region is shown in (B) showing the 
5’GMP ligand dissociates over time. 
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 The reaction of [Au(dien)(5’GMP)]2+ with N-AcMet and N-AcCys was also followed 
over time by NMR (Figure 6.13).  It is important to know how the Au(III) compounds interact 
with the amino acids on a small scale to help gauge how the compound will interact with the 
intact zinc finger protein.  As seen with other AuN4 compounds in Chapter 3, 
[Au(dien)(5’GMP)]2+ does not react readily with N-AcMet. Due to the ‘soft’ nature of the 
Au(III) metal center, it is more likely that the Au(III) complex would interact with the sulfur 
containing amino acids due to sulfur being a ‘soft’ base, however the presence of a methyl group 
on the sulfur atom in N-AcMet slows down the reaction tremendously when compared to that of 
N-AcCys. A small peak corresponding to free 5’GMP was present with [Au(dien)(5’GMP)]2+, 
however this is likely an impurity of the compound itself; the S-methyl peak of N-AcMet does 
not shift over time indicating no reaction. Upon immediate mixing of [Au(dien)(5’GMP)]2+ with 
N-AcCys, however, a large peak at 7.9 ppm corresponding to free 5’GMP was present and the 
solution was cloudy.  A white solid formed over time, and at 4 hours only free 5’GMP was 
present.  Though all AuN4 compounds react readily with N-AcCys, [Au(dien)(5’GMP)]2+ is the 
only compound that results in loss of ligand over time (refer to Chapter 3 for studies with 
[Au(dien)(DMAP/9-EtG)]3+ compounds and N-AcCys).	   	  	   [Au(N-Medien)(DMAP)]Cl3 was reacted with 2.5 equivalents of N-AcMet, Figure 6.14. 
Unlike the reactions highlighted in Chapter 3 for [Au(dien)(N-heterocycle compounds)]3+ and N-
AcMet where no reaction is observed, [Au(N-Medien)(DMAP)]Cl3 appears to react slightly with 
N-AcMet, indicated by an upfield shift in the S-CH3 peak. This peak shifts slightly from 2.13 to 
2.24 ppm with a second S-CH3 peak appearing at 2.54, as seen previously with the AuN3Cl 
species (Chapter 3). The S-CH2 multiplet also shifts slightly upfield indicating sulfur binding to 
gold. Peaks corresponding to the DMAP ligand shift upon reaction with N-AcMet, however 
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there is no indication of free DMAP. Similarly, the N-Medien peaks shift slightly upfield, 
however there is no indication of free N-Medien ligand. An upfield shift in the N-Me peak 
suggests sulfur binding resulting in more electron density on the gold metal center and therefore 
a shielding effect on the N-Me group. With both the DMAP and N-Medien ligands remaining 
bound, this suggests a ring opening mechanism similar to what has been previously reported in 
the literature [11-12], where the NH2-Au bond breaks and the nucleophilic sulfur binds, Figure 
A) 
 
B) 
 
Figure 6.14. NMR spectra of [Au(N-Medien)(DMAP)]Cl3 + NAcMet over time.  N-Medien 
region shown in (A) and aromatic region shown in  (B). 
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6.15. In Chapter 2 we report that the presence of the DMAP ligand stabilizes the N-Medien 
ligand and prevents ring opening. However, it may be possible that the further decrease in pH 
(pH ~3.0 after addition of N-AcMet) as well as the presence of the nucleophlic sulfur atom 
induces this ring-opening mechanism. 
	  
It is clear the methyl group on the center nitrogen of the dien ligand affects the reactivity 
of the complex. Previous CV studies show a less negative peak potential for [Au(N-
Medien)(DMAP)]Cl3 when compared to the non-methylated analogue, indicating the Au(III) 
metal center is less stable. This decrease in stability may be cause for a greater reactivity and 
susceptibility to reduction by the nucleophlic sulfur.  
 
6.4.3 Reactivity with Cys3His and Cys2His2 mutant zinc finger proteins 
 Cys2His2 and Cys3His mutant peptides containing the same sequence of the C-terminal 
NCp7 zinc finger with a methionine deleted from the sequence (compare Figure 3.1 and Figure 
6.16) were studied. It was originally thought that eliminating the methionine would eliminate any 
competitive metal binding on the backbone. 
AuH2N
N
S
N
N
NH2
Figure 6.15. Suggested structure of product from reaction of [Au(N-Medien)(DMAP)]3+ and 
N-AcMet. 
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6.4.3.1 CD experiments 
 CD experiments were performed to determine the change in structure, if any, of the zinc 
finger protein upon reaction with the Au(III) complexes.  As indicated in Figure 6.17, the Au(III) 
complexes react extremely fast with the Cys3His mutant peptides, all resulting in immediate zinc 
ejection and complete loss of ordered structure. It is thought that this may be due to the fact that 
the coordination sphere is constricted and therefore more susceptible to loss of zinc. As expected, 
the Cys2His2 mutant zinc finger reacts slower than that of the Cys3His due to the fewer number 
of reactive cysteine residues.  As seen for the non-mutated NCp7(F2) and Sp1(F3) peptides, data 
shown in Chapter 3, the 9-EtG species appears to react slightly slower than the chloride species 
and, as a result, cause less zinc ejection. Due to the extremely fast reactivity of the Cys3His 
mutant zinc finger, further studies with this peptide were not performed.  
6.4.3.2 Fluorescence experiments 
 As seen for the non-mutated peptides, a Ka value was not able to be calculated for the 
Au(III) complexes due to the rapid Zn ejection; a large amount of quenching is observed for all 
Au(III) compounds, including the –Cl species, indicating the decrease in fluorescence is likely to 
result from a change in peptide conformation upon zinc ejection. Fluorescence time studies, 
Figure 6.18, clearly show the difference in reactivity between the Cys3His and Cys2His2 peptides. 
Figure 6.16. Model mutant peptide; 
X = (His)2; (His)(Cys). 
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For the Cys3His mutant, all compounds appear to react in a similar manner and on a similar time 
scale (Figure 6.18A). All compounds react fast, with an immediate sharp drop in fluorescence 
from 0 to 6 minutes, after which the fluorescence intensity no longer decreases. For the Cys2His2, 
there is an initial decrease in fluorescence, the DMAP species decreasing the most  (Figure 
6.18B).  This is likely due to the fact that the DMAP species has a higher Ka than  [Au(dien)(9-
EtG)]3+, therefore this initial decrease in fluorescence is due both to initial recognition through π-
stacking, followed by immediate zinc ejection. After this initial decrease in fluorescence 
Figure 6.17.  CD Spectra of Au(III) compounds reacted with Cys3His (A) and Cys2His2 (B) 
mutant zinc finger peptides.  Reactions are 1:1 and spectra were recorded at time 0. 
A) 
B) 
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intensity, the signal remains constant for each compound, perhaps suggesting no more zinc is 
being ejected and/or the tryptophan residue in the Cys2His2 mutant peptide does not change 
significantly in conformation when zinc is ejected. 
6.4.3.3 PAR Zn ejection Assay with Cys3His mutant peptide 
PAR assays (PAR = 4-(2-pyridylazo)resorcinol) are often performed to quantitatively 
measure the amount of free zinc present in a solution.  Free PAR has a maximum absorption at 
A) 
 
B) 
 
Figure 6.18. Fluorescence time studies for 1:1 reactions of Au(III) compounds and Cys3His 
(A) and Cys2His2 (B) zinc fingers.  
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~410nm; when bound to zinc, forming the complex Zn(PAR)2, the maximum absorption is at 
~500 nm. This technique is often used to monitor the amount of zinc ejection over a period of 
time.  This method, however, was not successful in these experiments.  As a control, increasing 
concentrations of Zn acetate were titrated into a 50 µM solution of PAR. Though a suitable 
calibration curve was observed, the absorbance intensity decreased over time, suggesting the 
Zn(PAR)2 complex was not stable in solution. When a solution containing both ZF and PAR 
was analyzed by UV/VIS, a large peak at 500 nm was present, suggesting that the PAR chelates 
zinc from the zinc finger (this was also seen for TSQ – a fluorescence method used to monitor 
zinc ejection – by another member of the group). [Au(dien)(9-EtG)](NO3)3 (1.3 equivalents) was 
added to the ZF/PAR solution and the reaction was monitored over time.  The peak at 500 nm 
(that indicating Zn bound to PAR) decreased over time.  If zinc is being ejected from the zinc 
finger, as indicated by CD experiments, this peak should increase over time. Due to these results 
and the fact that the PAR appears to chelate the Zn from this particular peptide sequence, this 
technique was not further optimized. 
 
6.4.4 ESI-MS studies with NCp7(F2) and Sp1(F3) zinc finger and apo-peptides 
The ESI-MS studies reported in Chapter 3 were also performed for [Au(N-
Medien)(DMAP)]3+ with the Cys3His NCp7 C-terminal zinc finger, Figure 6.19. Unlike what 
was seen for both [Au(dien)(9-EtG)]3+ and [Au(dien)(DMAP)]3+, intact Au(III)-complex was not 
seen for the reaction of NCp7(F2) and [Au(N-Medien)(DMAP)]3+. Compared to its non-
methylated analogue, [Au(N-Medien)(DMAP)]3+ reacts more rapidly, resulting in primarily apo-
species (740.9975 m/z, 3+) as well as Au/F (806.3173 m/z, 3+) and Au2/F (872.3093 m/z, 3+); no 
peaks pertaining to intact NCp7(F2) were present. This increase of reactivity may be due to the 
	   158	  
decrease in stability of the Au(III) metal center as indicated from CV experiments (Chapter 2) 
for the N-methyldien compounds.  
ESI-MS studies were also performed with apo-peptide (both Cys3His and Cys2His2) and 
[Au(dien)(DMAP)]3+. For the reaction with apo-NCp7(F2), intact [Au(dien)(DMAP)]3+ was not 
observed, however a large peak pertaining to [AuCl(dien)]2+ was present. The primary species 
present was apo-peptide (741.3292 m/z, 3+) at “time 0” with no formation of Au/F, Figure 
6.20A. Similar to that seen for the reaction with the NCp7(F2) zinc finger, the 24 hour spectra 
was difficult to interpret, with multiple unidentifiable peaks present (Figure 6.20B). There is a 
large peak present at 605.1428 m/z (4+) indicating the presence of Au/F. This peak was not 
present at the 24 hour time point for the reaction with NCp7(F2) zinc finger. 
Figure 6.19. ESI-MS spectrum of [Au(N-Medien)(DMAP)]3 + NCp7(F2) at initial time 
point. 
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Figure 6.20. ESI-MS spectra of NCp7(F2) apo-peptide + [Au(dien)(DMAP)]3+ at initial 
(A) and 24 hr (B) time points. 
A)	   B)	  
A)	   B)	  
Figure 6.21. ESI-MS spectra of Sp1(F3) apo-peptide + [Au(dien)(DMAP)]3+ at initial (A) 
and 24 hr (B) time points. 
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ESI-MS studies with apo-Sp1(F3) and [Au(dien)(DMAP)]3+ were similar to that performed with 
zinc finger. Initial time points showed the main species to be apo-peptide, with no formation of 
Au/F, Figure 6.21A. Unlike the zinc finger reaction, however, no intact Au(III) compound was 
present; only [AuCl(dien)]2+ was visible. The rate of reactivity with apo-peptide was somewhat 
slower than that of the zinc finger, with less Au/F present after 24 hours. Figure 6.21B shows the 
primary species to still be apo-peptide.	  	  	  
6.4.5 Reactivity with the full HIV-NCp7 Zinc Finger Protein 
Chapter 5 discusses the reactivity of [Au(dien)(9-EtG)]3+ with the full NCp7 zinc finger 
and SL2-RNA. This section continues those studies and expands to that of 
[Au(dien)(DMAP)]Cl3. 
6.4.5.1 FT-ICRMS Experiments  
In collaboration with Drs. Daniele Fabris and John Mangrum from SUNY-Albany, FT-
ICRMS experiments were performed with the full NCp7 zinc finger protein, SL2-RNA, and 
Au(III) complexes including [Au(dien)(DMAP)]3+ and [Au(dien)(9-EtG)]3+.  
In addition to those experiments already described (Chapter 5), [Au(dien)(9-EtG)]3+ and 
SL2-RNA were added simultaneously to a solution of NCp7 in a 1:1:2 ratio, respectively, to 
mimic competitive binding conditions. At time 0 (MS was run immediately after mixing 
reagents), the NCp7/RNA complex appeared to be the only species present (Figure 6.22). After 
incubating for 15 minutes, a new peak pertaining to Au2F was present. In agreement with 
experiments in Chapter 5 of this dissertation, this suggests that over time, [Au(dien)(9-EtG)]3+ 
can disrupt RNA/NCp7 complex formation.  
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A 1:1 and 1:0.5 reaction of NCp7 and [Au(dien)(DMAP)]3+ was performed to determine 
if the DMAP ligand decreased the rate of reactivity when compared to the 9-EtG. The Ka value 
for [Au(dien)(DMAP)]3+ with free N-AcTrp is 25.5 M-1 compared to a lower Ka of 16.7 for the 
9-EtG complex, therefore it is expected that the Au(III)-DMAP complex would be more likely to 
π-stack with the Trp residue in the C-terminal finger of NCp7, therefore slowing down the 
covalent binding and resulting Zn ejection/Au replacement. Many species are present in the 1:1 
Figure 6.22. FT-ICRMS spectra (negative ion mode) of competitive binding study. 
[Au(dien)(9-EtG)]3+ and SL2-RNA were added simultaneously to a solution of NCp7 and the 
reaction was monitored over time. Top spectrum was recoreded immediately and bottom 
spectrum was recorded after 15 minutes incubation. 
Time	  0	  
15	  min	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Figure 6.23. FT-ICRMS spectrum of 1:1 reaction of [Au(dien)(DMAP)]3+ and NCp7.  
Figure 6.24.  FT-ICRMS spectra of 0.5:1 reaction of [Au(dien)(DMAP)]3+ (A) and 
[Au(dien)(9-EtG)]3+ (B) with NCp7. 
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reaction, including AuF, Au2F, and Au3F which we also see for the Au(III)-9-EtG complex.  
However, we do see the presence of intact NCp7 (two Zn ions present) as well as NCp7 with 1 
Zn and 1 Au atom bound (Figure 6.23). The presence of these species supports the theory that 
the DMAP ligand would slow down the reaction with NCp7. The 1:0.5 reaction of 
[Au(dien)(DMAP)]3+ : NCp7 shows only the presence of intact ZF (Figure 6.24A). In the 
presence of the 9-EtG complex, however, peaks representing NCp7 with 1Zn and 1Au bound as 
well as Au2F and Au3F are present (Figure 6.24B), again showing the DMAP ligand slows down 
the reaction with the NCp7 zinc finger protein. 
6.4.5.2 EMSA Gel Assays 
In Chapter 5, EMSA gels (performed by Erica Peterson) were used to determine whether 
the Au(III)/Pt(II) drugs were inhibiting the formation of the NCp7/RNA complex. In the case of 
[Au(dien)(9-EtG)]3+ the gel showed no complex inhibition. This was contrary to the MS results, 
which showed free RNA after addition of drug to pre-formed NCp7/RNA complex. The 
following studies expand on those previously discussed.  
In order to mimic the MS experiment more closely, NCp7 was incubated with SL2-RNA 
for 30 minutes followed by the addition of Au(III)-drug.  As shown in Figure 6.25A/B, no 
inhibition was observed. NCp7 also binds strongly to SL3, with a Kd = 28±3 nM [13]. An EMSA 
gel experiment was performed with [Au(dien)(DMAP)]3+ and SL3, Figure 6.25C, however like 
that of SL2, no inhibition was observed. 
It is possible that the binding buffer for NCp7 and SL2 contains something that is 
interfering with the reaction, therefore similar experiments were performed in buffer with low 
concentration of ZnCl2, Figure 6.26. Inhibition of the NCp7/SL2 complex was observed in the 
presence of [Au(dien)(DMAP)]3+ and [Au(dien)(9-EtG)]3+, with IC50 values of 2 mM and
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Figure 6.25. Effect of [Au(dien)(N-heterocycle)]3+ on SL2 RNA -NCp7 protein interaction, 
[Au(dien)(9-ETG)]3+ (A) and [Au(dien)(DMAP)]3+ (B). NCp7 was incubated with NC for 30 
minutes followed by addition of drug for 1 h. Lane 1 contains SL2 only, Lane 2 SL2 and 
NCp7 only; Lanes 3-9 contain NC, SL2 and 500, 250, 125, 62.5, 31.3, 15.6, and 7.8 µM of I 
respectively.  (C) Similar study as shown in (B), with SL3 instead of SL2. 
A)	   B)	   C)	  
Figure 6.26. Effect of low-zinc containing buffer on EMSA gel assay. (A) NCp7/RNA + 
increasing concentrations of [Au(dien)(DMAP)]3+. (B)  NCp7/RNA +  increasing 
concentrations of [Au(dien)(9-EtG)]3+; red box indicates presence of high aggregate species in 
the sample well. IC50 graphs are shown for both drugs. 	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456 µM, respectively. In the case of [Au(dien)(9-EtG)]3+ a large band shifts to the top of the 
sample well, indicating formation of higher aggregate species. It was determined that this species 
was due to a SL2-drug species, as this band was the same intensity with or without NCp7, Figure 
6.27.   
 
 It is difficult to directly compare the results of the FTICR-MS experiments to those of the 
EMSA gels; the parameters for each experiment are quite different from one another. The MS 
experiments were performed in water and we have shown that the buffers used for the EMSA 
gels may contain elements that interfere with the reaction. The relative concentrations used are 
also quite different. For MS studies, the NCp7/RNA complex was formed in a 2:1 ratio, whereas 
for the EMSA gel the final concentration of NCp7 was 100 nM compared to 2 nM final 
concentration of SL2-RNA. This large excess of NCp7 could be a key factor towards preventing 
complex inhibition by the Au-complexes.	  	  	   
Figure 6.27. High aggregate species is due to drug:SL2 complex. Lane 1: SL2, Lane 2: 
NCp7/SL2, Lane 3: NC/1 mM [Au(dien)(9-EtG)]3+ + SL2, Lane 4: 1 mM [Au(dien)(9-
EtG)]3+ + SL2. 	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6.4.6 MTT Cytotoxicity Assay 
An MTT assay was used to determine the IC50 values of the Au(III) metal compounds in 
both HCT116 (colorectal carcinoma) and A2780 (ovarian cancer) cell lines, Table 6.3.  Trials 
indicated with a * are those performed with fresh drug solution prepared immediately before the 
assay was performed.  All other trials were performed with a drug solution that had been stored 
in the freezer over a period of time. When a drug solution that has been frozen over time is used, 
the IC50 values are much lower than when a fresh solution is used.  It is possible that these 
compounds are not stable over time, or perhaps the difference in reactivity is related to their pH 
dependency [9]. 	  
 
Recently the cytotoxicity experiments were repeated for [AuCl(dien)]Cl2 and 
[Au(dien)(DMAP]Cl3 and the IC50 values for [Au(dien)(9-EtG)](NO3)3, [AuCl(N-Medien)]Cl2 
and [Au(N-Medien)(DMAP)]Cl3 were also calculated, Table 6.4. Higher concentrations of drug 
were used in order to calculate a more exact IC50 value. In these experiments, a fresh solution 
was used for each trial. All values are higher than those in Table 6.3. The reported IC50 value for 
[AuCl(dien)]Cl2 in the literature is 8.2 + 0.93 µM in A2780/S cell lines [14].  The closest values 
we get to those in the literature are from assays performed with drug solutions that have been 
frozen (A2780 Trial 1, Table 6.3). It is unclear as to why we are getting much higher values with 
Table 6.3. IC50 values for Au(III) compounds in HCT116 and A2780 cell lines. 
  HCT116 A2780 
  Trial 1*        Trial 2 Trial 3 Trial 4* Trial 1 Trial 2*  
Compound Name 
IC50 
(µM) 
IC50 
(µM) 
IC50 
(µM) 
IC50 
(µM) 
IC50 
(µM) 
IC50 
(µM) 
[AuCl(dien)]2+ >50 20.6 10.6 >50 4.65 19.8 
[Au(dien)(DMAP)]3+ >50 11.2 10.3 >50 3.65 17.3 
[Au(dien)(2am4pic)]3+ >50 22.1 12.6 >50 5 21.4 
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fresh solutions than reported in the literature.  Further experiments need to be performed to 
determine the stability of these compounds in solution over time as well as the effect of 
temperature on their stability.   
 
Table 6.4. Recent IC50 values for Au(III) compounds in HCT116 and  
A2780 cell lines 
  HCT116 A2780 
  Trial 1  Trial 2 Trial 1 
Compound Name IC50 (µM) IC50 (µM) IC50 (µM) 
[AuCl(dien)]Cl2 186 154 60.57 
[AuCl(N-Medien)]Cl2 133 160 66.59 
[Au(dien)(DMAP)]Cl3 160 185 70.55 
[Au(dien)(9-EtG)](NO3)3 163 180 48.81 
[Au(N-Medien)(DMAP]Cl3 112 --- 42.16 
 
6.4.7 HIV testing  
Table 6.5. Reported IC50 values for [Au(dien)(5’GMP)]2+ against three viral isolates 
of HIV-1. Values for azidothymidine (AZT), a drug currently used for treatment of 
HIV, are given for comparison. 
 
Compound Virus IC90 µM* IC50 µM* TC50 µM† 
Therapeutic 
Index∂ 
[Au(dien)(5’GMP)]2+ 
Ba-La >100 54.1 
>100 
> 1.85 
NL4-3b >100 >100 N/A 
91US001c 91.8 50.8 >1.97 
Azidothymidine 
(AZT) 
Ba-La 909 nM 11.2 nM 
>1,000nM 
>89.1 
NL4-3b 498 nM 29.3 nM >34.2 
91US001c 37.1 nM 2.55 nM >392 
a CCR5-tropic, Group M Subtype B, lab-adapted isolate 
b CXCR4-tropic, Group M Subtype B, molecular clone 
c CCR5-tropic, Group M Subtype B, clinical isolate 
*IC50 and IC90 = 50% and 90% inhibition of virus replication, respectively 
†TC50 = 50% cytotoxicity 
∂Therapeutic Index = TC/IC 
 
[Au(dien)(5’GMP)]2+ was sent to the Southern Research Institute for HIV testing. 
[Au(dien)(5’GMP)]2+ inhibited both HIV-1 Ba-L and HIV-1 91US001 with IC50 values in the 50 
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µM range; but it also appeared to significantly enhance the replication of HIV-1 NL4-3 in the 
10-32 µM range, Table 6.5 and Figure 6.28. 
 
A)	  
B)	  
C)	  
Figure 6.28. HIV-testing results from the Southern Research Institute for 
[Au(dien)(5’GMP)]2+ with three HIV isolates. 
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  The following compounds have been sent out for similar testing: [AuCl(dien)]2+, 
[Au(dien)(9-EtG)]3+, [Au(dien)(DMAP)]3+, and [Au(N-Medien)(DMAP)]3+.. We are currently 
awaiting the results. 
 
6.5 Conclusions 
Multiple Au(III)-dien-N-heterocycle compounds have been synthesized in addition to 
those published [9]. Successful compounds were characterized by NMR, UV/VIS, and elemental 
analysis. Preliminary studies showed that the 5’GMP and 1-MetCyt compounds were pH 
dependent as previously seen for the 9-EtG and DMAP analogs [9]. Further studies will need to 
be performed once a pure [Au(dien)(1-MetCyt]3+ compound is synthesized, however preliminary 
studies show possibility of rotamers in solution as previously seen for the Pt(II)-1-MetCyt 
compound [6]. Further stability studies should be performed for all Au(III)-dien-N-heterocycle 
compounds synthesized; cytotoxicity studies showed varying results for fresh vs. frozen 
solutions. Fresh solutions gave IC50 values above 100 µM, however when solutions that had been 
frozen for a period of days/weeks were used, IC50 values were reduced to approximately 10-20 
µM.  
DNA proved not to be a primary target for all of the Au-dien compounds studied, 
however the Au-terpy compounds appeared to bind strongly and thus further study of these 
compounds was not continued. All Au(III) compounds studied π-stack effectively with N-AcTrp. 
As seen previously, Au(III) compounds appear to π-stack more efficiently than the 
isostructural/isoelectronic Pt(II) analogs, except in the case of [Au(dien)(guanosine)]3+ which has 
a slightly lower Ka value than [Pt(dien)(guanosine)]2+. The AuN4 coordination sphere slowed 
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down reactivity with NAcMet when compared to that of AuN3Cl, however the compounds are 
still highly reactive with N-AcCys.   
Studies with mutant zinc finger peptides showed that all Au(III) compound studied were 
highly reactive with both the Cys3His and Cys2His2 zinc fingers, resulting in immediate zinc 
ejection.  It is possible that removing the methionine from the sequence altered the zinc 
coordination sphere in such a way that caused the peptide to be more reactive, however it was 
evident that the Cys2His2 was slower to react, which is expected due to the fewer number of 
reactive sulfur containing cysteine residues.  
Studies with the full intact NCp7 zinc finger showed [Au(dien)(DMAP)]3+ to be less 
reactive than the 9-EtG compound, with intact zinc finger and Zn/Au-finger species be present. 
EMSA gel assays investigating the possibility of NCp7/RNA complex inhibition were 
performed. It is likely the binding buffer used has some effect on the reaction taking place, as 
removing the ZnCl2 allowed for an IC50 value of 2mM and 456 µM to be calculated for 
[Au(dien)(DMAP)]3+ and [Au(dien)(9-EtG)]3+, respectively. The micromolar IC50 value of the 
Au(III)-9-EtG complex is within the range of other reported NCp7/RNA antagonists in the 
literature [15].  It is possible that this HIV nucleocapsid-nucleic acid antagonism may result in a 
loss of viral activity. Antiviral studies at the Southern Research Institute are currently underway.  
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Chapter 7. General Conclusions and Future Directions 
Zinc finger proteins exhibit a variety of functions, including transcription, DNA repair, 
and apoptosis [1]. Displacement of the central zinc ion, along with mutation of coordinated 
amino acids can result in a loss of biological function. There has been an increasing interest to 
synthesize complexes that selectively target zinc finger proteins, in turn inhibiting DNA/ZF 
interactions and therefore resulting in loss of protein function, Figure 7.1. Au(I) and Au(III) 
compounds including auranofin and multinuclear compounds have been designed to target zinc 
finger proteins such as the Cys2His2 containing Sp1 transcription factor and the Cys3His 
containing PARP-1 zinc finger proteins. In all cases, zinc is immediately ejected and replaced by 
either Au(I) or Au(III) ions [2-6]. Au(I) and Au(III) have a high affinity for protein thiols due to 
their ‘soft’ nature. This can significantly reduce the cellular activity and selectivity of these 
drugs, as they may easily react with other sulfur containing proteins such as human serum 
albumin (HSA). 
Figure 7.1. Graphical representation of ZF/DNA antagonism.  
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The HIV nucleocapsid zinc finger, NCp7, is of particular interest in this work. NCp7 is 
involved in multiple steps of the HIV life cycle, thus making it a desirable drug target. 
Recognition of NCp7 with DNA/RNA occurs via π-stacking interactions between guanine in the 
DNA/RNA and the tryptophan in the C-terminal zinc finger of the NCp7 protein, F2. Mutation 
of this tryptophan residue significantly reduces the nucleic acid chaperone activity of NCp7, 
which correlates to inhibition of viral replication [7]. 
 Electrophilic attack by [MCl(dien)]n+ (M = Pt(II), Pd(II), Au(III); dien = 
diethylenetriamine) on NCp7(F2) results in conformational changes and ejection of Zn. For the 
Au analog, as indicated by electrospray ionization mass spectrometry (ESI-MS) experiments, all 
ligands were displaced and ‘goldfingers’ were formed [8]. To slow down this reaction and make 
the drugs more selective, the Cl- was replaced with a more substitution-inert nitrogen donor. 
Platinated nucleobases such as [Pt(dien)(9-EtG)]2+ (9-EtG = 9-ethylguanine) were shown to π-
stack effectively in a non-covalent manner with tryptophan of the C-terminal finger of HIV 
Nucleocapsid, NCp7(F2) [9]. In this work, this concept was expanded to Au(III) complexes as 
Au(III) is isoelectronic and isostructural with Pt(II).  
Novel AuIII(dien)(N-heterocycle) compounds were synthesized and characterized. 
Previously reported studies show [AuCl(dien)]Cl2 to exhibit pH dependency with the central 
nitrogen on the tridentate dien ligand deprotonated at a pKa of 4.0 [10]. The acidity of the dien 
ligand is affected by the nature of the fourth ligand as a leaving group; [Au(dien)(9-EtG)]3+ 
reduces the pKa to 3.3 and [Au(dien)(DMAP)]3+ (DMAP = 4-dimethylaminopyridine) increases 
the pKa to 4.7, with no evidence of hydrolysis at basic pH. The metal center of [Au(dien)(N-
heterocycle)]3+ compounds was shown to be more stable to reduction than when Cl− is present, 
with consequences for reactivity with biomolecules: specifically, significant enhancement of π−π 
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stacking interactions with tryptophan was observed relative to isostructural and isoelectronic 
platinum(II) and palladium-(II) compounds. 
NMR studies show the presence of a more inert N-donor as the leaving group slows 
down the reaction with the sulfur-containing amino acid N-acetylmethionine (N-AcMet). All 
Au(III) compounds react readily with N-acetylcysteine (N-AcCys), however lack of N-
heterocycle ligand dissociation indicates, to our knowledge, the first long-lived N-heterocycle-
Au-S species in solution.  
Of the Au(III) compounds studied, [Au(dien)(DMAP)]3+ appears to be the least reactive, 
with ESI-MS studies showing presence of intact NCp7(F2) ZF at initial reaction times.  
Reactivity of the Cys3His NCp7 zinc finger was compared to the Cys2His2 Sp1(F3) zinc finger. 
CD experiments showed a slower rate of reactivity for Sp1(F3) which is to be expected due to 
the fewer number of nucleophilic cysteines. Interestingly, ESI-MS studies show no presence of 
intact zinc finger for experiments performed with Sp1(F3). This suggests the mode of action of 
these compounds is dependent on the nature of the zinc binding core. It is also important to note 
that NCp7 contains a tryptophan amino acid and the Sp1(F3) does not, indicating the possible 
importance of this key residue in slowing down the reactivity of these Au(III) compounds. 
Mass spectrometry studies were expanded to that of the full HIV NCp7 zinc finger. 
[Au(dien)(9-EtG)]3+ reacts quickly with NCp7, resulting in immediate zinc ejection and 
replacement with up to three gold ions. Similar to studies with the C-terminal finger, 
[Au(dien)(DMAP)]3+ appears to react slower indicated by the presence of intact NCp7. Addition 
of [Au(dien)(9-EtG)]3+ to preformed NC-SL2 complex results in release of free RNA; based on 
EMSA (electrophoretic mobility shift assay) studies, [Au(den)(9-EtG)]3+ disrupts the NCp7-
RNA complex with an IC50 of ~450 uM. 
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Though [Au(dien)(DMAP)]3+ was shown to be more stable and less reactive than the 
parent [AuCl(dien)]2+ species, it is still too reactive to be considered a selective compound to any 
degree. However, through the extensive characterization of the [Au(dien)(N-heterocycle)]+3 
compounds, we now have a better understanding of the chemistry and can work towards 
synthesizing more stable compounds. A compound of particular interest, as discussed in Chapter 
6, is [Au(dien)(1-MetCyt)]3+ (1-MetCyt = 1-methylcytosine). Previous studies on the Pt(II) 
analogue show an increased Ka value with tryptophan compared to that of 9-EtG [11.]. It is 
possible that the hindered rotation around the M-N3 axis could reduce the rate of reactivity. Once 
a pure product is achieved, the solution chemistry of the Au(III)-1-MetCyt complex will need to 
be investigated further due to likely pH dependency and possible metal migration and 
deamination [12,13]. Using accumulated Pt(II) data as a guide, other planar nucleobase ligands 
such as xanthosine may also be investigated due to their high π-stacking ability. 
Due to the severe pH dependency of the center nitrogen on the dien ligand when bound to 
Au(III), we are investigating the use of other possible chelating ligands. Expanding from the 
Au(III)(N-Medien) species, methyl groups can be added to the primary amines, ultimately 
having a pentamethylated dien species. The presence of methyl groups may aid in eliminating 
the pH sensitivity of the Au(III) compounds.  The 1H NMR spectrum of the [Pt(Me4dien)(9-
EtG)]2+ compound (recent unpublished work by Samantha Tsotsoros) shows two H(8) signals 
indicating restricted rotation around the Pt-purine bond; this is also confirmed by molecular 
modeling. The shorter Au(III) bond should enhance this effect.  
Another chelate ligand of interest is based on an early Au(III) compound, 
[AuCl2(dampa)] (dampa =  2’[(dimethylamino)methyl]phenyl), Figure 7.2, made as a cisplatin 
analog incorporating an anionic phenyl donor in a 5-membered chelate ring [14,15]. The 
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unpublished bis(substituted) 
compound, Figure 7.2, is an 
interesting C-based analog of dien. 
The chemistry of [AuCl2(dampa)] 
causes slow substitution of Cl- by N-
donor ligands; pyridine only 
displaces the Au-Cl bond upon 
activation [16]. Au-NH3 compounds 
have been reported [17], therefore we will likely prepare [AuCl(NH3)(dampa)]+ for incorporation 
of the N-heterocycle ligand, the first N-donor ligands being 9-EtG and DMAP for comparison 
with the completed work. This slow substitution rate will ideally translate to a slower rate of 
reactivity.  
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Abstract: 
This entry describes the interactions of zinc finger peptides with metallated DNA and 
small molecule platinum-metal probes. The interactions have biological consequences from 
sequence-specific inhibition of zinc finger function to hijacking of transcription factors by 
binding to platinated DNA. Small molecule interactions have chemical consequences because the 
formal analogy between alkylation and metallation suggests the possibility of electrophilic attack 
of the cysteine and histidine residues with eventual zinc ion ejection and loss of tertiary structure 
and consequently biological function. These approaches create new opportunities to investigate 
the chemical properties of zinc fingers and may possibly produce new leads for disease 
intervention where zinc finger function is implicated. 
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Introduction: 
In biology, zinc serves either a structural or catalytic purpose. When zinc acts in a 
catalytic manner, it is bound to a water molecule that is converted to a hydroxyl ligand. 
Structural zinc is characterized by coordination to four amino acids, generally histidine and 
cysteine. These types of zinc sites include zinc fingers (ZF), which compose 2-3% of the human 
genome [1]. The most common role of zinc fingers in biology is in the binding of DNA to 
transcription factors and they are also involved in RNA packaging, transcriptional activation, 
regulation of apoptosis and protein folding and assembly.  
 Zinc fingers are defined by the number and type of amino acids coordinated to the central 
zinc atom (Figure A1).  Analysis of Cys2His2 zinc finger proteins has allowed for elucidation of 
DNA recognition mechanisms and their role in transcriptional regulation. The Cys3His motif is 
involved in RNA and DNA recognition, cell-cycle control and cellular signaling pathways. The 
third common zinc Cys4 finger motif is found in human DNA repair enzymes and many nuclear 
localized systems [2].   
Coordination to zinc enhances the nucleophilicity of the Zn-Cys bond, allowing for attack 
by small electrophiles. The chemical reactivity is dependent on the nature of the zinc 
coordination sphere (Cys2His2; Cys3His, Cys4) [2].  The interaction of zinc finger proteins with 
Figure A1: The three main coordination environments of zinc fingers: Cys2His2, Cys3His and 
Cys4. 
 
Sp1 (F2) 
X1 - RFTRSDEL 
 
NCp7(F2) XPA 
X2 - EFMDSYLMNHFDL 
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DNA and RNA can be inhibited upon chemical modification of the zinc binding ligands.  There 
is a formal analogy between alkylation and metallation, where in the latter case chemical 
modification refers to electrophilic attack of the cysteine and histidine residues by Pt and Co 
agents respectively (Figure A2).   
 
In both cases, however, eventual loss of zinc is seen and the proteins lose tertiary 
structure and therefore loss of biological function.  Tethering of the electrophilic agent to a 
sequence-specific DNA may allow for targeting and differentiation between different zinc 
fingers and enhancement of selectivity.  In this review, the approaches to the use of small 
molecule metal-based electrophiles and formation of DNA-protein crosslinks as probes for zinc 
finger conformation and reactivity will be discussed. These approaches create new opportunities 
to investigate the chemical properties of zinc fingers and may possibly produce new leads for 
disease intervention where zinc finger function is implicated.  
Targeting of Zinc Fingers by Cobalt Schiff Base Complexes 
Cobalt(III) Schiff-base (Co-sb) complexes may disrupt the structure of a zinc finger 
peptide by axial ligation of the Co(III) ion to the nitrogen of the imidazole ring of a histidine 
Figure A2: General schematic of electrophilic agent attack on a zinc finger. Platinum agents 
attack at cysteine residues, while cobalt agents attack at histidine residues. X=(Cys)(His) or 
Cys2. 
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residue [3]. The reaction of Co(III)-sb with histidine is a dissociative ligand exchange process, 
with  loss of the labile axial NH3 ligands by H2O facilitating histidine binding. Following this 
recognition, the axial NH3 ligand is displaced by water. The reaction of Co(III)-sb at the zinc 
finger site irreversibly inhibits protein activity as a result of zinc ejection due to the binding of 
cobalt to histidine [4]. Zinc ejection causes loss of tertiary structure and therefore loss of 
function.  
Initial studies showed that cobalt complexes inhibit binding of the human transcription 
factor Sp1, to its consensus sequence. DNA-coupled conjugates of the cobalt complexes 
selectively inhibited Sp1 in the presence of several other transcription factors. The Snail family 
of Cys2His2 zinc finger transcription factors, Slug, Snail, and Sip1, are emerging as anti-cancer 
drug targets as they are implicated in tumor metastasis through the regulation of epithelial-to-
mesenchymal (EMT) transitions. Slug, Snail, and Sip1 bind to the Ebox consensus sequence 
CAGGTG in the promoter region of target genes with high specificity to mediate transcriptional 
repression. To improve specificity for the Snail family of transcription factors, an 
Figure A3: Scheme for zinc finger-specific inactivation using Co(III)-sb-DNA conjugates. 
Co(III)-Ebox is recognized by the Snail family of transcription factors. Loss of axial ligands 
and subsequent binding of histidine results in eventual ejection of Zn2+ and transcription 
factor inactivation.  
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oligonucleotide containing the DNA consensus sequence was conjugated to the Co(III) complex 
yielding Co(III)-Ebox (Figure A3) [4].  
No significant changes in the structure of DNA occurred upon conjugation. Through 
addition of the Ebox DNA sequence to the Co(III) metal complex, peptide-binding specificity 
was improved 150-fold over Co(III)-sb. Co(III)-Ebox was found to effectively inhibit the Slug, 
Snail and Sip1 zinc finger transcription factors from binding to their DNA targets with eventual 
loss of Zn2+ [4]. Studies demonstrate that neither the oligo, or the Co(III) Schiff base complex 
alone, are sufficient for transcription factor inactivation at concentrations where the conjugated 
complex mediates inhibition. 
Subsequently, a Co(III) Schiff base DNA-conjugate has been designed to target the Gli 
C2H2 transcription factors in the Hedgehog (Hh) pathway, which has been implicated in the 
formation and development of certain cancers such as medulloblastomas and basal cell 
carcinomas [5].  In order to test the specificity and efficacy of Co(III)-DNA complex, the authors 
tested the Ci consensus sequence alone, Co(III)-sb, Co(III)-Ci, and Co(III)-Mut (one base pair 
mutation). The complete structure of Co(III)-Ci was found to be the most effective at inhibiting 
Gli family ZF transcription factors. The mutation of one base pair in Co(III)-CiMut inhibited its 
specific and potent activity. The activity of Co(III)-Ci was specific, as no other zinc finger 
transcription factor tested was inhibited by the addition of the complex [5]. These results show 
that subtle changes in the oligomer attached to Co(III) can modulate the specificity and activity 
of these Co(III)-DNA conjugates both in vitro and in vivo.  
The studies performed using Co(III)-DNA complexes demonstrate the development of a 
versatile class of specific and potent complexes that may be used to study zinc finger proteins 
and may prove valuable as an experimental tool and as anti-cancer therapeutics. 
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Pt Complexes as DNA/Protein Crosslinkers 
The structure and nature of DNA adducts of platinum complexes may be manipulated to 
facilitate ternary DNA-Pt-protein crosslinks. Table A1 summarizes the compounds studied. One 
of the first examples is the use of trans-diamminedichloroplatinum(II) (TDDP). In order to map 
the section of HIV1 RNA that was recognized by the nucleocapsid NC protein, TDDP was used 
as a crosslinking agent. After digestion of a crosslinked solution of HIV1 RNA and NC protein, 
the crosslink was shown to form between positions 315-324 of the RNA. This suggests the 
possible recognition site for the NC protein on HIV1 RNA [6].  
Various mononuclear and dinuclear platinum complexes have been analyzed for their 
crosslinking abilities to zinc finger containing proteins such as the DNA repair proteins, UvrA 
and UvrB, and Sp1. The repair of the DNA adducts of the anticancer agent cis-
diamminedichloroplatinum(II) (cisplatin, CDDP) was examined with the bacterial UvrABC 
complex [7]. A sterically hindered analog, exo-[N-2-methylamino-2,2,1-
bicyclohepane]dichloroplatinum(II) (BCH) was compared for its protein crosslinking abilities.   
UvrAB proteins recognized the mono and diadducts of BCH with a higher affinity than those of 
cisplatin. Analysis of the crosslinks showed the involvement of UvrB in the ternary nucleo-
protein complexes. In general, UvrB has a greater affinity for the adducts formed by BCH over 
those formed by cisplatin [7]. 
Dinuclear platinum complexes bind to DNA in a manner that is unique from cisplatin and 
other mononuclear complexes, the main adducts being long-range (Pt,Pt) interstrand crosslinks 
[8]. Dinuclear complexes may be formally bi, tri or tetrafunctional (depending on number of 
substitution-labile chlorides present – see Table A1).  Even in the presence of a CDDP-like cis  
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Table A1. Various metal compounds form crosslinks with zinc finger proteins and DNA 
Compound Structure DNA Studied 
Zn 
Finger 
Studied 
 
Crosslink
  
Reference 
 
CDDP 
 Plasmid 
pSP65 
 
UvrAB DNA 
monoadduct 
crosslink 
formation of 
UvrB 
[6] 
 
TDDP 
 32P HIV-1 
RNA 
(311-415) 
HIV1 
NC 
Crosslink 
formation 
between 
RNA 
(between 
positions 
315-324) and 
HIV1 NC 
[5] 
 
 
Pt-BCH 
 Plasmid 
pSP65 
 
UvrA 
UvrB 
DNA 
monoadduct 
crosslink 
formation of 
UvrB 
[6] 
 
(Pt-Pt)-
2,2/c,c 
 
49 bp 
duplex 
UvrA 
UvrB 
Sp1 
Crosslink 
formation 
between 
platinated 
DNA and 
UvrA and 
UvrB 
[8] 
 
(Pt-Pt)-
1,1/t,t 
 
49 bp 
duplex 
UvrA 
UvrB 
Sp1 
Crosslink 
formation 
between 
platinated 
DNA and 
UvrA and 
UvrB 
[7,8] 
 
 
(Pt-Pt)-
1,2/t,c  
Plasmids 
pSP73KB 
and 
pUC19 
 
Sp1 Crosslink 
formation 
between 
platinated 
DNA and Sp1 
[7] 
 
 
(Pt-Pt)-
1,2/c,c 
 
Plasmids 
pSP73KB 
and 
pUC19 
 
Sp1 Crosslink 
formation 
between 
platinated 
DNA and Sp1 
[7] 
 
 
(Pt-Ru) 
 
49 bp 
duplex 
UvrA 
UvrB 
Crosslink 
formation 
between 
platinated 
DNA and 
UvrA and 
UvrB 
[8] 
Pt
Cl
Cl
H3N
Pt
NH3Cl
Cl NH2(CH2)4NH2
Pt
Cl
NH3
H3N
Pt
NH3Cl
H3N NH2(CH2)4NH2
2+
Pt
Cl
Cl
H3N
Pt
NH3Cl
H3N NH2(CH2)6NH2
+
Pt
Cl
Cl
H3N
Pt
NH3H3N
Cl NH2(CH2)6NH2
+
Pt
Cl
Cl
H3N
Ru
DMSODMSO
Cl NH2(CH2)4NH2
DMSO
Cl
Pt
Cl
Cl
H3N
H3N
Pt
NH3
Cl
Cl
H3N
Pt
Cl
Cl
H2
N
N
H2
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-[PtCl2(amine)2] coordination sphere the (Pt,Pt)-interstrand crosslinks form preferentially (Figure 
A4).   
Thus, upon bifunctional binding to DNA, the third Cl- site can then bind to a protein, 
preferentially at Cys, His, or Met residues [8]. Platinum complexes are known to bind in the 
major groove of DNA and the ability of the dinuclear complexes to crosslink UvrA and UvrB 
suggests that the proteins contact the major groove of the DNA helix within 4-4.5Å [9]. The 
flexibility of the dinuclear platinum adducts may be important in their crosslinking to Sp1 due to 
the DNA bending induced upon Sp1 binding [8].  
The results of these platinum crosslinking studies suggest that the formation of metal-
mediated DNA-protein complexes may play a role in the cytotoxic properties of these 
compounds due to the irreversible crosslinking, and therefore sequestering, of repair proteins or 
transcription factors to DNA. The differences between mononuclear and dinuclear platinum 
complexes may also explain the different cytotoxic properties of the two classes of anticancer 
drugs.  The differences in DNA adduct structure between mononuclear and dinuclear complexes 
may also be used to probe protein recognition of structurally different DNA crosslinks [8]. 
 
Figure A4: The binding of dinuclear platinum complexes to DNA. (1) Initial monofunctional 
binding, (2) long-range bifunctional interstrand crosslink formation with second platinum unit 
and (3) binding of protein at the third active site. 
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Interaction of Platinum Molecules with Zinc Fingers: 
The demonstration of zinc finger crosslink formation by platinated DNA is 
fundamentally an example of coordination compounds acting as electrophiles towards the 
peptide cysteine residues. Small molecule platinum-metal agents have therefore been explored 
for their ability to target the HIV nucleocapsid retroviral protein NCp7. Figure A5 shows the 
structures of the metal complexes studied as well as that of NCp7 nucleocapsid protein. Again, 
functionality can be studied by use of structurally distinct compounds such as CDDP, trans-
[PtCl(9-EtGua)(pyr)2]+, [PtCl(terpy)]+ and [PtCl(dien)]+ [10].  Further, the reactivity of the 
central metal ion may be altered by use of the general structure [MCl(chelate)] (M = Pt(II), 
Pd(II), or Au(III) and chelate = dien or terpy). Interestingly, both Pt(II) and Pd(II)-dien species
 
showed evidence of adduct formation on ZF2 by replacement of the M-Cl bond with zinc-bound 
thiolate.  Eventual loss of the dien ligand, as well as zinc ejection, was observed.  Due to the 
strong thiol affinity of gold drugs, both Au(III) compounds reacted extremely fast, producing 
Figure A5.  Structures of HIV NCp7 nucleocapsid protein (ZF; C-terminal finger, ZF2, 
shown in dashed box) and the platinum-metal complexes studied for molecular recognition 
and electrophilic attack.   	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only “gold fingers”.  For all terpy compounds, metal exchange occurred, producing the product 
[Zn(terpy)]2+.  These results show that by modifying both the metal and ligand of the reacting 
compound, the chemical reactivity of zinc finger proteins can by altered [2]. 
 A major challenge for all small molecule electrophiles is selectivity.  To enhance the 
selectivity of these drugs, it is important to understand the details of the zinc finger – DNA 
interaction. The recognition of DNA or RNA by the HIV nucleocapsid protein NCp7 is 
dominated primarily by π-stacking between the purine nucleic acid bases and the planar aromatic 
amino acid residues, especially between guanine and tryptophan37 [2].  Fluorescence quenching 
studies have shown that metallation of nucleobase compounds significantly enhances the π - π 
stacking interactions with L-tryptophan.  Metallation modifies frontier orbital properties, 
lowering the π -acceptor LUMO of the metallated nucleobase, thus improving the overlap 
towards the π -donor HOMO of the tryptophan.  Study of the biologically relevant C-terminal 
peptide (ZF2) of the HIV-NCp7 zinc knuckle showed that [Pt(dien)(9EtGua)]2+ and 
[Pt(dien)(5’GMP)] quench tryptophan fluorescence with Ka association constants of 7.5 x 103 
and 12.4 x 103 M-1 respectively.  Though there is little difference between their binding with the 
simple amino acid tryptophan, the extra phosphate group on the 5’GMP causes a significant 
increase in binding with ZF2 [11]. ESI-MS of both [Pt(dien)9EtGua]2+ and [Pt(dien)(5’GMP)] 
with ZF2 showed formation of a 1:1 adduct between the peptide and Pt-complex.  It is most 
likely that this adduct formation is facilitated by the π - π stacking interactions between the 
tryptophan and the platinated nucleobase.  Incubation of cis-[Pt(NH3)2(Guo)2]2+ with ZF2 
showed significantly less formation of the 1:1 adduct, possibly due to steric hinderance from the 
mutually cis-oriented purines [11].  
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The monofunctional trans-[PtCl(9-EtGua)(pyr)2]+ has high reactivity towards sulfur over 
nitrogen, and it has also been shown to cause Zn ejection in model chelates (see below).  In the 
presence of a 1:1 stoichiometric ratio of trans-[PtCl(9-EtGua)(pyr)2]+, the ESI-MS of ZF2 
showed numerous peaks consistent with multiple adduct formation.  The peak corresponding to 
the adduct ([ZF2(Pt[pyr]2)2-Zn) shows two [Pt(pyr)]2 units bound to the protein with resultant 
loss of Zn.  CD experiments revealed changes in the three-dimensional structure of the protein, 
consistent with the loss of tertiary structure due to Zn ejection.  Therefore, the proposed 
mechanism for attack of Pt-nucleobase compounds on zinc fingers consists of two steps: 1) non-
covalent recognition through π-π stacking of tryptophan with platinated nucleobase and 2) 
covalent interaction with Pt-S bond formation followed by zinc ejection [11]. 
Platinated DNA Affects Zinc Finger Conformation: 
To expand on the studies of platinum-nucleobase complex - zinc finger interactions, the 
interaction of Pt(dien)(6-mer) (6-mer = d(5’-TACGCC-3’) with the C-terminal finger of the HIV 
NCp7 zinc finger, ZF2, was studied by NMR Spectroscopy.  In this case the Pt(dien) moiety was 
bound to the single guanine residue (Figure A6-a) [10].  The solution structures of ZF2, the 6-
mer/ZF2, and Pt(dien)6mer/ZF2 adducts were calculated from NOESY-derived distance 
constraints.  For the 6-mer/ZF2 structure, stacking with tryptophan was observed as well as 
showed that there was an interaction between Trp37 and the ribose protons of the carbohydrate 
moiety of Gua4, confirming the carbohydrate-aromatic ring interaction as a key recognition site 
between NCp7 protein and oligonucleotides [10]. The NMR spectrum of ZF2 in the presence of 
Pt(dien)6-mer showed weakening of the Trp37-Gua4 contact attributed by the steric effects 
caused by platination of Gua4.  The aromatic ring of the tryptophan residue changes orientation  
(Figure A6-b), causing the DNA to be in a completely different position than when platinum is 
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absent [10].   
Molecular dynamics calculations of the DNA-protein interactions showed that the π-
stacking between Trp37 and Gua4 as well as the hydrogen bonding between the pentose and 
phosphate oxygen(s) of Cyt5 and Gua4 both help stabilize the interactions between the 6-mer 
and ZF2.  Once platinum is bound, the 6-mer is less flexible and stays in one stable conformation 
on the surface of the zinc finger.  The Gua4−Trp37 interaction is disrupted, resulting in hydrogen 
bonding interactions between Cyt6 and Cys49 and Thr50.  Additionally, the backbone CH group 
is close to N3 of Cyt6.  With the addition of this third hydrogen bond, the bonding mode imitates 
the three intermolecular Cyt−Gua base pair hydrongen bonds (Figure A6-c) [10]. 
In conclusion, these results show for the first time structural characterization of platinated 
single-stranded DNA interacting with a zinc finger protein, resulting in conformational change of 
the peptide.  These results further demonstrate the feasibility of using DNA-tethered 
coordination compounds to target specific zinc finger proteins [10]. 
Figure A6.  
(A) Superposition of the minimized structures of the 6-mer/ZF2 adduct (green) and the 
Pt(dien)(6-mer)/ZF2 adduct (orange).  
(B) Change in conformation of Trp37 upon platination of Gua4. 
(C) Stabilizing interactions of Cyt6 with the protein residues, Cys49 and Thr50, in the 
Pt(dien)(6-mer)/ZF2 adduct (hydrogen bonding highlighted in red box).  	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Small Molecule Models for Platinated DNA-Zinc Finger Interactions: 
To provide a small molecule model for the reactions of platinum complexes with ZFs, the 
chelate N,N’-bis(2-mercaptoethyl)-1,4-diazacycloheptanezinc(II), [Zn(bme-dach)]2, was studied.  
Structures for model metal/DNA/protein crosslinks and zinc ejection were deduced from ESI-
MS spectra of this [Zn(bme-dach)]2 with trans-[PtCl(9-EtGua)(pyr)2]+, a model for a 
monofunctional adduct of platinum on DNA.  The schematic of the reaction is shown in Figure 
A7. The intermediate species [Zn(bme-dach)-Pt(9-EtGua)(pyr)2]+ was observed and after 20 
hours was identified as the major species present.  This is considered to be the first 
heterodinuclear Pt,Zn monothiolate bridged species to be identified using biologically relevant 
species.  MS experiments showed the final product to be [Pt(bme-dach)]+, giving proof of Zn 
ejection followed by platinum replacement [12].  Similar experiments were performed for 
[Pt(dien)Cl]Cl and [Pt(terpy)Cl]Cl.  Results showed formation of mono- and dithiolate bridged 
intermediates as well as metal exchange and multimetallic aggregate species [2].  These results 
Figure A7.  Reaction pathway of [Zn(bme-dach)]2 with trans-[PtCl(9-EtGua)(pyr)2]+ 
with formation of monothiolate bridged and metal exchanged species [13].  	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represent suitable models for the molecular structure of ternary DNA–protein complexes 
involving zinc finger proteins discussed above [12].    
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